AUTHOR INDEX

Aannestad, A., 994
Abumrad, N.N., 1266, 1509
Abusamra, L.C., 531
Acheson, K., 428
Adriaanse, R., 782
Adumrad, N.N., 211
Agnani, G., 397
Ahmad, T., 163
Ajami, A., 114
Akazawa, S., 830
Akivias, A., 1543
Akpan, J.O., 860
Alberti, K.G.M.M., 842
Aldred, H.E., 836
Ali, M.R., 1305
Almdal, T.P., 328
Alvarez de Buergo, M., 417
Amatruda, J., 441
Ament, M., 1462
Amiri, H.S., 333
Andersen, T., 315
Andreotti, A.C., 1207
Anton, E.E., 1389
Antonio, M., 706
Arakawa, K., 360
Armellini, F., 390
Ashkenazi, A., 1543
Asplund, K., 1579
Asscheman, H., 935
Astrup, A., 109
Attvall, S., 883
Austin, M.A., 1438
Aviram, M., 11
Avogaro, P., 1332
Azevedo, J.L., Jr, 1047

Baba, H., 670
Bågedahl-Strindlund, M., 1563
Bages, J., 614
Bahr, R., 565
Baker, S., 531
Balbi, V., 1426
Baldo, A., 257
Ball, M., 310
Ball, R.O., 487
Ballinger, A.B., 735
Ballmer, P.E., 697
Balsano, F., 965
Bao, W., 1042
Baracos, V.E., 899
Bard, J.M., 397
Barjon, J.N., 1233
Barnard, R., 441
Barnhart, R.L., 233
Barrett, E.J., 285
Baruffaldi, L., 1481
Bateman, B., 1462
Batta, A.K., 1018, 1446
Baudelin, A., 1079
Bauman, W.A., 749
Bausserman, L.L., 808
Beech, J.S., 518
Benelli, C., 1030
Benhamamouch, S., 397
Berenson, G.S., 470, 1042
Berg, A.-L., 90
Bergamo-Andreis, I.A., 390
Bergman, R., 523
Bernasconi, S., 372
Bevilacqua, S., 285
Bianchi, G.P., 1023
Billardon, C., 397
Birkeland, K.I., 423
Bistrian, B.R., 279
Blackett, P.R., 1457
Blau, N., 413
Blok, G.J., 199
Blom, H.J., 1475
Blonk, M.C., 501
Blum, W.F., 579
Boers, H.J., 1475
Bofill, C., 614
Bois, B., 403
Bon, G.B., 1332
Boothe, H.W., 1266
Borel, M.J., 1509
Børglum, J., 872
Borm, G.F., 1475
Børsheim, E., 565
Boschetti, M., 819
Bosello, O., 390
Bouchard, C., 18, 814
Bovee, K.C., 1073
Boyle, P.J., 24
Brabant, G., 782
Bracy, D.P., 1266, 1310
Branch, S., 114
Bravi, C., 965
Brennan, M.F., 70
Brescaini, E., 893
Breum, L., 315
Briggs, K., 1079
Brook, J.G., 11
Brousseau, T., 397
Brown, M.R., 1134
Brown, R.G., 1558
Bruce, R., 1275
Brundin, T., 626
Bruscalupi, G., 677
Bryła, J., 1187
Buchman, A.L., 1462
Buemann, B., 109
Buffington, C.K., 584, 1367
Buggiani, A., 435
Bullock, J., 855
Burke, J.F., 114
Burtin, M., 403
Busby-Whitehead, M.J., 190
Buse, M.G., 1389
Butler, P.C., 842
Butterfield, G.E., 1226

Cabezas, M.C., 293
Caffarri, G., 514
Calles-Escandón, J., 1000
Cama, A., 1568
Camanni, F., 223
Cameron-Smith, D., 728
Camps, J., 614
Candiloros, H., 1182
Capeau, J., 757
Cappa, M., 223
Capretti, L., 514
Carella, M.J., 923
Carey, K.D., 1006
Carlsson, L.M.S., 357
Carlström, K., 217
Carnielli, V.P., 1287
Caro, J.F., 1047
Caron, M., 757, 1030
Cartaña, J., 959, 1086
Cartee, G.D., 61
Carter, W.J., 1119
Casimirri, F., 706
Castelli, S., 390
Castillo, L., 114
Caumo, A., 1207
Cavallé, P., 614
Cavallero, E., 270
Chapman, T.E., 114
Charbonnel, B., 1410
Charles, M.A., 665, 803
Chen, T., 855
Chen, Z.-Y., 940
Cherqui, G., 757, 1030
Cherrington, A.D., 1310
Cheung, S.S.C., 135
Chiasson, J.-L., 462
Chinet, A., 931
Chiodera, P., 514
Chisholm, A., 310
Choksi, R.M., 481
Choo, D.C.A., 1148
Chopra, I.J., 793
Chowdhary, I.R., 855, 1446
Christensen, J.S., 87
Christensen, K.K., 1093
Christensen, N.J., 776
Christiansen, J.S., 315
Chugani, H.T., 1462
Cianflone, K., 257
Clark, M.L., 735
Clavey, V., 397
Clot, J.-P., 1030
Cogan, U., 11
Cohen, R.D., 518
Coiro, V., 514
Colla, R., 514
Collier, G.R., 728
Conte, G., 140
Coon, P.J., 867
Copeland, K.C., 1401
Corsetti, J.P., 681
Corssmit, E.P., 1503
Crastes de Paulet, A., 1233
Crawley, J., 887

Crook, D., 1275
Cunnane, S.C., 940
Cunningham, J.J., 1558
Curatola, G., 1470
Curry, D.L., 860
Curtius, H.-C., 413
Cynober, L., 822, 899

Dachet, C., 270
Dahn, M.S., 476
Daini, S., 140
D'Amore, A., 174, 1426
Dan, T., 123
Daneman, D., 591
Dauchy, R.T., 1488
Davidson, M.B., 348
Davis, J., 1329
Davis, T.M.E., 887, 974
Davit-Spraul, A., 945
Davoli, C., 514
De Boer, H., 199
De Brandt, J.P., 822
De Bruin, T.W.A., 293
Decrouy, A., 931
De Fronzo, R.A., 85, 285, 1419
De Gallé, B., 1030
Degenhart, H.J., 1287
De Gennes, J.L., 397
De Graaf, J., 799
De Haan, A.F.J., 799
De Jong, M., 1282, 1355
Del Buergo, M.A., 263
Déléris, G., 1300
Del Rosso, A., 435
Demacker, P.N.M., 799
De Marinis, L., 140
De Mattia, G., 965
Demigne, C., 157
Dengel, D.R., 867
Dennne, S.C., 378
Descomps, B., 1233
Després, J.-P., 18
De Tinguy, E., 1300
De Vito, R., 367
Dickerson, F.D., 1442
Didyk, R.B., 1389
Dienstl, A., 633
Dimitrov, N.V., 923
Dini, G., 435
Docter, R., 1282, 1355
Dohm, G.L., 1047
Donner, M., 1182
D'Onofrio, F., 174, 1426
Dousset, N., 1470
Drinkwater, D.T., 867
Drouin, P., 1182
Druml, W., 1104
Dulloo, A.G., 931
Dunaif, A., 803, 1568

Ebara, T., 248, 299
Ehmann, S., 1108
Ehnholm, C., 470
Eikelboom, F., 935
Elased, K.M., 1221
Eliasson, M., 1579
El-Kebbi, I., 953
Elliott, E., 591
Elmansour, A., 1410
Elmer, D.S., 333
Elvius, M., 1563
Endert, E., 782, 1503
Endres, W., 413
Epstein, S., 1114
Erecińska, M., 1187
Erkelens, D.W., 293
Ernest, I., 1517
Eskes, T.K.A.B., 1475
Estrada, D.E., 591
Evans, R.W., 1196
Evans, S.J.W., 518
Everts, M.E., 1282
Evrin, P.-E., 1579

Fabbri, A., 1023
Fabrizi, M.L., 140
Fahrenbach, M.C., 808
Fasching, P., 385
Fehmann, H.-C., 787
Feillet, C., 1233
Feingold, K.R., 450
Fenstermacher, E.A., 1073
Ferber, S., 1346
Fermo, I., 1481
Ferrannini, E., 285, 1419
Ferretti, G., 1470
Ferro, F.M., 140
Fesmire, J.D., 1457
Finkelstein, J.D., 1475
Fiumara, C., 140
Flakoll, P.J., 211, 1509
Florant, G.L., 714
Föger, B., 633
Fok, A.C.K., 1148
Forsman, J.A., 1241
Forte, T.M., 1035
Fouque, F., 1030
Franklin, L.A., 1384
Friedberg, C.E., 501
Friedman, J.E., 1047
Frindik, J.P., 1457
Frölich, M., 640
Fruchart, J.C., 397
Fryer, L.G., 1171
Frystyk, J., 315
Fu, A., 1558
Fujioka, S., 32
Fukuda, H., 4
Fukushima, M., 714
Fumelli, P., 1470
Furman, B.L., 1221
Furukawa, S., 248, 299
Fyhrquist, F., 878

Gaber, A.O., 333
Galassi, R., 1470
Galli-Kienle, M., 1481
Galzerano, D., 174, 1426
Gambardella, A., 174
Ganguli, S., 1384
Garbagnati, E., 819
Geiss, H.C., 572
Genter, P., 98
Georgopoulos, A., 1063
Getz, G.S., 1006
Ghawji, M., 333
Ghigo, E., 223
Ghiselli, A., 965
Ghiselli, G., 1332
Ghizzoni, L., 372
Giboudeau, J., 822
Gilbert, M., 1079
Gin, H., 1300
Gingerich, R., 847
Gingerich, R.L., 860
Giovanelli, P., 1023
Giovannelli, G., 372
Girelli, A., 893
Giugliano, D., 1426
Giustina, A., 893
Givens, J.R., 584
Glazer, G., 204
Glueck, C.J., 647
Godsland, I.F., 446, 1275
Göke, B., 787
Goldberg, A.P., 190, 867
Goodwin, C.W., 913
Gooren, L.J.G., 935
Gossain, V.V., 923
Goto, M., 1248
Graham, S., 538
Graves, J.E., 847
Greger, N.G., 1457
Greif, R.L., 913
Gries, F.A., 227
Gross, A.S., 1373
Grunfeld, C., 450
Guerci, B., 1182
Guillot, C., 1300
Gullestad, L., 565
Gunderson, H., 38
Gupta, A.K., 665

Haak, T., 267
Habib, M.P., 1442
Hacker, T.A., 61
Haenni, A., 455
Haffner, S.M., 523, 599
Hagberg, J.M., 847, 867
Hahn, T., 719
Hall, J.L., 61
Hallén, J., 565
Hameed, M., 538
Hamer, T., 647
Hammarqvist, F., 1158
Hansen, E.S., 1201
Hansson, P., 565
Hardman, A.E., 836
Harris, E., 1462
Harry, D.S., 1171
Hartzell, C., 38
Hashimoto, Y., 44
Hathaway, D.K., 333
Hatton, M.W.C., 1430
Hauge, E.-M., 1201

Hauner, H., 227
Hauser, S., 1446
Havel, P.J., 860
Heath, G.W., 847
Heine, R.J., 501
Heiniluoma, K.M., 531
Hennemann, G., 1282, 1355
Henriksen, E.J., 994
Herman, W.H., 803
Hermansen, K., 1406
Hernández, E.R., 417
Hersey, W.C., III, 847
Heslin, M.J., 70
Hill, J.O., 211
Hilsted, J., 104, 315, 776
Hiramatsu, S., 766
Hirano, T., 248, 299
Hirschberg, A.L., 217
Hirst, K., 1241
Hjortdal, V.E., 1201
Hochgraf, E., 11
Hoffer, L.J., 320, 462, 1338
Hollenberg, C.H., 144
Hollis, B.W., 1093
Holloway, P.A., 974
Holst, J.J., 104
Horie, M., 1395
Hsu, B.Y.L., 1073
Hsu, C.J., 476
Hu, H., 913
Huang, T.-S., 544
Hübl, W., 1104
Hudson, R., 1318
Hughes, S.M., 333
Hughes, T.A., 333
Hurd, R.E., 793
Hvidberg, A., 104, 776

Iles, R.A., 518
Imura, H., 714
Ingerslev, J., 1406
Inoue, K., 766
Ipp, E., 98
Iron, A., 1300
Ishida, H., 1395
Ishida, K., 1214
Isobe, K., 739
Istfan, N.W., 279
Ito, T., 559
Iughetti, L., 372
Iuliano, L., 965

Jackson, R.L., 233
Jacob, R.J., 1329
Jacobs, M.A.J.M., 501
Jacotot, B., 270
Jain, S.K., 306
Jeevanandam, M., 1305
Jefferson, L.S., 476
Jensen, T., 328
Jéquier, E., 428
Jesprsen, J., 1379
Jones, R.H., 131
Jørgensen, J.O.L., 579, 872
Joven, J., 614
Jungmann, E., 267
Jurkovitz, C., 403

Kafonek, S.D., 1063
Kahn, C.R., 1346
Kahri, J., 1498
Kalhan, S.C., 378
Kaprio, J., 1255
Karter, D., 974
Kashyap, M.L., 665
Kato, S., 1395
Katori, T., 4
Katsuragawa, K., 44
Katz, I., 1543
Katz, M.S., 599
Katzel, L.I., 190
Kaufman, L.N., 1
Kawachi, M., 745
Kawai, K., 739
Kawamura, H., 714
Kazi, U., 1293
Kee, A.J., 1373
Keen, C.L., 1462
Kelley, D., 1549
Keno, Y., 32
Kerasin, E., 719
Kern, P.A., 348
Kimura, S., 4
Kindler, S., 144
Kinoshita, M., 44
Kirata, K., 360
Kirkland, J.L., 144
Kitabchi, A.E., 584, 1367
Kjeldsen, S.E., 423
Kleinknecht, C., 403
Klip, A., 591
Kloosterboer, H.J., 935
Knowler, W.C., 803
Kobatake, T., 32
Kobayashi, T., 1013
Kochman, M.L., 468
Kohanski, R.A., 1568
Kolanowski, J., 180
Koller, E., 1568
Konno, R., 1153
Kono, N., 745
Kosaka, K., 1013
Kotani, K., 32
Kraemer, F.B., 241
Krauss, R.M., 190, 655, 1438
Krenning, E.P., 1282, 1355
Krentz, A.J., 24
Kriauciunas, K.M., 1346
Krishna, S., 974
Kristan, M.A., 531
Kroon, A.A., 1164
Kruszynska, Y.T., 1171
Kujala, U.M., 1255
Kunkel, K., 670
Kuo, T.H., 604
Kushwaha, R.S., 1006
Kusnierz, J.P., 397
Kuwaijma, M., 745
Kvist, H., 1517
Kwong, L.K., 450
Laakso, M., 523
Lacy, D.B., 1266, 1509
Landry, J.-F., 18
Landsberg, L., 180, 509
Lange, M.P., 476
Lanza-Jacoby, S., 691
Lanzi, R., 1207
Laouari, D., 403
Lapin, H., 320
Larivière, F., 462
Larsen, J.L., 1241
Lau, D.C.W., 906
Laurenti, O., 965
Le Bricon, T., 899
Lechleitner, M., 633
Lee, B., 793
Leino, A., 523
Lemonnier, A., 945
Lerman, R.H., 982
Lerner, S., 855
Lestavel-Delattre, S., 397
Levy, J., 604, 1055
Levy, Y., 11
Lewis, D.S., 1006
Lewis-Barned, N.J., 1362
Li, W., 186
Librenti, M.C., 1481
Lichtenberg, R.C., 1248
Lickley, H.L.A., 1134
Lillioja, S., 803
Lim, S.K., 822
Lima, N., 969
Lin, R.C., 1523
Lindahl, B., 1579
Lindholm, C., 217
Ling, P.R., 279
Lithell, H., 455
Liu, C.C., 1114
Liu, R., 360
Liu, Z., 591
Llobet, J., 614
Loche, S., 223
Lochs, H., 1104
Lodi, A., 1023
Lönn, L., 1517
Lowe, S., 549
Lozano, J.L., 665
Luc, G., 397
Lucas, C.C., 822
Luk, J.K.H., 1531
Lundblad, D., 1579
Lupien, P.J., 18
Lynch, M.E., 1119

Maccario, M., 223
McCole, S.D., 847
Macdonald, L.M., 24
McGill, H.C., Jr, 1006
McGuinness, O.P., 1310
McIntyre, N., 1171
McNamara, P.D., 1073
McVie, R., 306
Madsen, D.C., 1373
Madsen, J., 109
Magni, F., 1481

Mamo, J.C.L., 299
Manatunga, A.K., 186
Mancini, A., 140
Manzi, P., 677
Manzoni, M.F., 1207
Marai, L., 487
Marchesi, C., 514
Marchesini, G., 1023
Mari, A., 1419
Marino, M., 677
Marsden, P.J., 1536
Martignat, L., 1410
Martina, V., 223
Mathe, D., 270
Matsuo, T., 32
Matsushima, T., 44
Matsuzawa, Y., 32, 745
Mauras, N., 357
May, M.M., 211
Mazzanti, L., 1470
Mazzeo, R.S., 1226
Mazzuoli, G., 1261
Mearkle, P.L., 1558
Medeiros-Neto, G., 969
Megens, J.A.J., 935
Meinders, A.E., 640
Méjean, L., 1182
Melton, M.E., 468
Mendez, B., 279
Mendoza, S., 647
Mengel, A., 842
Menick, D.R., 1389
Merimee, T.J., 357
Metsärinne, K., 878
Metzger, B.E., 830
Meyerovitch, J., 1346
Michalik, M., 1187
Miles, P.D.G., 1134
Miller, C.H., 633
Miller, S., 1241
Mineo, I., 745
Minisola, S., 1261
Mino, A., 390
Minocha, A., 1144
Miralles, R., 614
Mizuno, A., 1214
Moan, A., 423
Mokan, M., 1549
Mokshagundam, S.P., 1144
Møller, N., 579, 842, 872
Monnier, L.H., 1233
Monti, L.D., 1481
Mooradian, A.D., 1442
Moorjani, S., 18
Moran, C., 1310
Morand, C., 157
Moreschi, A., 1207
Moretti, C., 1287
Morselli, L., 706
Moser, A.H., 450
Motta, E., 1023
Muller, S., 1182
Munoz, K.A., 994
Murase, N., 135, 533
Murase, T., 1013
Murdoch, A., 1536
Murphy, S., 357
Murrell, S., 1310
Mykkänen, L., 523, 599

Nadeau, A., 18
Nagachinta, B., 887
Nagano, S., 248, 299
Nagata, I., 714
Nagata, Y., 1153
Naggert, J.K., 554
Nair, C.P.P., 1575
Nakai, T., 739
Nakai, Y., 714
Nakajima, H., 745
Nakanishi, K., 1013
Nardi, E., 367
Nasser, R., 1481
Nauman, J., 38
Nauta, J.J.P., 501, 935
Nawata, H., 766
Nelson, J., 1187
Nelson, R., 163
Nemeth, P.M., 481
Ness, G.C., 1446
Neufcour, D., 270
Newman, E., 70
Nguyen, L.B., 855, 1446
Nielsen, M.T., 104
Nilsson-Ehle, P., 90
Nishida, M., 32
Nishimura, T., 745
Nishina, P.M., 549, 554
Niwa, A., 1153
Nolan, K.M., 518
Nordby, G., 423
Nordenström, J., 1563
Normand, S., 428
Noronha, J.M., 1575
Nowotny, P., 385
Nuamah, I.F., 378

Oates, P.J., 492
Ochsenbein, A.F., 697
Odaka, H., 32
O'Dea, K., 728
Ohashi, S., 739
Ohneda, A., 771
Ohneda, K., 771
Okada, Y., 1395
Okamoto, Y., 1395
Okazaki, S., 44
Onkenhout, W., 640
Ono, A., 745
Onoma, M., 123
Onuma, E., 123
Orchard, T.J., 1196
Orlando, C., 435
Ørskov, H., 842
Ørskow, C., 104
Os, I., 423
Ozawa, K., 123

Pachiaudi, C., 428
Pacini, G., 367
Pacitti, M.T., 1261
Paigen, B., 549, 554
Palmieri, M.J., 1073
Paolisso, G., 174, 1426
Paradisi, R., 706
Paroulek, E., 1446
Parry, S.J., 860
Parzer, S., 385
Pasquali, R., 706
Patel, D.M., 378
Patsch, J.R., 633
Paul, H.S., 168
Pazzagli, M., 435
Pedersen, S.B., 842, 872
Pedrinola, F., 969
Peiris, A.N., 1144
Pencharz, P.B., 487
Pere, M.C., 1079
Perozim, L., 969
Perrin, M., 1233
Perry, I.C., 836
Persson, B., 883
Petersen, K.R., 1379
Petersen, S.C., 1305
Peterson, M.M., 1
Petrides, A.S., 85
Petruschke, T., 227
Petruzzi, E., 435
Pezzoli, A., 706
Phillips, M., 199
Piatti, P.M., 1481
Picard, J., 757
Piccardo, M.G., 367
Piccioni, A.L., 1261
Pijl, H., 640
Pinzani, P., 435
Pisters, P.W.T., 70
Plassart, F., 822
Podl, T.R., 808
Poehlman, E.T., 621, 1401
Poilet, R.J., 953
Pollock, M.L., 847
Pontiroli, A.E., 1207, 1481
Poon, I., 591
Popp-Snijders, C., 501
Poretsky, L., 1568
Pories, W.J., 1047
Pørksen, N., 842
Poupon, R., 822
Pourci, M.L., 945
Powrie, J.K., 131
Pozza, G., 1481
Pratt, H., 1362
Pratt, J.H., 186
Prior, D.E., 803
Procopio, M., 223
Proudler, A.J., 446
Prud'homme, D., 18
Pugliese, G., 492
Pukrittayakamee, S., 887, 974

Qi, Y., 1006
Quaade, F., 109

Raab, C., 267
Rabini, R.A., 1470

Radder, J.K., 640
Raikhel, I., 1063
Rasmussen, M.H., 315, 776
Rasmussen, O., 1406
Ratheiser, K., 385
Ravussin, E., 481
Rea, C.T., 1073
Reardon, C.A., 1006
Reeves, J.T., 1226
Reho, S., 706
Reitsma, J.B., 293
Remesy, C., 157
Rempinski, D., 604, 1047
Reuland, D.J., 1384
Revilla, M., 263, 417
Rey, C., 822
Reynet, C., 757
Rice, D.E., 211
Rice, K.S., 1006
Richelsen, B., 842, 872
Richter, W.O., 572
Rico, H., 263, 417
Rigalleau, V., 1300
Riou, J.-P., 428
Rissanen, J., 1318
Ritsch, A., 633
Ritter, M.M., 572
Rivabene, R., 677
Robbi, R., 390
Robinson, K.A., 1389
Robinson, K.M., 233
Rodby, R.A., 1126
Rodgerson, D., 1462
Rogus, E.M., 190
Rolland, R., 799
Romagnoli, E., 1261
Romijn, J.A., 1503
Roncari, D.A.K., 144
Rönnemaa, T., 523
Ronnenberg, W., 1093
Rosa, M.S., 367
Rosato, E.L., 691
Rosen, C.J., 1401
Roser, S., 953
Ross, R., 1318
Ross-Ouellet, B., 1430
Rossi, G., 514
Rosso, R., 1261
Roth, F., 1104
Rothwell, N.J., 1086
Rovner, D.R., 923
Rowe, B., 1373
Rubino, P., 174
Rucinski, B., 1114
Ruiz-Contreras, D., 263, 417
Russell, J.C., 538
Ruzumna, P.A., 1266

Saccomanno, F., 1426
Saï, P., 1410
Saijonmaa, O., 878
Sakamaki, R., 299
Sako, Y., 766
Saku, K., 360
Salen, G., 855, 1018, 1446
Sammartano, L., 140
Samols, E., 1144
Sana, S., 1255
Sans, T., 614, 1214
Santambrogio, G., 1481
Santini, F., 793
Sauer, L.A., 1488
Sauer, P.J.J., 1287
Sauerwein, H.P., 1503
Savage, S., 38
Savin, S.M., 378
Scarnecchia, L., 1261
Schade, D.S., 24
Schaefer, G.B., 1457
Schedl, H.P., 1093
Schenker, E., 1568
Schiffrin, A., 462
Schmitz, O., 842
Schouten, J.A., 199
Schütz-Hofmann, S., 697
Schwandt, P., 572
Segal, S., 1073
Segués, T., 1086
Seino, Y., 1395
Sejersted, O.M., 565
Sekas, G., 168
Selam, J.-L., 665
Senecat, O., 1410
Sesodia, S., 481
Sestini, R., 435
Sheetz, M.J., 233
Shefer, S., 855, 1018, 1446
Sherwin, R.S., 1329
Shewmon, D.A., 531
Shi, K., 1214
Shillabeer, G., 906
Shima, K., 1214
Shimizu, T., 745
Shimomura, I., 32
Shiomi, M., 360, 559
Shireman, R.B., 847
Shore, V., 1035
Sidelmann, J., 1379
Sidransky, H., 79
Siguel, E.N., 982
Silliman, K., 1035
Simoneau, J.-A., 814
Simsolo, R.B., 348
Singh, S.P., 1108
Sjöström, L., 1517
Skouby, S.O., 1379
Smith, G.D., 131
Smith, K.R., 61
Smith, R.C., 1373
Smith, S.M., 1
Sniderman, A.D., 257
Snyder, A.K., 1108
Soldan, S., 1332
Solera, M.L., 1470
Soni, T., 945
Sönksen, P.H., 131
Sorbara, L.R., 1568
Sørensen, S.S., 1201
Sosa, F., 647
Southward, S., 1430
Sparks, C.F., 681
Sparks, J.D., 681
Sparrow, D., 509
Speedy, A., 492
Speroni, G., 514
Spierto, F., 847
Spungen, A.M., 749
Srinivasan, S.R., 470, 1042
Srivastava, L., 923
Stagner, J.I., 1144
Stalenhoef, A.F.H., 1164
Stanley, W.C., 61
Starzl, T.E., 135, 533
Statt, M., 441
Steegers-Theunissen, R.P.M., 1475
Stefanick, M.L., 655, 917
Stern, J.S., 860
Stern, M.P., 599
Stevenson, J.C., 446
Stock, J.L., 531
Stock, M.J., 959, 1086
Stoltz, J.F., 1182
Stouthard, J.M.L., 1503
Stratta, R.J., 1241
Strowski, M., 787
Stuart, P., 1329
Subbaiah, P.V., 1126
Suchman, A.L., 204
Sulkers, E.J., 1287
Sum, C.F., 1148
Sun, A., 1531
Supanaranond, W., 887, 974
Supputamongkol, Y., 974
Sutherland, W.H.F., 310, 1362
Suzuki, S., 739
Swinkels, D.W., 1164
Syvänne, M., 1498
Sztalryd, C., 241

Tabachnik, E., 719
Taborsky, G.J., Jr., 860
Tai, J., 135, 533
Taimela, S., 1255
Takahaski, T., 248, 299
Tan, C.E., 1148
Tan, E.H., 1148
Tang, Z., 1568
Tanganelli, E., 435
Taniguchi, A., 714
Tappy, L., 428
Tarui, S., 32
Taskinen, M.-J., 1498
Tassi, C., 893
Tateishi, K., 360
Taus, M., 1470
Taveroff, A., 320, 462, 1338
Taylor, R., 163, 1536
Taylor, R.J., 1241
Taylor, S.I., 1568
Teasuro, P., 174
Teerlink, T., 501
Teng, C., 1079
Ten Hoor, F., 152
Teramoto, T., 44
Terry, R.B., 808

Thomas, C.M.G., 1475
Thompson, P.D., 808
Thomsen, C., 1406
Tillman, H.C., 1362
Tilton, R.G., 492
Tint, G.S., 855, 1018
Tischler, M.E., 994, 1451
Todesco, T., 390
Tokunaga, K., 32, 714
Toornvliet, A.C., 640
Törring, O., 1563
Toth, M.J., 621
Tremblay, A., 18, 814
Trentalance, A., 677
Trifon, S., 719
Trijbels, F.J.M., 1475
Tsuji, K., 1395
Tsukamoto, K., 44
Tsuura, Y., 1395
Tucker, M., 1384
Tung, A.S.F., 487
Turner, D., 665
Tze, W.J., 135, 533

Umeda, F., 766
Unterman, T., 830
Urbanovicius, V., 883
Urbini, D., 1023
Usadel, K.H., 267
Uurzemann, S., 385

Vaisman, N., 719, 1543
Valdez, R.A., 599
Valdiguié, P., 1470
Valentini, U., 893
Valle, D., 140
Van Buuren, J.C.J., 1282
Van der Hoek, H., 1355
Van der Mooren, M.J., 799
Van Dongen, P.W.J., 1164
Van Goudoever, J.B., 1287
Van Loon, B.J.P., 640
Vargas, J., 1462
Varricchio, M., 174, 1426
Varzaneh, F.E., 906
Vassault, A., 403
Vazquez, J.A., 1293
Velazquez, E.M., 647
Veneman, T., 1549
Venkatesan, N., 348
Venturoli, S., 706
Verboeket-van de Venne, W.P.H.G., 152
Verity, A., 1462
Verney, E., 79
Verstuyft, J., 554
Verza, M., 174
Vescovi, P.P., 514
Vilella, E., 614
Villa, L.F., 263, 417
Vilstrup, H., 328
Vinnars, E., 1158
Vinters, H.V., 1462
Virdis, R., 372
Visser, T.J., 1282
Viswanathan, G., 1575
Voerman, H.J., 199
Voet, H., 719, 1543
Vogel, R.L., 1144
Vokonas, P.S., 509
Volpe, C., 1426
Volpi, R., 514
Volta, C., 372
Von der Decken, A., 1158
Von Schoultz, B., 217
Vottero, A., 372
Vranic, M., 1134
Vranizan, K.M., 655, 917

Wahren, J., 626, 1419
Wajchenberg, L., 969
Waldhäusl, W., 385
Walgren, M.C., 51
Walker, R.J., 1362
Walton, C., 1275
Wang, J., 549
Wang, K.W., 1148
Wang, X., 333
Ward, K.D., 509
Wasserman, D.H., 1266
Watanabe, T., 44
Wattigney, W.A., 470
Wattimena, J.L.D., 1287
Watts, G.F., 131
Weber, A.B., 1329
Weeke, J., 579
Wehmeyer, N., 38
Wehrli, S.L., 1073
Weiss, D.J., 803
Weiss, S.T., 509
Welle, S., 441
Wentzel, L.S., 1509
Wernerman, J., 1158
Westerterp, K.R., 152
White, N.J., 887, 974
Wicek, D., 757
Widgren, B.R., 883
Wiersinga, W.M., 782
Williams, P.E., 1266, 1509
Williams, P.T., 655, 917, 1438
Williams, S.C.R., 518
Williamson, D.H., 887
Williamson, J.R., 492
Wilson, D.E., 450
Wilson, D.P., 1457
Winsett, R.P., 333
Winters, S.J., 168
Wirquin, E., 270
Wisneski, J.A., 61
Wohlfarter, T., 633
Wolf, R.F., 70
Wolfe, R.R., 670
Wolfel, E.E., 1226
Wong, E.F.C., 1531
Wong, K.-L., 906
Wong, N.D., 665
Wong, N.L.M., 1531
Wood, L.C., 450
Wood, P.D., 655, 917
Wouters, M.G.A.J., 1475
Wynn, V., 1275

Xia, J., 1568

Yair, S., 1543
Yamanaka, M., 44
Yamashita, K., 739
Yamatani, K., 1134
Yandrasitz, J.R., 1073
Yang, J., 940
Yasuda, H., 4
Yebras, M., 1086
Yki-Järvinen, H., 878
Yokota, C., 739
Yoneya, T., 123
Yoshida, S., 32
Young, J.B., 51, 180, 509
Young, V.R., 114
Yu, Y.-M., 114
Yurgalevitch, S.M., 808

Zacchello, F., 1287
Zadik, Z., 1543
Zamboni, M., 390
Zeller, W.P., 1248
Zello, G.A., 487
Zhang, B., 360
Zhang, M.-Y., 1523
Zhang, X.-j., 670
Zhao, B., 1563
Ziegler, O., 1182
Zinman, B., 591
Ziveri, M., 372
Zmuda, J.M., 808
Zuppi, P., 140
Zurio, F., 481

SUBJECT INDEX

AA(s), *see* Amino acid(s)
AA-193 (5-chloro-7,8-dihydro-3-phenylfuro[2,3g]-1,2-benzisoxazole-7-carboxylic acid, hypouricemic and uricosuric actions of, in hyperuricemia, 123-138
Absorptiometry, dual-energy x-ray, near-infrared interactance and, in study of four-compartment model, 417-422
Acetate
  drinking habits and changes in serum, 747
  see also 4β-Phorbol 12β-myristate 13α-acetate
Acetylated low-density lipoproteins (LDLs), effects of, on cholesterol synthesis and on apo E synthesis in peritoneal macrophages, 1523-1530

Acidosis, lactic, DCA for, in severe malaria, 974-981
Acipimox slow release (ACX-SR), lipolysis blockade with, normalizing nocturnal GH levels and pulsatility in obesity, 1207-1213
Acromegaly, IGF-I, IGF-II, IGF-BP1, IGF-BP2, and IGF-BP3 in, before and after adenomectomy, 579-583
ACTH (adrenocorticotropin hormone), *see* Corticotropin
α (alpha)-Actin mRNA (messenger ribonucleic acid), skeletal muscle, effects of immobilization on expression of, 1391
Acute febrile disease, albumin TER in, 699-700
Acute glucagon removal, effects of, on metabolic response to stress hormone infusion in conscious subjects, 1310-1317
Acute hyperinsulinemia, effects of, on plasma CETP activity in NIDDM and normal subjects, 1362-1366
Acute infectious disease, albumin TER correlating with plasma albumin concentrations in, 697-705
Acute stress in response to pertussis toxin, role of humoral β-cell tropic factors in hyperinsulinemia induced by, 1221-1225
ACX-SR (acipimox slow release), lipolysis blockade with, normalizing nocturnal GH levels and pulsatility in obesity, 1207-1213
Acyltransferase
  abnormal activities of, and accelerated CET in NS, 1126-1133
  glycerol-3-phosphate, fatty infiltration of liver during gram-negative sepsis and activities of, 693-694
  lecithin:cholesterol, *see* Lecithin:cholesterol acyltransferase
Adaptation
  adaptive changes in T_3 transmembrane transport and metabolism in livers of fed and fasted hypothyroidic and hyperthyroidic subjects, 1355-1361
  of glucose metabolism to short-term fasting, sex difference in, 1503-1508
  see also Adaptation to varying dietary protein intake
Adaptation to varying dietary protein intake
  leucine turnover and, 1338-1345
  short-term, to protein restriction, 320-327
Adenine dinucleotide diphosphate, *see* NADPH cytochrome C reductase in kidney BLM
Adenine diphosphate (ADP)
  and GDH activity in pancreatic islets, 1189
  in uremia, sucrose effects on, 407
Adenine nucleotides in uremia, sucrose effects on, 407
Adenomectomy, IGF-I, IGF-II, IGF-BP1, IGF-BP2, and IGF-BP3 in acromegaly before and after, 579-583
Adenosine monophosphate, *see* cAMP
Adenosine triphosphatase, *see* ATPase
Adenosine triphosphate, *see* ATP
Adenylate cyclase-activating polypeptide, pituitary, effects of, on secretion of adrenal hormone, glucagon, and insulin, and on glucose and lipid metabolism in conscious subjects, 739-744
Adipocyte(s)
  of amenorrheic subjects with PCOS, insulin action in, 1536-1542
  HSL expression in, regional differences in, 241-247
  MDL 29311 effects on LPL activities in, 237
  see also Adipocyte precursors
Adipocyte glycerol-3-phosphate dehydrogenase (G3PD), long-chain FA effects on, 147-149
Adipocyte precursors
  differentiation of, *see* Adipocyte precursors, differentiation of
  LPL activity in, effects of LCFAs on, 144-151
Adipocyte precursors, differentiation of
  ET-1 inhibiting, 227-232
  extracellular matrix components secreted by microvascular endothelial cells stimulating, 906-912
Adipose tissue (body fat; AT)
  clenbuterol effects on, 1087
  DEXA and near-infrared interactance of, in normal adult subjects, 417-422
  distribution of, *see* Adipose tissue distribution
  and effects of insulin on glucose metabolism and whole-body proteolysis, 443
  exercise and, *see* Adipose tissue, exercise and
  and hepatic insulin transit, 1145
  intercapsular brown, *see* Intercapsular brown adipose tissue
  intraabdominal, relationship between total serum T and, in obese women, 390-395; *see also* Adipose tissue distribution in obese women
  of vegetarians and nonvegetarians, RMR and, 622
  visceral, androgens, plasma lipids and, in obese men, 1318-1323
  see also Adipocyte(s); Adipose tissue lipoprotein lipase activities; Fat-free mass
Adipose tissue (AT), exercise and
  and brisk walking effects on PP lipemia in normolipidemic young men and women, 837
  impact of endurance exercising on skeletal muscle metabolism and AT in young men and women, 814-818
  increased LPL activities and plasma TG clearance and, 809
  serum CCK response to food intake and, 218
Adipose tissue (AT) distribution
  impact of obesity, energy restriction and, on IGF-I, IGF-BP3, insulin, and GH, 315-319; *see also* Adipose tissue distribution in obese women
  insulin sensitivity and, in normotensive men with heredity for hypertension, 883-886
  weight-independent effects of, on clinical, hormonal, and metabolic features of PCOS, 706-713
Adipose tissue (AT) distribution in obese women
  changes in body composition and, following therapy of Cushing's syndrome, 1517-1522
  relationship between total serum testosterone and, 390-395
  24-hour energy expenditure and substrate oxidation rates unaffected by, 109-113
Adipose tissue lipoprotein lipase (LPL) activities
  PB effects on, in NIDDM, 351, 353-354
  reduced responses of, in older athletes with silent myocardial ischemia, 190-198
ADP, *see* Adenine diphosphate
Adrenal androgens, familial influences on excretion rate of, during adrenarche, 186-189
Adrenal effects of low-dose aminoglutethimide therapy alone for advanced breast cancer in postmenopausal women, 723-727
Adrenal hormones
  PACAP effects on secretion of, in conscious subjects, 739-744
  see also specific adrenal hormones
Adrenal hyperplasia, nonclassic congenital, 24-hour pulsatile control of cortisol, 17-hydroxyprogesterone, and androstenedione release in prepubertal subjects with, 372-377
Adrenal weight (AW), dexamethasone effects on, 545
Adrenaline, *see* Epinephrine
Adrenarche, familial influences on excretion rate of adrenal androgens during, 186-189
α (alpha)-Adrenergic blockers in acute stress-induced hyperinsulinemia in response to pertussis toxin, 1223
β (beta)-Adrenergic blockers
  with β_2 agonism, effects of, on glucose and lipid metabolism in essential hypertension, 455-461
  effects of, on EPOC, 565-571
Adrenocortical activity, enhanced, as contributing factor to NIDDM in hyperandrogenic women, 584-590
Adrenocorticotropin hormone, *see* Corticotropin

Adrenosympathetic system, *see* Sympathoadrenal system
Adult-onset diabetes mellitus, *see* Non–insulin-dependent diabetes mellitus
Adult subjects, *see* Age; Male subjects; Men; Normal adult subjects; Women
A-DV (arterial-deep venous) differences in AAs, hyperinsulinemia and, 73
Advanced breast cancer, low-dose Ag therapy alone for, in postmenopausal women, adrenal effects of, 723-727
Adverse effects of nandrolone decanoate therapy, 206
Aerobic exercise, effects of weight loss by diet alone or combined vith, on body composition of older obese men, 867-871
African-American subjects, *see* Race and ethnicity
Ag (aminoglutethimide) therapy alone, low-dose, for advanced breast cancer in postmenopausal women, adrenal effects of, 723-727
Age
  and adaptation of glucose metabolism to short-term fasting, 1504
  of CF subjects, 164
  of cirrhotic subjects, 86, 1172
  of congestive heart failure subjects, 175
  and effects of insulin on glucose metabolism and whole-body proteolysis, 443
  energy metabolism, skeletal muscle biochemistry and, 482
  of essentially hypertensive subjects, effects of β-blockers and, 457
  and excretion rate of adrenal androgens during adrenarche, 187, 188
  of exercising men, *see* Age of exercising men
  of exercising women, *see* Age of exercising women
  and four-compartment model of body composition, 418, 419
  and hepatic insulin transit, 1145
  of hypercholesterolemic subjects, 573, 400
  of hyperinsulinemic subjects, 71, 804, 1580
  of hyperthyroidic subjects, 1024
  of hypertriglyceridemic subjects, 573
  of IDDM subjects, *see* Age of IDDM subjects
  of IGT subjects, 715
  of infectious and malignant disease subjects, 698
  insulin sensitivity and, 424, 525-527
  and iodothyronine metabolism, 795
  of ISS subjects, 358
  of lithium therapy subjects, 1565
  of malaria subjects, 975
  of multiple trauma victims, 1306
  of NCCAH subjects, 373
  of NIDDM subjects, *see* Age of NIDDM subjects
  of noncirrhotic alcoholic subjects, 368
  of normolipidemic subjects, 1333, 1334
  of normotensive men, insulin sensitivity and, 884
  of obese subjects, *see* Age of obese subjects
  of paraplegic and quadriplegic veterans, 750
  of PCOS subjects, *see* Age of PCOS subjects
  of PKT subjects, 1242
  of postpubertal women, bone mineral content and density and, 264
  of pregnant subjects with homozygous FH, 1165
  of prepubertal lean girls, uric acid homeostasis and, 820
  of preterm infants fed MCT-containing formula, 1288
  serum lipid levels and, *see* Age, serum lipid levels and
  and testosterone and DHEA concentrations in nondiabetic men, glucose and insulin concentrations and, 600, 601
  and THL effects on postprandial lipemia, 294
  of type I-A familial OI subjects, 1262
  of vegetarians and nonvegetarians, RMR and, 622
Age (*Continued*)
  see also Children; Girls; Normal adult subjects *and entries beginning with terms*: Neonatal, Older, Young
Age, serum lipid levels and
  and association between plasma insulin, insulin sensitivity, and serum lipid levels, 525-527
  in GH-deficient men, 200
  and nandrolone decanoate effects on serum lipids, 205
  and relationship between urinary excretion of E and serum lipid levels, 511
Age of exercising men
  and effects of endurance training on IGF-I, 1403
  and kinetics of plasma lipids, apos, and CETP after endurance exercise, 634
  normolipidemic, and brisk walking effects on PP lipemia, 837
  older men, *see* Older men, exercising
  and prevalence of NIDDM, hypertension, and ischemic heart disease in former athletes, 1256-1258
  young men, *see* Young men, exercising
Age of exercising women
  and blood pressure during submaximal exercise, 19
  and effects of endurance training on IGF-I, 1403
  LPL activity and plasma TG clearance and, 809
  older women, *see* Older women, exercising
  and serum CCK response to food intake, 218
  young women, *see* Young women, exercising
Age of IDDM subjects
  and ATP release in erythrocytes, 436
  with chronic renal failure, 334
  and erythrocyte aggregation, 1183
  GSH erythrocyte content and, 307
  oxidized lipids and, 1198
  PP TGRLP effects in, 1064
  of pregnant IDDM subjects, 379
  RCT alterations associated with implantable IP insulin delivery and, 666
  using oral contraceptives, 1380
Age of NIDDM subjects
  AAs and, 429, 641
  and ATP release in erythrocytes, 436
  with and without CAD, plasma CETP activity and, 1499
  and effects of acute hyperinsulinemia on plasma CETP activity, 1363
  and insulin production following IV glucose, arginine, and valine, 386
  Lps and, *see* Age of NIDDM subjects, Lps and
  mepacrine effects and, 132
  of obese NIDDM men, 429, 1048
  postprandial glucose utilization and, 1550
  and prevalence of NIDDM, hypertension, and ischemic heart disease in former athletes, 1256-1258
  pyridostigmine effects on GH response to GH-RH and, 894
  and relationship between oxidative stress and insulin action, 1427
  and urea synthesis in controlled NIDDM, 329
  and von Willebrand factor levels after high-MUFA diet, 1407
Age of NIDDM subjects, Lps and
  and insulin sensitivity, 501, 505, 506
  and PP amplification of Lp abnormalities, 271
Age of obese men
  and effects of ACX-SR blockade of lipolysis on nocturnal GH levels and pulsatility, 1208
  and impact of obesity, AT distribution, and restricted energy intake on IGF-I, IGF-BP3, and GH, 316
  with NIDDM, 429, 1048

Age of obese men (*Continued*)
of older obese men, effects of weight loss by diet or combined with aerobic exercise on body composition, 868
with uncomplicated obesity, association between insulin sensitivity, FFAs, and TG metabolism independent of, 1276
VAT, plasma lipids, androgens and, 1319, 1321
Age of obese subjects
of JCR:LA corpulent subjects, 539
of prepubertal obese girls, uric acid homeostasis and, 820
see also Age of obese men; Age of obese women
Age of obese women
with Cushing's syndrome, 1518
and effects of ACX-SR blockade of lipolysis on nocturnal GH levels and pulsatility in, 1208
and impact of obesity, AT distribution, and restricted energy intake on IGF-I, IGF-BP3, and GH, 316
with NIDDM, 429, 1048
with or without NIDDM, insulin-induced decline of plasma AA concentrations and, 641
normolipidemic, effects of brisk walking on, 837
of normotensive exercising women, 19
and relationship between total serum T and intraabdominal AT, 391, 392
and 24-hour EE and substrate oxidation rates unaffected by AT distribution, 110
Age of PCOS subjects, 708
and defects in insulin metabolism, 1368
and insulin action in adipocytes, 1537
with insulin resistance, 1569
Metformin therapy and, 649
Aggregation
erythrocyte, in IDDM, and its relationship to plasma factors, 1182-1186
platelet, lovastatin normalizing, in hypercholesterolemia, 11-17
AICA (5-amino-4-imidazolecarboxamide)-ribosome, influence of, on extracellular pH effects on hepatocyte lactate uptake, 159-160
Alanine
blood, *see* Blood alanine
effects of, on NH_3 in hyperthyroidism, 1025
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
in hepatic failure and uremia, 1106
insulin effects on metabolism of, 73
plasma, *see* Plasma alanine
in pregnancy, 1082-1084
see also D-Alanine; L-Alanine; Blood alanine
D-Alanine, effects of, on AA levels in D-amino acid oxidase deficiency, 1153-1157
L-Alanine
in amino acid mixture supplying arginine-free or arginine-rich diet, 115
effects of, on AA levels in D-amino acid oxidase deficiency, 1153-1157
Albumin
in IDDM, *see* Albumin in IDDM
in NS, 1129
plasma, *see* Plasma albumin
serum, *see* Serum albumin
TNF-α effects on production of, in hepatocytes, 476-480
urinary excretion of, *see* Urinary excretion, albumin
in well-nourished mildly cirrhotic subjects, 86
see also Prealbumin
Albumin in IDDM
and increased erythrocyte platelet aggregation in IDDM, 1183, 1184
and Lp composition following chronic renal failure, 334, 335
Alcohol intake
and association between insulin sensitivity, FFAs, and TG metabolism independent of uncomplicated obesity, 1276
effects of daily, on ethanol-induced hyperuricemia, 745-748
and glucose-deprivation neurotoxicity in cortical cells, 1108-1113
in NIDDM, insulin sensitivity, Lps and, 502, 506
by PCOS subjects, AT distribution and, 708
urinary excretion of epinephrine, serum lipid levels and, 511
Alcoholic subjects
noncirrhotic, hepatic insulin extraction in, following alcohol withdrawal, 367-371
see also Cirrhosis
Aldose reductase (AR), effects of inhibition of, on erythrocyte GSH redox status in NIDDM, 965-968
Aldosterone, effects of low-dose Ag therapy of advanced breast cancer in postmenopausal women on, 724
Alkaline phosphatase (ALP) in malaria patients, 975
Alleles, TAP, in IDDM, 1015, 1016
Alloxan-diabetes, effects of ICV somatostatin octapeptide on hormonal and metabolic responses to stress in, 1134-1143
ALP (alkaline phosphatase) in malaria patients, 975
Alpha (α)-actin mRNA (messenger ribonucleic acid), skeletal muscle, effects of immobilization on expression of, 1391
Alpha (α)-adrenergic blockers in acute stress-induced hyperinsulinemia in response to pertussis toxin, 1223
Alpha (α)-ketoglutarate, ornithine, limiting muscle protein breakdown without stimulation of tumor cell growth in Yoshida ascites hepatoma, 899-905
[^{14}C]Alpha (α)-ketoisocaproic acid (α-KIC), hyperinsulinemia effects on kinetics of, 74
Alpha (α)-linoleic acid, balance method to determine accumulation, metabolism, and oxidation of, in pregnancy, 940-944
Alpha (α)-lipoproteins, *see* High-density lipoprotein(s)
Alpha (α)-macroglobulin, effects of high-MUFA diet on, 1408
Altitude, sympathoadrenal response to high, as determined by urinary and arterial EPI and NE, 1226-1232
Amenorrheic subjects with PCOS, insulin action in adipocytes of, 1536-1542
Amide(s), proglucagon 78-107, *see* Glucagon-like peptide 1
Amino acid(s) (AAs)
D-alanine administration effects on levels of, in D-amino acid oxidase deficiency, 1153-1157
dipeptide structure effects on clearance of, 1373-1378
effects of hyperinsulinemia with infusions of, on skeletal muscle protein turnover, 70-78
effects of supratherapeutic dose of androgenic steroids on basal and insulin-stimulated metabolism of, 1266-1274
glucagon role in control of metabolism of, 1509-1516
hepatic, *see* Hepatic amino acids
in hepatic failure and uremia, 1106
influence of diet with and without, on polyamine urinary excretion in multiple trauma victims, 1305-1309
in lean subjects, *see* Non-obese subjects, AAs in
in obesity, *see* Obesity, AAs in
OKG effects on Yoshida ascites hepatoma on, 901-902
plasma, *see* Plasma amino acids
protein ingestion effects on concentrations of, 629
skeletal muscle protein, *see* Skeletal muscle protein, AAs in
see also specific amino acids
D-Amino acid oxidase deficiency, effects of D-alanine on AA levels in, 1153-1157

Aminoglutethimide (Ag) therapy alone, low-dose, for advanced breast cancer in postmenopausal women, adrenal effects of, 723-727
5-Amino-4-imidazolecarboxamide (AICA)-ribosome, influence of, on extracellular pH effects on hepatocyte lactate uptake, 159-160
Amino-nitrogen, hepatic conversion of, to urea in hyperthyroidism, 1023-1029
Ammonia (NH_3)
  effects of alanine and thionamide on, in hyperthyroidism, 1025
  hypocaloric high-protein diet effects on, 1484
AMP (adenosine monophosphate), *see* cAMP
Amylin, relative hypersecretion of insulin to, in STZ-induced NIDDM, effects of insulin therapy on, 766-770
AN (anorexia nervosa), naloxone effects on preprandial and PP GH response to GH-RH in, 140-143
Anabolic effects of clenbuterol
  digoxin effects on, 959-964
  of long-term clenbuterol treatment and withdrawal, 1086-1092
Anabolic steroids (ASs)
  effects of, on serum lipids, 204-210
  see also specific anabolic steroids
Androgens
  adrenal, familial influences on excretion rate of, during adrenarche, 186-189
  altered serum, hyperinsulinemia associated with irregular menses and, in Pima Indian women, 803-807
  effects of supratherapeutic dose of, on basal and insulin-stimulated glucose and amino acid metabolism, 1266-1274
  VAT, plasma lipids and, in obese men, 1318-1323
  see also Hyperandrogenic women *and specific androgens*
Android obesity, effects of calorie restriction with and without D-fenfluramine therapy on GH release after stimulation with GRF in, 969-973
Androstenedione
  effects of low-dose Ag therapy of advanced breast cancer in postmenopausal women on, 724
  in hyperandrogenic NIDDM women, 585
  in PCOS, *see* Androstenedione in PCOS
  24-hour pulsatile control of release of cortisol, 17-hydroxyprogesterone and, in normal and 21-hydroxylase-deficient prepubertal children, 372-377
Androstenedione in PCOS, 709
  hyperandrogenemia and, 1369
  insulin action in adipocytes and, 1537
  Metformin therapy and, 649
  plasma levels of, 1569
Anemia, pernicious, vitamin B_{12} and etidronate reversing severe osteoporosis in, 468-469
ANF (atrial natriuretic factor), cGMP responses to, 1531-1535
Anorexia nervosa (AN), naloxone effects on preprandial and postprandial GH response to GH-RH in, 140-143
Anterior pituitary cells, T_3S uptake and suppression of TSH secretion in, 1282-1286
Anthropometric indices
  effects of exercise on fat-free mass, REE and, in obese men, 1148-1152
  see also specific anthropometric indices
Antigens
  pancreatic islet, neonatal glucose and arginine injections increasing expression of, in lean diabetic subjects, 1410-1418
  transporter associated with processing of, lack of association between Japanese IDDM and, 1013-1017
Antiglucocorticoid(s), RU38486 as, effects of, on metabolism of skeletal muscle protein in unweighted muscle, 1451-1455
Aorto-pulmonary arterial O_2 (oxygen) difference, protein ingestion and, 627
Apheresis, LDL, as long-term therapy of pregnancy with homozygous FH, 1164-1170
APM (aspartame) with high-protein diet, effects of, on plasma phenylalanine concentrations in heterozygotes for PKU, 413-416
Apo(s), *see* Apolipoprotein(s)
Apolipoprotein(s) (apos)
  and brisk walking effects on PP lipemia in normolipidemic subjects, 837
  effects of Metformin therapy of PCOS on, 650
  in exercising women, 809
  in FH, effects of lipid-lowering diet on, 400
  in GH-deficient children during GH therapy, 1457-1461
  plasma, *see* Plasma apolipoprotein(s)
  postprandial, in NIDDM, 272
  serum, *see* Serum apolipoprotein(s)
  see also Lipoprotein *and specific apolipoproteins*
Apolipoprotein A (apo A)
  effects of Metformin therapy of PCOS on, 649
  VAT, androgens and, in obese men, 1319
Apolipoprotein A-I (apo A-I)
  effects of phenotype and dietary fats on, 1009
  in exercising women, 809
  in FH, effects of lipid-lowering diet on, 400
  GH deficiency and, 1458, 1459
  in IDDM, *see* Apolipoprotein A-I in IDDM
  in NIDDM, *see* Apolipoprotein A-I in NIDDM
  in PCOS, 649, 710
  plasma, *see* Plasma apolipoprotein A-I
  serum, *see* Serum apolipoprotein A-I
  T therapy effects on, 936, 937
Apolipoprotein A-I (apo A-I) in IDDM
  with chronic renal failure, effects of pancreas-kidney transplantation on, 338, 339
  and effects of insulin on C synthesis in newly-treated IDDM, 1234, 1237
  erythrocyte aggregation and, 1183
  and lipid peroxidation in LDLs and erythrocyte membranes, 1471
  and RCT, 667
Apolipoprotein A-I (apo A-I) in NIDDM
  and autologous blood transfusions for repeated phlebotomies, 616
  insulin sensitivity and, 505
  and lipid peroxidation in LDLs and erythrocyte membranes, 1471
  newly insulin-treated NIDDM effects on, 1234, 1237
Apolipoprotein A-II (apo A-II)
  in exercising women, 809
  in FH, effects of lipid-lowering diet on, 400
  in IDDM, 339, 339, 667
  plasma, *see* Plasma apolipoprotein A-II
  T therapy effects on, 936, 937
Apolipoprotein A-III (apo A-III) in exercising women, 809
Apolipoprotein B (apo B)
  in exercising women, 19, 20, 809
  in FH, effects of lipid-lowering diet on, 400
  GH deficiency and, 1458, 1459
  in IDDM, *see* Apolipoprotein B in IDDM
  LDL amount of cholesterol relative to, in children, 1042-1046
  liver regeneration and secretion of, by hepatocytes, following partial hepatectomy, 681-690
  in NIDDM, *see* Apolipoprotein B in NIDDM

Apolipoprotein B (apo B) (*Continued*)
in PCOS, AT distribution and, 710
plasma, *see* Plasma apolipoprotein B
serum, *see* Serum apolipoprotein B
in STZ-DM, 301, 302
T therapy effects on, 936, 937
VAT, androgens and, in obese men, 1319
Apolipoprotein B (apo B) in IDDM
and cholesterol synthesis in newly-treated IDDM, 1234, 1237
erythrocyte aggregation and, 1183, 1184
and lipid peroxidation in LDLs and erythrocyte membranes, 1471
RCT and, 667
Apolipoprotein B (apo B) in NIDDM
and effects of insulin on cholesterol synthesis, 1234, 1237
and lipid peroxidation in LDLs and erythrocyte membranes, 1471
with repeated phlebotomies, 616
Apolipoprotein C-III (apo C-III)
in FH, effects of lipid-lowering diet on, 400
GH deficiency and, 1458, 1459
Apolipoprotein E (apo E)
CM-R effects on synthesis of, in Hep G2 cells, 44-50
effects of acetylated and oxidative-modified LDLs on synthesis of, in peritoneal macrophages, 1523-1530
in FH, effects of lipid-lowering diet on, 400
Apolipoprotein E (apo E) phenotypes, relationship between serum Lps and obesity in children with different, 470-475
AR (aldose reductase), effects of inhibition of, on erythrocyte GSH redox status in NIDDM, 965-968
Arginine (ARG)
and effects of C-terminal glucagon fragments on insulin secretion, 772-773
effects of FFA interaction with, on GH secretion, 223-226
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
insulin production following IV glucose, valine and, in patients with impaired glucose tolerance and in NIDDM, 385-389
in multiple trauma victims, 1308
neonatal injections of, enhancing diabetes and increasing islet antigen expression in non-obese diabetic subjects, 1410-1418
plasma, kinetics of, in response to arginine-free diet in men, 114-122
Arterial blood, hepatic, in pregnancy, 1080-1082
Arterial blood flow (BF), hepatic, in pregnancy, 1080
Arterial-deep venous (A-DV) differences in AAs, hyperinsulinemia and, 73
Arterial epinephrine (E; EPI; adrenaline) in determination of sympathoadrenal response at high altitude, 1226-1232
Arterial glucagon, and postprandial glucose utilization in NIDDM, 1551-1552
Arterial glucose, and postprandial glucose utilization in NIDDM, 1551-1552
Arterial insulin, and postprandial glucose utilization in NIDDM, 1551-1552
Arterial ischemia, ET release in myocutaneous island flaps in response to gradually insetting, 1201-1206
Arterial lactate, effects of increased concentration of, on hepatoma lactate release, 1490-1492
Arterial norepinephrine (NE) in determination of sympathoadrenal response at high altitude, 1226-1232
Arterial plasma amino acids (AAs), hyperinsulinemia and concentration of, 73
Arteriohepatic venous O_2 (oxygen) difference, protein ingestion and, 627
Arteriovenous (AV)-difference method in measurement of glucose absorption and production following oral glucose, 1419-1425
AS(s), *see* Anabolic steroids
Ascites hepatoma, Yoshida, OKG limiting muscle protein breakdown in, without stimulation of tumor cell growth, 899-905
Asparagine, glucagon role in control of metabolism of, 1512, 1513
Aspartame (APM; L-aspartyl-L-phenylalanine methyl ester) with high-protein diet, effects of, on plasma phenylalanine concentrations in heterozygotes for PKU, 413-416
Aspartate
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
plasma, after adaptation to diets with different protein content, 1341
D-Aspartate, effects of receptor antagonists of *N*-methyl-, on glucose deprivation-induced neurotoxicity, 1110
L-Aspartate in AA mixture supplying arginine-free or arginine-rich diet, 115
Aspartate transaminase, plasma, in cirrhotic subjects, 1172
L-Aspartyl-L-phenylalanine methyl ester (aspartame) with high-protein diet, effects of, on plasma phenylalanine concentrations in heterozygotes for PKU, 413-416
Astrocytes, ethanol effects on glutamate uptake by, 1111
AT, *see* Adipose tissue
Ataxia, cerebellar, Cu deficiency and development of, 1462-1463
Atherosclerosis in genetically obese subjects, 554-558
Athletes, *see* Men, exercising; Women, exercising *and specific forms of exercise; for example*: Running
ATP (adenosine triphosphate)
release of, by osmotic shock and HbA_{1c} in erythrocytes of IDDM and NIDDM subjects, 435-440
in uremia, sucrose effects on, 407
ATPase (adenosine triphosphatase)
$(Ca^{2+}+Mg^{2+})$-, *see* $(Ca^{2+}+Mg^{2+})$-ATPase in kidney BLM, hormone-specific defect in insulin regulation of
$Na^{+}+K^{+}$-, in kidney BLM of STZ-induced NIDDM subjects, 606
Atrial natriuretic factor (ANF), cGMP responses to, 1531-1535
Atrophy, skeletal muscle, due to running, protein content and synthesis with, 994-999
Autologous blood transfusions for repeated phlebotomies in NIDDM, 614-620
AV (arteriovenous)-difference method in measurement of glucose absorption and production following oral glucose, 1419-1425
AW (adrenal weight), dexamethasone effects on, 545
Awake subjects, *see* Conscious subjects

Balance method to determine accumulation, metabolism, and oxidation of linoleic and α-linoleic acids in pregnancy, 940-944
Basal metabolism, glucose and AA, effects of supratherapeutic doses of androgenic steroids on, 1266-1274
Basal rates of heat production, 932
Basolateral membrane, kidney, *see* $(Ca^{2+}+Mg^{2+})$-ATPase in kidney BLM, hormone-specific defect in insulin regulation of
BCAAs (branched-chain amino acids), *see* Amino acid(s)
Beta (β)-adrenergic blockers, *see* β-Adrenergic blockers

Beta (β) cells
beta TC-1 cells, interaction between GLP-1 and somatostatin-14 characterized on signal transduction, proinsulin gene expression and, 787-792
in neonatal STZ-DM, Ca^{2+}-channel currents of, 1395-1400
response of, to alcohol withdrawal by noncirrhotic alcoholic subjects, hepatic insulin extraction and, 367-371
role of tropic factors of, in acute stress-induced hyperinsulinemia in response to pertussis toxin, 1221-1225
17Beta (β)-estradiol-dihydrogesterone therapy, changes in LDL with, 799-802
Beta (β)-hydroxybutyrate (OHB), and glucagon in control of protein and AA metabolism, 1511, 1512
Beta (β)-lipoproteins, *see* Low-density lipoprotein(s)
Beta (β)-oxidation, hepatic peroxisomal, 169
4Beta (β)-phorbol 12β-myristate 13α-acetate, *see* 4β-Phorbol 12β-myristate 13α-acetate
BF, *see* Blood flow
Bicarbonate, *see* HCO_3
Bicycle marathon, kinetics of plasma lipids, apos, and CETP after, 633-639
Bile acids, lovastatin and
CDCA and lovastatin effects on plasma cholestanol levels and bile acid metabolism in CTX, compared, 1018-1022
in regulation of ileal HMG-CoA reductase activity, 1446-1450
Bilirubin, plasma, in cirrhotic subjects, 1172
Binding protein(s)
GH-, levels of, in ISS subjects, 357-359
see also Insulin-like growth factor–binding protein-1; Insulin-like growth factor–binding protein-2; Insulin-like growth factor–binding protein-3
Biochemical hyperparathyroidism, long-term lithium therapy and, 1563-1567
BLM (basolateral membrane), kidney, *see* $(Ca^{2+}+Mg^{2+})$-ATPase in kidney BLM, hormone-specific defect in insulin regulation of
Blood alanine
in controlled NIDDM, urea synthesis and, 330
effects of supratherapeutic dose of androgenic steroids on, 1272
hypocaloric high-protein diet effects on, 1482
in severe *Plasmodium falciparum* infection, 889
Blood ethanol, drinking habits and changes in, 747
Blood flow (BF)
and bone mineral content and density in young postpubertal women, 264, 265
capillary, in myocutaneous island flaps with gradually insetting venous stasis and/or arterial ischemia, 1203
effects of protein ingestion on, 626-632
hepatic, portal, and hepatic arterial, in pregnancy, 1080
regional myocardial, in hyperglycemic STZ-DM, 65
Blood folate, fasting, maternal hyperhomocysteinemia and, 1477
Blood fructosamine, AR inhibition effects on, in NIDDM, 967
Blood glucose
concentrations of, during energy intake restriction, 317
fasting, *see* Fasting blood glucose
hypocaloric high-protein diet effects on, 1482
in IDDM, 667, 1183, 1184
in NIDDM, 330, 967
in normotensive men, insulin sensitivity and, 885
in obesity with STZ-DM, effects of starvation on, 1350
Blood glutamine, effects of supratherapeutic dose of androgenic steroids on, 1272
Blood glycerol
effects of supratherapeutic dose of androgenic steroids on, 1272
hypocaloric high-protein diet effects on, 1482
in severe *Plasmodium falciparum* infection, 889
Blood 3-hydroxybutyrate (3-OHB) in cirrhotic subjects, 1173
Blood lactate
in cirrhotic subjects, 1173
drinking habits and changes in, 747
effects of supratherapeutic dose of androgenic steroids on, 1269-1270
hypocaloric high-protein diet effects on, 1482
in severe *Plasmodium falciparum* infection, 889
Blood pressure (BP)
effects of Metformin therapy of PCOS on, 647-654
fasting, of CF subjects, 164
high resting, during submaximal exercise by obese normotensive women, as risk factor for cardiovascular disease, 18-23
in hyperinsulinemia, 1580
of IDDM subjects using oral contraceptives, 1380
insulin sensitivity and, *see* Blood pressure, insulin sensitivity and
of malaria patients, 975
and nandrolone effects on serum lipids, 205
of nephrotic hypertriglyceridemic subjects, 249
in NIDDM, *see* Blood pressure in NIDDM
in STZ-DM, 64, 494
of vegetarians and nonvegetarians, RMR and, 622
see also Hypertension; Normotension
Blood pressure (BP), insulin sensitivity and
association between insulin sensitivity, FFAs, and TG metabolism independent of uncomplicated obesity, 1276
determinants of insulin sensitivity and their consequences for, in NIDDM, 501-508
and relationship between insulin sensitivity and hemorrheologic factors, 424, 425
Blood pressure (BP) in NIDDM
determinants of insulin sensitivity and their consequences for, 501-508
insulin action and oxidative stress and, 1427
plasma CETP, Lps and, 1363
Blood pyruvate, hypocaloric high-protein diet effects on, 1482
Blood temperature, effects of protein ingestion on, 626-632
Blood transfusions, autologous, for repeated phlebotomies in NIDDM, 614-620
Blood urea nitrogen (BUN) in multiple trauma victims, 1307
BMI, *see* Body mass and body mass index
BNP (brain natriuretic peptide), cGMP responses to, 1531-1535
Body composition
changes in, with GH therapy of children of short stature, 1543-1548
changes in AT distribution and, in women with Cushing's syndrome following therapy, 1517-1522
clenbuterol effects on, 960, 1087
endurance exercise effects on, in older women, 847-854
of normal subjects, DEXA and near-infrared interactance in study of four-compartment models in, 417-422
of older men, *see* Body composition of older men
see also Adipose tissue; Fat-free mass; Lean body mass
Body composition of older men
endurance exercise effects on, 847-854
obese, effects of weight loss by diet alone or combined with aerobic exercise on, 867-871
Body fat, *see* Adipose tissue
Body mass and body mass index (BMI)
of CF subjects, 164
of cirrhotic subjects, 1172

Body mass and body mass index (BMI) (*Continued*)
of congestive heart failure subjects, 175
of essentially hypertensive subjects, effects of β-blockers and, 457
of exercising men, *see* Body mass and body mass index of exercising men
of exercising women, *see* Body mass and body mass index of exercising women
D-fenfluramine therapy effects on, 970
and four-compartment model, 418, 419
of GH-deficient men, serum lipid levels and, 200
and hepatic insulin transit, 1145
of hyperinsulinemic subjects, 71, 804, 1580
hypocaloric high-protein diet effects on, 1482
of IDDM subjects, *see* Body mass and body mass index of IDDM subjects
of IGT subjects, 715
insulin sensitivity, *see* Body mass and body mass index, insulin sensitivity and
of lithium therapy patients, 1565
of multiple trauma victims, 1306
of NIDDM subjects, *see* Body mass and body mass index of NIDDM subjects
of normolipidemic subjects, 1333, 1334
in obesity, *see* Body mass and body mass index in obesity
of PCOS subjects, *see* Body mass and body mass index of PCOS subjects
of PKT subjects, 1242
of prepubertal lean girls, uric acid homeostasis and, 820
and testosterone and DHEA concentrations in nondiabetic men, glucose and insulin concentrations and, 600, 601
and THL effects on postprandial lipemia, 294
urinary excretion of epinephrine, serum lipid levels and, 511
of vegetarians and nonvegetarians, RMR and, 622
of young postpubertal women, bone mineral content and density and, 264, 265
see also Adipose tissue; Body weight; Fat-free mass; Height; Lean body mass; Waist-to-hip ratio; Waist-to-thigh circumference ratio
Body mass and body mass index (BMI), insulin sensitivity and
and association between insulin sensitivity, FFAs, and TG metabolism independent of uncomplicated obesity, 1276
Lps and, in NIDDM, 502, 505
in normotensive men, 885
and relationship between insulin sensitivity and hemorrheologic factors, 424, 425
serum lipids and Lps and, 525-527
Body mass and body mass index (BMI) of exercising men
and effects of weight loss in older men, 868, 918
and lipid kinetics, 634
and PP lipidemia in older athletes, 192
and prevalence of hypertension, ischemic heart disease, and NIDDM in former athletes, 1257-1258
Body mass and body mass index (BMI) of exercising women
exercise blood pressure and risk factors for CV disease and, 19, 20
and LPL activities and plasma TG clearance, 809
and serum CCK response to food intake, 218
Body mass and body mass index (BMI) of IDDM subjects
and effects of acute hyperinsulinemia on plasma CETP activity, 1363
and effects of newly insulin-treated IDDM on cholesterol synthesis, 1234
erythrocyte aggregation and, 1183
Body mass and body mass index (BMI) of IDDM subjects (*Continued*)
and esterified cholesterol accumulation in THP-1 macrophages, 1064
using oral contraceptives, endothelial function and, 1380
Body mass and body mass index (BMI) of NIDDM subjects
with and without CAD, plasma CETP activity and, 1499
and effects of newly insulin-treated NIDDM on cholesterol synthesis, 1234
effects of weight loss by diet alone or combined with aerobic exercise on, 868
and enhanced adrenocortical activity contributing to NIDDM in hyperandrogenic women, 585
and glucose metabolism in skeletal muscle, 1048
and insulin production following IV glucose, arginine, and valine, 386
and lipid infusion effects on glucose R_a, 1301
Lps and insulin sensitivity and, 502, 505
mepacrine effects and, 132
of obese men and women with and without NIDDM, insulin-induced plasma AA concentrations and, 641
and postprandial amplification of Lp abnormalities, 271
postprandial glucose utilization and, 1550
and prevalence of hypertension, ischemic heart disease, and NIDDM in former athletes, 1257-1258
pyridostigmine effects on GH response to GH-RH and, 894
and relationship between oxidative stress and insulin action, 1427
urea synthesis and, 329
and von Willebrand factor levels after high-MUFA diet, 1407
Body mass and body mass index (BMI) of obese men
of dieting and exercising moderately obese men, 656
effects of ACX-SR blockade of lipolysis on nocturnal GH levels and pulsatility on, 1208
impact of IGF-I, IGF-BP3, insulin, and GH on, 316, 317
with and without NIDDM, insulin-induced decline of plasma AA concentrations and, 641
with uncomplicated obesity, association between insulin sensitivity, FFAs, and TG metabolism independent of, 1276
VAT, plasma lipids, androgens and, 1319
Body mass and body mass index (BMI) of obese women
effects of ACX-SR blockade of lipolysis on nocturnal GH levels and pulsatility on, 1208
of exercising normotensive obese women, 19, 20
impact of IGF-I, IGF-BP3, insulin, and GH on, 316, 317
with or without NIDDM, insulin-induced decline of plasma AA concentrations and, 641
and relationship between total serum T and intraabdominal AT, 391, 392
and 24-hour EE and substrate oxidation rates unaffected by AT distribution, 110
Body mass and body mass index (BMI) in obesity
of prepubertal obese girls, uric acid homeostasis and, 820
see also Body mass and body mass index of obese men; Body mass and body mass index of obese women
Body mass and body mass index (BMI) of PCOS subjects, 708
and defect in insulin metabolism, 1368
and insulin action in adipocytes, 1538
with insulin resistance, 1569
Metformin therapy and, 649
Body weight (BW)
and adaptation of glucose metabolism to short-term fasting, 1504
AT distribution effects on clinical, hormonal, and metabolic features of PCOS independent of, 706-713
and $(Ca^{2+}+Mg^{2+})$-ATPase activity in kidney BLM, 1056

Body weight (BW) (*Continued*)
of cirrhotic subjects, 1172
clenbuterol and, *see* Body weight, clenbuterol and
dexamethasone effects on, 545
dietary fat effects on, 2, 53
and effects of insulin on glucose metabolism and whole-body proteolysis, 443
energy metabolism and skeletal muscle biochemistry and, 482
of essentially hypertensive patients, effects of β-blockers and, 457
and excretion rate of adrenal androgens during adrenarche, 187, 188
and exercise, 995; *see also* Body weight of exercising men; Body weight of exercising women
and four-compartment model, 418, 419
and hepatic insulin transit, 1145
and hyperinsulinemia effects on SM protein turnover, 71
of hyperthyroidic patients, 1024
hypocaloric high-protein diet effects on, 1482
of IDDM subjects, 343, 379
of IGT subjects, 715
of ISS subjects, 359
of malaria subjects, 975
of mildly cirrhotic subjects, hepatic glycogenolysis and, 86
of multiple trauma victims, 1306
and nandrolone effects on serum lipids, 205
of nephrotic hypertriglyceridemic subjects, 249
of NIDDM subjects, *see* Body weight of NIDDM subjects
of noncirrhotic alcoholic subjects, 368
of normotensive men, insulin sensitivity and, 884, 885
and OKG effects on Yoshida ascites hepatoma, 901
of PCOS subjects, 1537
in pregnancy, linoleic and α-linoleic acids effects on, 941
of preterm infants fed MCT-containing formula, 1288
salbutamol effects on, 1120-1121
of STZ-DM subjects, 301, 494, 730
of type I-A familial OI patients, 1262
urinary excretion of epinephrine, serum lipid levels and, 511
of young postpubertal women, bone mineral content and density and, 264, 265
see also Body mass and body mass index; Non-obese subjects; Obesity; Weight gain; Weight loss
Body weight (BW), clenbuterol and
anabolic effects of clenbuterol and, 961, 962, 1087
clenbuterol effects on skeletal muscle mass and, 1120-1121
Body weight (BW) of exercising men
and effects of endurance training on IGF-I, 1403
effects of intensity of exercise on, 816
and exercise effects on postprandial lipemia, 837
and post-exercise oxygen consumption, 566
Body weight (BW) of exercising women
effects of endurance training on IGF-I, 1403
effects of intensity of exercise on, 816
exercise effects on postprandial lipemia, 837
LPL activity and TG clearance and, 809
and serum CCK response to food intake, 218
Body weight (BW) of NIDDM subjects
effects of castration and/or hormonal replacement on, 1215-1216
and effects of glucose and AA infusions on glucose turnover, 429
and hormone-specific defect in insulin regulation of $(Ca^{2+}+Mg^{2+})$-ATPase activity in kidney BLM, 606
mepacrine effects on, 133
obese, and glucose metabolism in skeletal muscle, 1048
postprandial glucose utilization and, 1550
Body weight (BW) of NIDDM subjects (*Continued*)
RCT alterations associated with implantable IP insulin delivery and, 667
and relationship between oxidative stress and insulin action, 1427
and von Willebrand factor levels after high-MUFA diet, 1407
Bone(s)
effects of cyclosporine A and H on, compared, 1114-1118
see also Bone density; Bone mineral status *and entries beginning with element*: Osteo-
Bone density
effects of vitamin B_{12} and etidronate on, 469
in postpubertal young normal women, 263-266
Bone mineral status
long-term lithium therapy and, 1563-1567
see also Total-body bone mineral content
BP, *see* Blood pressure
Brain
AAs of, D-alanine effects on levels of, 1155
see also entries beginning with terms: Brainstem, Cerebrotendinous, Cortical, Intracerebroventricular
Brain natriuretic peptide (BNP), cGMP responses to, 1531-1535
Brainstem, moderate hypoglycemia impairing function of, in conscious subjects, 1329-1331
Branched-chain amino acids, *see* Amino acid(s)
Breast cancer
advanced, low-dose Ag therapy alone for, in postmenopausal women, adrenal effects of, 723-727
tamoxifen decreasing Lp(a) in, 531-532
Brown adipose tissue, *see* Intercapsular brown adipose tissue
Brush border membrane, *see* Renal brush border membrane
BUN (blood urea nitrogen) in multiple trauma victims, 1307
Buoyant high-density lipoproteins (HDLs), large, hypertriglyceridemia in late pregnancy associated with formation of small dense LDLs and presence of, 1035-1041
Burn injury, effects of, on mitochondrial oxygen consumption and glycerol phosphate shuttle, 913-916
BW, *see* Body weight

C, *see* Cholesterol
Ca (calcium)
fluidity and transport of, by renal brush border membrane, vitamin D and enterocyte effects on, 1093-1103
see also entries beginning with symbol: Ca^{2+}
Ca^{2+} (calcium)
fish oil suppressing heat production dependent on, in skeletal muscle, 931-934
long-term lithium therapy effects on bone, 1563-1567
see also entries beginning with symbol: Ca^{2+}
Ca^{2+} (calcium)-calmodulin system in PDGF-, FGF-, and insulin-induced ODC in NIH-3T3 cells, 4-10
Ca^{2+} (calcium)-channel currents of beta cells in neonatal STZ-DM, 1395-1400
$(Ca^{2+}+Mg^{2+})$-ATPase (calcium+magnesium-adenosine triphosphatase) in kidney BLM, hormone-specific defect in insulin regulation of
in obesity, 1055-1061
in STZ-induced IDDM, 604-613
CAD, *see* Coronary artery disease
CAH (congenital adrenal hyperplasia), nonclassic, 24-hour pulsatile control of cortisol, 17-hydroxyprogesterone, and androstenedione release in prepubertal subjects with, 372-377
Calcium, *see entries beginning with symbols*: Ca, Ca^{2+}

Calorie(s)
restriction of, *see* Calorie restriction
in vegetarian and nonvegetarian diet, 623
see also Diet; Fuel metabolism; Indirect calorimetry *entries beginning with term*: Energy *and element*: Therm-
Calorie restriction
effects of low-fat diet, running and, on Lp subfraction concentrations in moderately obese men, 655-663
with and without D-fenfluramine treatment, effects of, on GH release after stimulation with GRF in android obesity, 969-973
see also Hypocaloric diet
Calorimetry, *see* Indirect calorimetry
cAMP (cyclic adenosine monophosphate)
and defect in insulin regulation of $(Ca^{2+}+Mg^{2+})$-ATPase activity in kidney BLM of NIDDM subjects, 604-613
hepatic, in uremia, sucrose effects on, 407
plasma, PACAP effects on concentrations of, in conscious subjects, 740-742
theophylline effects on, in IDDM and normal subjects, 777
Cancer, *see* Malignant disease
Capillary blood flow (CBF) in myocutaneous island flaps with gradually insetting venous stasis and/or arterial ischemia, 1203
Carbachol, effects of, on hormonal and metabolic responses to stress in normal and diabetic subjects, 1134-1143
Carbicarb, effects of $NaHCO_3$ with and without, on skeletal muscle pH and hemodynamic status in hypovolemic shock, 518-522
Carbohydrate(s) (CHOs)
disorders in metabolism of lipids and, in paraplegic or quadriplegic veterans, 749-756
hepatic metabolism of, sucrose enhancing uremia-induced disturbances in, 403-412
intake of, *see* Carbohydrate intake
oxidation of, *see* Carbohydrate oxidation
propionate effects on metabolism of, in STZ-DM, 728-734
Carbohydrate (CHO) intake
effects of hypocaloric high-CHO diet on glucose oxidation and lean body mass, 1481-1487
by IDDM subjects, RCT alterations associated with implantable IP insulin delivery and, 667
of PCOS subjects, AT distribution and, 708
in vegetarian and nonvegetarian diet, 623
in weight-reducing diet, effects of, on plasma HDL, in men, 918
Carbohydrate (CHO) oxidation
in cirrhotic subjects, 1172, 1178
EE and, in obese women, 112
substrate utilization and, 152-156
Carbon dioxide, *see* $^{14}CO_2$
Carboxykinase, *see* Phosphoenolpyruvate carboxykinase mRNA
Carboxylic acid, 5-chloro-7,8-dihydro-3-phenylfuro[2,3g]-1,2-benzisoxasole-7-, hypouricemic and uricosuric actions of, in hyperuricemia, 123-128
Carboxy-terminal propeptide of type I procollagen (PICP), serum, in familial type I-A osteogenesis imperfecta, 1261-1265
Cardiac output, effects of protein ingestion on, 627
Cardiomyopathy, Cu deficiency and, 1464
Cardiovascular (CV) disease
high resting blood pressure during submaximal exercise as risk factor for, in obese normotensive women and, 18-23
see also Coronary artery disease
Cardiovascular (CV) system, *see* Blood flow; Blood pressure; Heart *entries beginning with terms*: Vascular, Venous *and elements*: Arteri-, Card-
Castration, effects of hormone replacement and, on incidence of NIDDM, 1214-1220
Catecholamines
EPOC and, 565-571
see also Dopamine; Epinephrine; Norepinephrine; [^{3}H]Norepinephrine
CBF (capillary blood flow) in myocutaneous island flaps with gradually insetting venous stasis and/or arterial ischemia, 1203
CCK (cholecystokinin), *see* Food intake, CCK and
CDCA (chenodeoxycholic acid), effects of lovastatin and, on plasma cholestanol levels and bile acid metabolism in CTX, compared, 1018-1022
Cell differentiation, *see* Adipocyte precursors, differentiation of
Cell growth, Hep G2, galactose effects on, 946
Cell morphology, Hep G2, galactose effects on, 946
Cerebellar ataxia, Cu deficiency and development of, 1462-1463
Cerebrotendinous xanthomatosis (CTX), effects of lovastatin and CDCA on plasma cholestanol and bile acid metabolism in, compared, 1018-1022
CET, *see* Cholesteryl ester transfer
CETP, *see* Cholesteryl ester transfer protein
CF, *see* Cystic fibrosis
cGMP (cyclic guanosine monophosphate), responses of, to ANF, BNP, and CNP, 1531-1535
Chemiluminescence, increased neutrophil production of, in CF, 719-722
Chenodeoxycholic acid (CDCA), effects of lovastatin and, on plasma cholestanol levels and bile acid metabolism in CTX, compared, 1018-1022
Children
amount of cholesterol relative to apo B in LDLs related primarily to HDL-C in, 1042-1046
with different apo E phenotypes, relationship between serum Lps and obesity in, 470-475
GH therapy of, *see* Growth hormone therapy of children
prepubertal, *see* Prepubertal children
of short stature, *see* Short-stature, children of
5-Chloro-7,8-dihydro-3-phenylfuro[2,3g]-1,2-benzisoxazole-7-carboxylic acid (AA-193), hypouricemic and uricosuric actions of, in hyperuricemia, 123-128
CHO(s), *see* Carbohydrate(s)
Cholecystokinin, *see* Food intake, CCK and
Cholestanol, plasma, in CTX, effects of lovastatin and CDCA on bile acid metabolism and levels of, compared, 1018-1022
Cholesterol (C)
and $(Ca^{2+}+Mg^{2+})$-ATPase activity in kidney BLM, 1056
effects of acetylated and oxidative-modified LDLs on synthesis of, 1523-1530
esterified, *see* Esterified cholesterol
in exercising women, 19, 20, 809
fasting, *see* Fasting cholesterol
and hormone-specific defect in insulin regulation of $(Ca^{2+}+Mg^{2+})$-ATPase activity in kidney BLM, 606
in hyperinsulinemia, 1580
in hyperthyroidic patients, 1024
in IDDM, *see* Cholesterol in IDDM
insulin sensitivity and, 502, 505, 525
LDL amount of, relative to apo B, related to HDL-C and, in children, 1042-1046
levels of, in older athletic men with silent myocardial ischemia, 193
in NIDDM, *see* Cholesterol in NIDDM
plasma, *see* Plasma cholesterol

Cholesterol (C) (*Continued*)
renal brush border membrane, in idiopathic Fanconi syndrome, 1075
serum, *see* Serum cholesterol
total, *see* Total cholesterol
see also High-density lipoprotein-cholesterol; Hypercholesterolemia; Lecithin:cholesterol acyltransferase; Low-density lipoprotein-cholesterol; Very–low-density lipoprotein-cholesterol
Cholesterol (C) in IDDM
alterations in RCT associated with implantable IP insulin delivery in IDDM, 665-669
effects of newly insulin-treated IDDM on synthesis of, 1233-1240
esterified, PP TGRLP increasing, in THP-1 macrophages, 1063-1072
Cholesterol (C) in NIDDM
and autologous blood transfusions for repeated phlebotomies, 616
with and without CAD, plasma CETP activity and, 1500
effects of newly insulin-treated NIDDM on synthesis of, 1233-1240
Cholesteryl ester transfer (CET)
abnormal acyltransferase activities and accelerated, in NS, 1126-1133
see also Cholesteryl ester transfer protein
Cholesteryl ester transfer protein (CETP)
and alterations in RCT associated with implantable IP insulin delivery in IDDM, 665-669
plasma, *see* Plasma cholesteryl ester transfer protein
Chronic intestinal pseudo-obstruction, Cu deficiency and, 1463-1464
Chronic malignant disease, albumin TER correlating with plasma albumin concentrations in, 697-705
Chronic renal failure, *see* Uremia
Chylomicron remnants (CM-R), effects of, on apo E synthesis in Hep G2 cells, 44-50
Cigarette smoking
and association between insulin sensitivity, FFAs, and TG metabolism independent of uncomplicated obesity, 1276
endothelin-1 levels after, 267-269
and hyperinsulinemia, 1580
by IDDM women using oral contraceptives, endothelial function and, 1380
insulin sensitivity, Lps and, in NIDDM, 502, 506
urinary excretion of epinephrine, serum lipid levels and, 511
Cilazapril, effects of, on glucose and insulin response to hyperlipidemia and hypercholesterolemia, 360-366
Circulating mononuclear cells (CMCs), regulation of glucose transport and GLUT3 mRNA expression in, in IDDM and nondiabetic subjects, 591-598
Cirrhosis
hepatic extraction of insulin and beta cell response to alcohol withdrawal by noncirrhotic alcoholics, 367-371
IV fructose in, lipid metabolism and substrate oxidation with, 1171-1181
well-nourished subjects with mild, glucagon failure to stimulate hepatic glycogenolysis in, 85-89
Citrulline
glucagon role in control of metabolism of, 1512, 1513
in multiple trauma victims, 1308
plasma, arginine-free diet effects on, 119
Clenbuterol
anabolic effects of, *see* Anabolic effects of clenbuterol
effects of salbutamol and, on skeletal muscle mass, 1119-1125
Clinical course
of homozygous FH in pregnancy, 1166
of severe *Plasmodium falciparum* infection, 888
see also specific conditions
Clofibrate, testosterone role in proliferation of hepatic peroxisome induced by, 169-173
CMCs (circulating mononuclear cells), regulation of glucose transport and GLUT3 transporter mRNA expression in, in IDDM and nondiabetic subjects, 591-598
CM-R (chylomicron remnants), effects of, on apo E synthesis in Hep G2 cells, 44-50
CNP (C-type natriuretic peptide), cGMP responses to, 1531-1535
$^{14}CO_2$ (carbon dioxide)
conversion of [^{14}C-1]glucose and [^{14}C-6]glucose to, during organogenesis, 833
and galactose effects on Hep G2 cell production, 948, 949
production of, and glucagon role in control of protein and AA metabolism, 1513
Coenzyme A (CoA) reductase, HMG-, *see* Hepatic HMG-CoA reductase; Ileal HMG-CoA reductase *and specific HMG-CoA reductase inhibitors*
Collagen type IV, effects of, on preadipocyte differentiation induced by extracellular matrix components, 909
Colliculus, inferior, moderate hypoglycemia impairing function of, in conscious subjects, 1329-1331
Compartmental method in measurement of glucose absorption and production following oral glucose, 1419-1425
Congenital adrenal hyperplasia (CAH), nonclassic, 24-hour pulsatile control of cortisol, 17-hydroxyprogesterone, and androstenedione release in prepubertal subjects with, 372-377
Congestive heart failure, total-body and myocardial substrate oxidation in, 174-179
Connecting peptides, *see* C-peptides
Conscious subjects
hypoglycemia in, *see* Hypoglycemia in conscious subjects
PACAP effects on secretion of adrenal hormone, glucagon, and insulin, and on glucose and lipid metabolism in, 739-744; *see also* Glucagon in conscious subjects
pregnant, hepatic AA metabolism during hyperinsulinemia and hyperaminoacidemia in, 1079-1085
Continuous insulin delivery, effects of short-term pulsatile versus, on lipid metabolism and whole-body glucose metabolism in obesity, 842-846
Contraceptives, *see* Oral contraceptives
Copper (Cu)
deficiency in, secondary to Cu transport defect, 1462-1469
and hyperzincuria in IDDM, 1560
Coronary artery disease (CAD)
EFA metabolism in, 982-993
in FH, 400
plasma CETP activity in NIDDM with and without, 1498-1502
Corpulent subjects, *see* Obesity
Cortical cells, alcohol intake and glucose-deprivation neurotoxicity in, 1108-1113
Corticosterone
effects of low-dose Ag therapy of advanced breast cancer in postmenopausal women on, 724
plasma, dexamethasone effects on, 545-546
Corticotropin (adrenocorticotropin hormone; ACTH)
effects of, on plasma Lp metabolism, 90-97
secretagogues of, facilitating recovery of HPA axis suppressed by prolonged dexamethasone therapy, 544-548
Corticotropin-releasing hormone (CRH), dexamethasone effects on content of, in hypothalamus, 546

Cortisol (hydrocortisone)
concentrations of, in PCOS, AT distribution and, 709
in Cushing's syndrome, 1517-1522
effects of, on LDL receptor activity in Hep G2 cells, 95
effects of ICV ODT8-SS on responses of, to stress, 1140, 1141
effects of low-dose Ag therapy of advanced breast cancer in postmenopausal women on, 724
effects of stress hormone infusion on, 1312-1313
in multiple trauma victims, 1307
plasma, *see* Plasma cortisol
serum, ACTH and dexamethasone effects on level of, 92
theophylline effects on, in IDDM and normal subjects, 777
24-hour pulsatile control of release of 17-hydroxyprogesterone, androstenedione and, in normal and 21-hydroxylase-deficient prepubertal children, 372-377
urinary, in obese women, relationship between total serum T, intraabdominal AT and, 391
Counterregulatory hormones, plasma, in congestive heart failure, 176
C-peptides (connecting peptides)
fasting, *see* Fasting C-peptides
levels of, in CF, 164
in mild cirrhosis, hepatic glycogenolysis and, 87
in NIDDM, *see* C-peptides in NIDDM
in noncirrhotic alcoholic subjects, 369
in PCOS, 708, 710, 1368
plasma, *see* Plasma C-peptides
C-peptides (connecting peptides) in NIDDM
fasting plasma, 133, 391, 1237
fasting serum, pyridostigmine effects on GH response to GH-RH and, 894
and insulin production following IV glucose, IV arginine, and IV valine, 386
postprandial amplification of Lp abnormalities in NIDDM and its relationship to postprandial lipemia and levels of, 270-278
Cr, *see* Creatinine
C-reactive protein (CRP)
in acute infectious disease, 699
in chronic malignant disease, 702
Creatinine (Cr)
clenbuterol and salbutamol effects on concentrations of, in skeletal muscle, 1122, 1123
and effects of newly insulin-treated NIDDM and IDDM on cholesterol synthesis, 1234
in nephrotic hypertriglyceridemia, 249
plasma, of cirrhotic subjects, 1172
serum, *see* Serum creatinine
in uremia, 334, 335, 343, 405
CRF (chronic renal failure), *see* Uremia
CRH (corticotropin-releasing hormone), dexamethasone effects on content of, in hypothalamus, 546
CRP, *see* C-reactive protein
CsA (cyclosporine A), effects of cyclosporine H and, on bones, compared, 1114-1118
C-terminal glucagon fragments, effects of, on insulin secretion, 771-775
CTX (cerebrotendinous xanthomatosis), effects of lovastatin and CDCA on plasma cholestanol and bile acid metabolism in, compared, 1018-1022
C-type natriuretic peptide (CNP), cGMP responses to, 1531-1535
Cu, *see* Copper
Cushing's syndrome
obese women with, therapy and changes in body composition and AT distribution in, 1517-1522
pulsatile TSH secretion in, 782-786
CV (cardiovascular) system, *see* Blood flow; Blood pressure; Heart *entries beginning with terms*: Vascular, Venous *and elements*: Arteri-, Card-
Cyclic adenosine monophosphate, *see* cAMP
Cyclic guanosine monophosphate (cGMP), responses of, to ANF, BNP, and CNP, 1531-1535
Cyclosporine A (CsA), effects of cyclosporine H and, on bones, compared, 1114-1118
Cysteine, effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159
Cystic fibrosis (CF)
increased neutrophil chemiluminescence production in, 719-722
insulin sensitivity and insulin MCR in, 163-167
Cystine, effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
L-Cystine in AA mixture supplying arginine-rich or arginine-free diet, 115
Cytochrome C reductase, *see* NADPH cytochrome C reductase in kidney BLM
Cytochrome oxidase in kidney BLM
of obese subjects, 1056
of STZ-induced NIDDM subjects, 606
Cytosolic hepatic phosphoenolpyruvate carboxykinase (PEPCK) mRNA (messenger ribonucleic acid) in endotoxic shock, 1251

DA, *see* Dopamine
Daily alcohol intake, effects of, on ethanol-induced hyperuricemia, 745-748
Danazol, and insulin propeptide levels, 446-449
DCA (dichloroacetate) for lactic acidosis in severe malaria, 974-981
Decarboxylase, ornithine, PDGF-, FGF-, and insulin-induced, in NIH-3T3 cells, Ca^{2+}-calmodulin system in, 4-10
Dehydroepiandrosterone (DHEA; DHEAS)
decreased concentrations of, associated with increased insulin and glucose concentrations in nondiabetic men, 599-603
effects of low-dose Ag therapy of advanced breast cancer in postmenopausal women on, 724
in PCOS, 649, 709, 1368
plasma, effects of endurance exercising on, in older men and women, 848, 849
Dehydrogenase
glutamate, regulation of, in pancreatic islets and its consequences on insulin release, 1187-1195
hepatic pyruvate, PKC role in activation of, by insulin in hepatoma cells, 1030-1034
hepatic xanthine, AA-193 effects on, 127
see also Phosphate dehydrogenase
Demographics, *see* Age; Race and ethnicity; Sex
Dense low-density lipoproteins (LDLs), small, hypertriglyceridemia in late pregnancy associated with formation of, and presence of large buoyant HDLs, 1035-1041
Density of bones, *see* Bone density
Deoxycorticosterone, effects of low-dose Ag therapy of advanced breast cancer in postmenopausal women on, 724
Deoxycortisol, effects of low-dose Ag therapy of advanced breast cancer in postmenopausal women on, 724
2-Deoxyglucose (DG), pioglitazone effects on, 954-955
D-[6-^{3}H]2-Deoxyglucose (DG), metabolism of, in hyperglycemic STZ-DM, 65
Deoxyribonucleic acid, *see* DNA

Desensitization, phosphorylation and, of IR serine, effects of IR gene mutation at tyrosines 1162 and 1163 on, 757-765
DEX, *see* Dexamethasone
DEXA (dual-energy x-ray absorptiometry), near-infrared interactance and, in study of four-compartment model, 417-422
Dexamethasone (DEX)
ACTH secretagogues facilitating recovery of HPA axis suppressed by prolonged therapy with, 544-548
effects of, on amylin and insulin secretion in STZ-induced NIDDM, 767-768
effects of, on plasma Lp metabolism, 92, 93
DG, *see* 2-Deoxyglucose; D-[6-^{3}H]2-Deoxyglucose
DHAP (dihydroxyacetone phosphate), effects of uremia on, 407
DHEA (DHEAS), *see* Dehydroepiandrosterone
DHT (5α-dihydrotestosterone), T therapy effects on, 936
Diabetes mellitus, *see* Alloxan-diabetes; Gestational diabetes mellitus; Insulin-dependent diabetes mellitus; Neonatal diabetic subjects; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus
Diastolic blood pressure, *see* Blood pressure
Dichloroacetate (DCA) for lactic acidosis in severe malaria, 974-981
Diet
with and without AAs, influence of, on polyamine urinary excretion in multiple trauma victims, 1305-1309; *see also* Amino acid(s)
arginine-free, plasma arginine kinetics and, 114-122
lipid-lowering, effects of, on lipids and Lps in familial hypercholesterolemia, 400; *see also* Lipids; Lipoprotein
of PCOS subjects, AT distribution and, 707-708
reducing, *see* Weight-reducing diet, weight loss with
vegetarian, sympathetic nervous system activity and RMR with, 621-625
see also Calorie(s); Energy intake; Fasting; Fed subjects; Food intake; Refeeding; Restricted diet; Starvation *entries beginning with terms*: Dietary, Postprandial, Preprandial *specific food groups and substances*
Dietary fats
differential effects of, on SNS, 51-60
effects of, on plasma CETP activities and hepatic CETP mRNA levels, 1006-1012
effects of, on substrate utilization, 152-156
intake of, in weight-reducing diet, effects of, on plasma HDL, in men, 918
PCOS subjects' intake of, AT distribution and, 708
in vegetarian and nonvegetarian diet, 623
see also High-fat diet; Low-fat diet *and specific types of dietary fats*
Dietary protein
effects of, on splanchnic and whole-body O_2 consumption, blood flow, and blood temperature, 626-632
PCOS subjects' intake of, AT distribution and, 708
in vegetarian and nonvegetarian diet, 623
see also Adaptation to varying dietary protein intake; Dietary protein restriction; High-protein diet
Dietary protein restriction
effects of, on glucose and insulin metabolism in normal and IDDM subjects, 462-467
short-term adaptation to, 320-327
Digoxin, effects of, on anabolic response to clenbuterol, 959-964
5α-Dihydrotestosterone (DHT), T therapy effects on, 936
Dihydroxyacetone phosphate (DHAP), effects of uremia on, 407
Dilevalol, effects of, on lipid and glucose metabolism in essential hypertension, 455-461
diP, *see* Diphosphate
Dipeptides
clearance of, effects of structure on, 1373-1378
glutamine-containing, utilization of, in hepatic failure and uremia, 1104-1107
Diphosphate (diP)
activity of uridine diphosphate-glucuronyltransferase and proliferation of hepatic peroxisome, 170, 171
F-1,6-, and F-2,6-, in uremia, effects of sucrose on, 407
see also Adenine diphosphate; NADPH cytochrome C reductase in kidney BLM
DM (diabetes mellitus), *see* Alloxan-diabetes; Gestational diabetes mellitus; Insulin-dependent diabetes mellitus; Neonatal diabetic subjects; Non–insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus
DNA (deoxyribonucleic acid)
thyroid hormone effects on folate-mediated incorporation of [ring-2-^{14}C]histidine into, 1575-1578
values of, during organogenesis, 832
Dolichol, plasma, changes in levels, transport, and hepatic delivery of, during liver regeneration following partial hepatectomy, 677-680
Dopamine (DA)
accumulation of, in heart, dietary fats and, 59
urinary excretion of, and serum lipid levels, 511
Dose
high-dose zinc supplementation effects on hyperzincuria in IDDM, 1558-1562
low-dose Ag therapy alone for advanced breast cancer in postmenopausal women, adrenal effects of, 723-727
supratherapeutic androgenic steroid, effects of, on basal and insulin-stimulated glucose and amino acid metabolism, 1266-1274
Drinking habit, *see* Alcohol intake; Alcoholic subjects
Dual-energy x-ray absorptiometry (DEXA), near-infrared interactance and, in study of four-compartment model, 417-422

E, *see* Epinephrine
EC, *see* Esterified cholesterol
EE, *see* Energy expenditure
EFAs (essential fatty acids), metabolism of, in CAD, 982-993
EGF (epidermal growth factor), effects of, on apo B secretion following PH, 686-687
EI, *see* Energy intake
Elderly subjects, *see* Older subjects
Embryonic glucose, metabolism of, during organogenesis, 830-835
Endothelial cells
insulin effects on release of ET-1 in, 878-882
microvascular, extracellular matrix components secreted by, stimulating preadipocyte differentiation, 906-912
Endothelial function during oral contraception in IDDM women, 1379-1383
Endothelin (ET), release of, in myocutaneous island flaps in response to gradually insetting venous stasis or arterial ischemia, 1201-1206
Endothelin-1 (ET-1)
adipose differentiation of adipocyte precursors inhibited by, 227-232
insulin effects on release of, in endothelial cells, 878-882
levels of, after cigarette smoking, 267-269
Endotoxic shock, increased glucose disposal and decreased gluconeogenesis without hyperinsulinemia in, 1248-1254
Endotoxin, effects of systemic infusions of TNF, IL-1 and, on glucose metabolism, 279-284

Endurance exercise, *see* Men, exercising; Women, exercising *and specific forms of exercise; for example*: Running
Energetic status of Hep G2 cells, galactose effects on, 948
Energy expenditure (EE)
by cirrhotic subjects, 1175-1176
dietary fat and CHO effects on substrate utilization and, 154
by obese women, *see* Energy expenditure by obese women
resting, *see* Resting energy expenditure
total, protein ingestion and, 627
by vegetarians and nonvegetarians, 623
Energy expenditure (EE) by obese women
GH therapy effects on thyroid function, fuel metabolism and, 872-877
substrate oxidation rates and 24-hour, unaffected by AT distribution, 109-113
Energy intake (EI)
changes in, with GH therapy of children of short stature, 1545
impact of obesity, AT distribution, and restricted, on IGF-I, IGF-BP3, and GH, 315-319
of PCOS subjects, 708
polyunsaturated fat effects on, 2
total, insulin sensitivity, Lps and, in NIDDM, 502
see also Food intake; Thermic effect of food *and specific substances*
Energy metabolism, *see* Resting energy expenditure; Whole-body energy metabolism
Enterocytes, effects of vitamin D and, on fluidity and transport of calcium by renal brush border membrane, 1093-1103
EPI, *see* Epinephrine
Epidermal growth factor (EGF), effects of, on apo B secretion following PH, 686-687
Epinephrine (E; EPI; adrenaline)
arterial, in determination of sympathoadrenal response at high altitude, 1226-1232
concentration of, before and after glucose nadir during OGTT, 101, 102
effects of ICV ODT8-SS on responses of, to stress, 1136, 1139-1141
effects of stress hormone infusion on, 1312-1313
plasma, *see* Plasma epinephrine
theophylline effects on, in IDDM and normal subjects, 777
urinary excretion of, *see* Epinephrine, urinary excretion of
Epinephrine (E; EPI; adrenaline), urinary excretion of
in determination of sympathoadrenal response at high altitude, 1226-1232
relationship between serum lipid levels and, 509-513
EPO (erythropoietin), and autologous blood transfusions for repeated phlebotomies in NIDDM, 614-620
EPOC (excess post-exercise O_2 consumption), effects of β-adrenergic blockers on, 565-571
Erythrocyte(s) (red blood cells), *see* Erythrocyte membranes; Insulin-dependent diabetes mellitus, erythrocytes in; Non–insulin-dependent diabetes mellitus, erythrocytes in; Reduced glutathione in erythrocytes
Erythrocyte (red blood cell) membranes, increased susceptibility of, to lipid peroxidation in IDDM and NIDDM, 1470-1474
Erythropoietin (EPO), and autologous blood transfusions for repeated phlebotomies in NIDDM, 614-620
Essential fatty acids (EFAs), metabolism of, in CAD, 982-993
Essential hypertension, effects of β-blockers with β_2-agonism on lipid and glucose metabolism in, 455-461
Esterified cholesterol (EC)
effects of bile acids and lovastatin on, 1448
PP TGRLP increasing, in THP-1 macrophages in IDDM, 1063-1072
Estradiol
decreased concentrations of, associated with increased insulin and glucose concentrations in nondiabetic men, 599-603
in PCOS, 649, 709
T therapy effects on, 936
17β (beta)-Estradiol-dihydrogesterone therapy of postmenopausal women, changes in LDLs with, 799-802
Estrone in PCOS, AT distribution and concentrations of, 709
ET (endothelin), release of, in myocutaneous island flaps in response to gradually insetting venous stasis or arterial ischemia, 1201-1206
ET-1, *see* Endothelin-1
Ethanol, *see* Alcohol intake; Alcoholic subjects
Ethnicity, *see* Race and ethnicity
Etidronate, vitamin B_{12} and, reversing severe osteoporosis in pernicious anemia, 468-469
Excess post-exercise O_2 consumption (EPOC), effects of β-adrenergic blockers on, 565-571
Excretion, *see* Fecal fat excretion; Urinary excretion
Exercise and exercise training, *see* Men, exercising; Women, exercising *and specific forms of exercise; for example*: Running
Extracellular matrix components secreted by microvascular endothelial cells stimulating preadipocyte differentiation, 906-912
Extracellular pH, hepatic cell lactate utilization controlled by, AICA-ribosome influence on, 157-162

F (fructose), IV, in cirrhosis, lipid metabolism and substrate oxidation with, 1171-1181
FA(s), *see* Fatty acids
Familial coronary artery disease (CAD), FH and, 400
Familial hypercholesterolemia (FH)
homozygous, pregnancy with, long-term LDL apheresis for, 1164-1170
lack of deficiency of LDL receptor in, 397-402
treated with simvastatin, dietary fat effects on plasma noncholesterol sterols in, 311-313
Familial influences on adrenal androgen excretion rate during adrenarche, 186-189
Familial type I-A osteogenesis imperfecta (OI), serum PICP in, 1261-1265
Fanconi syndrome, idiopathic, renal brush border membrane lipid composition in, 1073-1078
Fasting
effects of arginine-free diet on plasma leucine, KIC, arginine, urea, ornithine, and citrulline during, 118, 119
in GDM, leucine kinetics during, 378-384
glycogen synthesis pathway during, 41
by hypothyroidic and hyperthyroidic subjects, adaptive changes in T_3 transmembrane transport and metabolism in liver during, 1355-1361
by NIDDM subjects, lipids in, 273-275
preprandial and postprandial GH response to GH-RH in AN during, naloxone effects on, 141, 142
short-term, adaptation of glucose metabolism to, sex difference in, 1503-1508
substrate oxidation in congestive heart failure and, 176, 177
see also entries beginning with term: Fasting
Fasting apolipoprotein A-I (apo A-I), serum, mepacrine effects on, in NIDDM, 132

Fasting apolipoprotein B (apo B), serum, mepacrine effects on, in NIDDM, 132
Fasting blood folate, maternal hyperhomocysteinemia and, 1477
Fasting blood glucose
of CF subjects, 164
in hyperinsulinemia, 1581
in IDDM, 1198, 1235
in NIDDM, 894, 1235
Fasting cholesterol (C)
levels of, in older athletic men with silent myocardial ischemia, 193
plasma, propionate effects on concentrations of, in STZ-DM, 731
Fasting C-peptides (connecting peptides)
and association between insulin sensitivity, FFAs, and TG metabolism independent of uncomplicated obesity, 1278
and hepatic insulin transit, 1145
in NIDDM, 585, 587, 894
plasma, 133, 391, 1237
and postprandial amplification of Lp abnormalities, 271
Fasting glucagon, and postprandial amplification of Lp abnormalities, 271
Fasting glucose
in exercising normotensive obese women, 19, 20
and hepatic insulin transit, 1145
in hyperinsulinemia, 804, 1581
insulin sensitivity and, 424
in NIDDM, 585, 1048
in normolipidemic subjects, 1333, 1334
in obesity, 1048, 1278
in PCOS with insulin resistance, 1569
and testosterone and DHEA concentrations in nondiabetic men, 600, 601
see also Fasting blood glucose; Fasting plasma glucose
Fasting high-density lipoprotein(s) (HDLs) in NIDDM, 274-275
Fasting high-density lipoprotein-cholesterol (HDL-C), levels of, in genetically obese subjects, 551
Fasting insulin
in exercising normotensive obese women, 19, 20
and hepatic insulin transit, 1145
in hyperinsulinemia, 1581
in IDDM, 502, 585, 587
insulin sensitivity and, 424, 502
in normolipidemic subjects, 1333, 1334
in obesity, *see* Fasting insulin in obesity
plasma, *see* Fasting plasma insulin
and testosterone and DHEA concentrations in nondiabetic men, 600, 601
Fasting insulin in obesity
with NIDDM, 1048
in normotensive obesity, 19, 20
in uncomplicated obesity, 1278
Fasting lipids
levels of, in older athletic men with silent myocardial ischemia, 193
plasma, 294-296, 730, 731
see also specific lipids
Fasting plasma cholesterol (C), propionate effects on concentrations of, in STZ-DM, 731
Fasting plasma C-peptides (connecting peptides) in NIDDM, 133, 391, 1237
Fasting plasma glucose
mepacrine effects on, in NIDDM, 133
in paraplegic or quadriplegic veterans, 751
and postprandial amplification of Lp abnormalities, 271
Fasting plasma glucose (*Continued*)
propionate effects on, in STZ-DM, 730, 731
and relationship between total serum T and intraabdominal AT in obese women, 391
Fasting plasma high-density lipoprotein-cholesterol (HDL-C), levels of, in genetically obese subjects, 551
Fasting plasma insulin
effects of cilazapril on, in hypercholesterolemia and hyperlipidemia, 362
in essential hypertension, β-blocker effects on, 458
in NIDDM, mepacrine effects on, 133
propionate effects on, in STZ-DM, 730
and relationship between total serum T and intraabdominal AT in obese women, 391
Fasting plasma lipids, 294-296, 730, 731
Fasting plasma triglycerides (TGs), 550, 731
Fasting serum apolipoprotein A-I (apo A-I), mepacrine effects on, in NIDDM, 132
Fasting serum apolipoprotein B (apo B), mepacrine effects on, in NIDDM, 132
Fasting serum C-peptides (connecting peptides) in NIDDM, pyridostigmine effects of GH response to GH-RH and, 894
Fasting triglycerides (TGs)
plasma, 550, 731
serum, mepacrine effects on, in NIDDM, 132
Fat, *see* Adipose tissue; Dietary fats; Fat-free mass *entries beginning with term*: Fatty *element*: Lip- *and specific classes of fats*
Fat-free mass (FFM)
and effects of glucose and AA infusions on glucose turnover in NIDDM, 429
endurance training effects on, 1402
hypocaloric high-protein diet effects on, 1484
in obesity, *see* Fat-free mass in obesity
of vegetarians and nonvegetarians, RMR and, 622
see also Lean body mass
Fat-free mass (FFM) in obesity, 110, 141, 863
effects of exercise on REE, anthropometric indices and, in obese men, 1148-1152
Fatty acids (FAs)
content of, in dietary fats, SNS responses to, 52
essential, metabolism of, in CAD, 982-993
free, *see* Free fatty acids
long-chain, *see* Long-chain saturated fatty acids
plasma non-esterified, in STZ-DM, 301
renal brush border membrane composition of, in idiopathic Fanconi syndrome, 1075, 1076
Fatty infiltration of liver during gram-negative sepsis, regulatory factors in development of, 691-696
F-1,6-diP (fructose-1,6-diphosphate) in uremia, effects of sucrose on, 407
F-2,6-diP (fructose-2,6-diphosphate) in uremia, effects of sucrose on, 407
Fe (iron), autologous blood transfusions for repeated phlebotomies in NIDDM and, 616
Febrile disease, acute, albumin TER in, 699-700
Fecal fat excretion, and differential SNS responses to dietary fats, 57
Fed subjects
extracellular pH and hepatic cell lactate utilization in, 158-159
hypothyroidic and hyperthyroidic, adaptive changes in T_3 transmembrane transport and metabolism in liver of, 1355-1361
intravenously, leucine turnover in, 1338-1345

Fed subjects (*Continued*)
mildly cirrhotic well-, glucagon failure to stimulate hepatic glycogenolysis in, 85-89
see also Diet
D-Fenfluramine therapy, effects of calorie restriction with and without, on GH release after stimulation with GRF in android obesity, 969-973
Ferritin, autologous blood transfusions for repeated phlebotomies in NIDDM and, 616
Fetal ultrasound in pregnancy with homozygous FH, 1167
FFAs, *see* Free-fatty acids
FFM, *see* Fat-free mass
FGF (fibroblast growth factor), ODC in NIH-3T3 cells induced by, Ca^{2+}-calmodulin involvement in, 4-10
FH, *see* Familial hypercholesterolemia
FHNC (functional hepatic nitrogen clearance), urea synthesis and, in controlled NIDDM, 329-332
Fibrinogen
in acute infectious disease, 699
in chronic malignant disease, 702
effects of high-MUFA diet on, 1408
in hyperinsulinemia, 1581, 1583
in IDDM, 1183, 1184
insulin sensitivity and, 424, 425
Fibroblast(s), LDL receptor on, in familial hypercholesterolemia, 399
Fibroblast growth factor (FGF), ODC in NIH-3T3 cells induced by, Ca^{2+}-calmodulin involvement in, 4-10
Fibronectin (Fn)
effects of, on preadipocyte differentiation induced by extracellular matrix components, 909
effects of high-MUFA diet on, 1408
in IDDM, 1183
Fibrosis, cystic, *see* Cystic fibrosis
Fish oil suppressing Ca^{2+}-dependent heat production in skeletal muscle, 931-934
FK506, immunosuppression with
effects of, on Leydig cell function, 533-537
in islet transplantation for STZ-DM, 135-139
Fluidity
Ca, and transport by renal brush border membrane, vitamin D and enterocyte effects on, 1093-1103
platelet, lovastatin normalizing, in hypercholesterolemia, 11-17
Fn, *see* Fibronectin
Folate
fasting blood, maternal hyperhomocysteinemia and, 1477
thyroid hormone effects on incorporation of [ring-2-^{14}C]histidine into DNA mediated by, 1575-1578
Follicle-stimulating hormone (FSH) in PCOS
AT distribution and concentrations of, 709
effects of Metformin therapy on, 649
and insulin action in adipocytes, 1537
Food intake
CCK and, *see* Food intake, CCK and
clenbuterol effects on, 1087
by IDDM subjects, RCT alterations associated with implantable IP insulin delivery and, 667
by NIDDM subjects, effects of castration and/or hormonal replacement on, 1215-1216
and OKG effects on Yoshida ascites hepatoma, 901
restricted, *see* Restricted diet
see also Energy intake *and specific substances*
Food intake, CCK and
CCK associated with reduced food intake, 735-738
serum CCK response to female athletes' food intake, 217-222
Four-compartment models of body composition in normal subjects, DEXA and near-infrared interactance in study of, 417-422
F6P (fructose-6-phosphate) in uremia, effects of sucrose on, 407
Free-fatty acids (FFAs)
association between TG metabolism, insulin sensitivity and, independent of uncomplicated obesity, 1275-1281
effects of arginine interaction with, on GH secretion, 223-226
ICV ODT8-SS effects on responses of, to stress, 1136, 1139-1141
intramuscular, and OKG effects on Yoshida ascites hepatoma, 902
liver uptake of, during gram-negative sepsis, 694
metabolism of, in hyperglycemic STZ-DM, 66, 67
nocturnal, ACX-SR effects on, 1210
plasma, *see* Plasma free-fatty acids
TNF-α effects on hepatic, 824, 826
Free insulin, theophylline effects on, in IDDM and normal subjects, 777
Free testosterone (T)
concentrations of, in nondiabetic men, glucose and insulin concentrations and, 600-602
in PCOS, 649, 709
Free thyroxine (T_4)
in GH-deficient men, 200
in vegetarians and nonvegetarians, 623
Free triiodothyronine (T_3)
in GH-deficient men, 200
in vegetarians and nonvegetarians, 623
Frequently sampled intravenous glucose tolerance test (FSIGTT)
of IGT subjects, 715-716
of noncirrhotic alcoholic subjects following alcohol withdrawal, 367-371
in PCOS with insulin resistance, 1569
Fructosamine
blood, AR inhibition effects on, in NIDDM, 967
in IDDM, 1183, 1184
Fructose (F), IV, in cirrhosis, lipid metabolism and substrate oxidation with, 1171-1181
Fructose-1,6-diphosphate (F-1,6-diP) in uremia, effects of sucrose on 407
Fructose-2,6-diphosphate (F-2,6-diP) in uremia, sucrose effects on, 407
Fructose-6-phosphate (F6P) in uremia, effects of sucrose on, 407
FSH, *see* Follicle-stimulating hormone in PCOS
FSIGTT, *see* Frequently sampled intravenous glucose tolerance test
Fuel metabolism
GH therapy effects on EE, thyroid function and, in obese women, 872-877
see also Resting energy expenditure; Whole-body energy metabolism
Functional hepatic nitrogen clearance (FHNC), urea synthesis and, in controlled NIDDM, 329-332

G, *see* Glucagon
Galactose
effects of, on Hep G2 cells, 945-952
in severe *Plasmodium falciparum* infection, 890
GAPDH (glyceraldehyde-3-phosphate dehydrogenase), vanadate effects on levels of, in obese STZ-DM subjects, 1347-1350
GCR (glucose counterregulation) following OGTT, thresholds of plasma glucose for, 98-103
GDH (glutamate dehydrogenase), regulation of, in pancreatic islets and its consequences on insulin release, 1187-1195
GDM (gestational diabetes mellitus), leucine kinetics during fasting in, 378-384

GDR (glucose disposal rate), and relationship between hemorrheologic factors and insulin sensitivity, 423-426
Gemfibrozil, effects of, on intracellular TGs, 257-262
Gene(s)
expression of proinsulin, in beta TC-1 cells, interaction between GLP-1 and somatostatin-14 characterized on signal transduction and, 787-792
IR, *see* Insulin receptor gene mutation
Genetic obesity, 549-558
atherosclerosis in, 554-558
plasma lipids in, 549-553, 555, 556
Genetics, *see* Heredity
Gestational diabetes mellitus (GDM), leucine kinetics during fasting in, 378-384
GFs, *see* Growth factor(s)
GH, *see* Growth hormone
GH-BP (growth hormone-binding protein), levels of, in ISS subjects, 357-359
GH-RH, *see* Growth hormone-releasing hormone, GH response to
Girls, prepubertal lean and obese, uric acid homeostasis in, 819-821
Globulin, *see* Sex hormone-binding globulin
GLP-1, *see* Glucagon-like peptide-1
Glucagon (G; hyperglycemic factor; hyperglycemic-glycogenolytic factor)
concentration of, before and after glucose nadir during OGTT, 101
in conscious subjects, *see* Glucagon in conscious subjects
effects of C-terminal fragments of, on insulin secretion, 771-775
failure of, to stimulate hepatic glycogenolysis in well-nourished mildly cirrhotic subjects, 85-89
ICV ODT8-SS effects on responses of, to stress, 1136, 1139-1141
independent and combined actions of IL-1β, TNF-α and, on hepatic amino acid metabolism, 822-829
in NIDDM, *see* Glucagon in NIDDM
octreotide inhibiting secretion of, 24-31
plasma, *see* Plasma glucagon
role of, in control of protein and amino acid metabolism, 1509-1516
theophylline effects on, in IDDM and normal subjects, 777
thermogenesis induced by, insulin dissociating hepatic glucose cycling from, 1000-1005
see also Glucagon-like peptide-1
Glucagon in conscious subjects
effects of acute removal of, on metabolic response to stress hormone infusion in conscious subjects, 1310-1317
PACAP effects on secretion of, 739-744
redundant parasympathetic and sympathoadrenal mediation of increased secretion of, during insulin-induced hypoglycemia, 860-866
Glucagon-like peptide-1 (GLP-1)
effects of, on HGP in healthy men, 104-108
interaction between somatostatin-14 and, characterized on signal transduction, and proinsulin gene expression in beta TC-1 cells, 787-792
Glucagon in NIDDM
arterial glucagon and postprandial glucose utilization in NIDDM, 1551-1552
glucagon levels and relationship of postprandial amplification of Lp abnormalities to postprandial lipemia in NIDDM, 270-278
Gluconeogenesis
from glycerol during weight reduction with very-low-calorie diet, 1283-1300
hepatic, effects of stress hormone infusion on, 1313
Gluconeogenesis (*Continued*)
increased glucose disposal and decreased, without hyperinsulinemia in endotoxic shock, 1248-1254
Glucose
alanine and thionamide effects on, in hyperthyroidism, 1025
alcohol intake and neurotoxicity induced by deprivation of, in cortical cells, 1108-1113
blood, *see* Blood glucose
concentrations of, in nondiabetic men with decreased testosterone and DHEA concentrations, 599-603
DCA effects on, 977
dietary protein restriction effects on metabolism of, in normal and IDDM subjects, 461-467
differential effects of insulin on metabolism of, in normal-weight women, 441-445
effects of β-blockers with β_2-agonism on metabolism of, in essential hypertension, 455-461
and effects of C-terminal glucagon fragments on insulin secretion, 771-773
effects of insulin, STZ-DM and, on lipid peroxidation, 1442-1445
effects of supratherapeutic dose of androgenic steroids on basal and insulin-stimulated metabolism of, 1266-1274
effects of systemic infusions of endotoxin, TNF, and IL-1 on metabolism of, 279-284
fasting, *see* Fasting glucose
HDL-C regulation by, in normolipidemia, 1332-1337
hepatectomy effects on metabolism of, 670-676
hepatic, *see* Hepatic glucose; Hepatic glucose production
ICV ODT8-SS effects on responses of, to stress, 1136, 1139-1141
increased disposal of, in endotoxic shock, without hyperinsulinemia, 1248-1254
IV, *see* Intravenous glucose
kinetics of, *see* Kinetics, glucose
and lactate uptake by hepatocytes, 158-160
metabolism of embryonic, during organogenesis, 830-835
in mild cirrhosis, hepatic glycogenolysis and, 87
in multiple trauma victims, 1307
neonatal injections of, enhancing diabetes and increasing islet antigen expression in non-obese diabetic subjects, 1410-1418
in NIDDM, *see* Glucose in NIDDM
in noncirrhotic alcoholic subjects, 369
in obesity, *see* Glucose in obesity
oral, *see* Oral glucose
PACAP effects on metabolism of, in conscious subjects, 739-744
in PCOS, 650-651, 708, 710, 1368
plasma, *see* Plasma glucose
postabsorptive rate of appearance of, *see* Postabsorptive rate of appearance, glucose
protein ingestion effects on concentrations of, 629
quantitative characterization of response of, in hyperlipidemia and hypercholesterolemia, cilazapril effects on, 360-366
serum, *see* Serum glucose
sex difference in adaptation of glucose metabolism to short-term fasting, 1503-1508
skeletal muscle flux of, hyperinsulinemia and, 74
stress hormone infusion effects on, 1312-1315
TNF-α effects on production of, in hepatocytes, 476-480
see also 2-Deoxyglucose; D-[6-^{3}H]2-Deoxyglucose; [1-^{13}C]Glucose; [^{14}C-1]Glucose; [^{14}C-6]Glucose; D-[(U)-^{14}C]Glucose; Glucose counterregulation; Glucose disposal rate; Glucose-6-phosphate; Glucose-6-phosphate dehydrogenase; Glu-

Glucose (*Continued*)
cose tolerance; Glucose transport; Hyperglycemia; Hypoglycemia *and entries beginning with elements*: Gluc-, Glyc-
[1-^{13}C]Glucose, determination of glycogen pathway synthesis with, 38-43
[^{14}C-1]Glucose, conversion of, to $^{14}CO_2$ during organogenesis, 833
[^{14}C-6]Glucose, conversion of, to $^{14}CO_2$ during organogenesis, 833
D-[(U)-^{14}C]Glucose, lactate release and uptake in hepatoma 7288CTC perfused in situ with, 1488-1497
Glucose counterregulation (GCR) following OGTT, thresholds of plasma glucose for, 98-103
Glucose disposal rate (GDR), and relationship between hemorrheologic factors and insulin sensitivity, 423-426
Glucose intolerance, *see* Glucose tolerance
Glucose in NIDDM
autologous blood transfusions for repeated phlebotomies in NIDDM and, 616
effects of AA infusions and glucose on glucose turnover in insulin-resistant obese and lean NIDDM subjects, 428-434
and effects of acute hyperinsulinemia on plasma CETP activity, 1363
effects of castration and/or hormonal replacement on, 1216-1217
effects of NIDDM and obesity on SM metabolism of, 1047-1054
and insulin effects on (Ca^{2+} + Mg^{2+})-ATPase, 606
PB effects on insulin-mediated metabolism of, 348-356
postprandial utilization of, 1549-1557
Glucose in obesity
differential effects of insulin on metabolism of, in reduced-obese and obese women, 441-445
effects of short-term pulsatile versus continuous delivery of insulin on lipid metabolism and whole-body metabolism of, 842-846
GH therapy effects on, in obese women, 874
metabolism of insulin and, in JCR:LA corpulent subjects, 538-543
nocturnal, ACX-SR effects on, 1211
Glucose-6-phosphate (G6P), effects of sucrose on, in uremia, 407
Glucose-6-phosphate dehydrogenase (G6PD), galactose effects on activity of, in Hep G2 cells, 948
Glucose tolerance
effects of endurance exercise on, in older men and women, 849
in endotoxic shock, 1251, 1252
in hyperinsulinemia, 1583
impaired, *see* Impaired glucose tolerance
insulin sensitivity and, in CF, 165
normal, insulin sensitivity, insulin secretion, and glucose effectiveness with, minimal model analysis of, 714-718
see also Intravenous glucose tolerance test; Oral glucose tolerance test
Glucose transport
pioglitazone regulating, in muscle cells, 953-958
see also Glucose transporters
Glucose transporters
myocardial, glycolytic metabolism during ischemia in hyperglycemic STZ-DM and, 61-69
see also GLUT1 transporter mRNA; GLUT2 transporter mRNA; GLUT3 transporter mRNA; GLUT4 transporter mRNA
Glucuronyltransferase, UDP-, activity of, and proliferation of hepatic peroxisome, 170, 171
GLUT1 transporter mRNA (messenger ribonucleic acid), immobilization effects on expression of, in skeletal muscle, 1389-1394
GLUT2 transporter mRNA (messenger ribonucleic acid), vanadate effects on, in obese STZ-DM subjects, 1346-1354
GLUT3 transporter mRNA (messenger ribonucleic acid), regulation of glucose transport and expression of, in CMCs of IDDM and nondiabetic subjects, 591-598
GLUT4 transporter mRNA (messenger ribonucleic acid), immobilization effects on expression of, in skeletal muscle, 1389-1394
Glutamate
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
ethanol effects on, 1111
glucagon role in control of metabolism of, 1512, 1513
plasma, after adaptation to diets with different protein content, 1341
L-Glutamate in AA mixture supplying arginine-free or arginine-rich diet, 115
Glutamate dehydrogenase (GDH), regulation of, in pancreatic islets and its consequences on insulin release, 1187-1195
Glutamate oxaloacetate transaminase, serum, in well-nourished mildly cirrhotic subjects, 86
Glutamine
blood, effects of supratherapeutic dose of androgenic steroids on, 1272
dipeptides containing, utilization of, in hepatic failure and uremia, 1104-1107
insulin effects on metabolism of, 73
Glutamine synthetase, effects of RU38486 and unweighting on activity of, in skeletal muscle, 1453
Glutathione, *see* Reduced glutathione in erythrocytes
Glycated Hb (hemoglobin), and effects of acute hyperinsulinemia on plasma CETP activity in NIDDM, 1363
Glycemic control, *see* Insulin-dependent diabetes mellitus, glycemic control of; Non–insulin-dependent diabetes mellitus, glycemic control of *and specific substances*
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), vanadate effects on levels of, in obese STZ-DM subjects, 1347-1350
Glycerol
blood, *see* Blood glycerol
effects of ICV ODT8-SS on responses of, to stress, 1139, 1140
effects of supratherapeutic dose of androgenic steroids on, 1270, 1272
and glucagon role in control of protein and AA metabolism, 1512
kinetics of, *see* Kinetics, glycerol
lipolysis and gluconeogenesis from, during weight reduction with very–low-calorie diet, 1293-1300
metabolism of, in severe *Plasmodium falciparum* malaria, 887-892
in multiple trauma victims, 1307
nocturnal, ACX-SR effects on, 1210
plasma, *see* Plasma glycerol
Glycerol-3-phosphate, and fatty infiltration of liver during gram-negative sepsis, 693-694
Glycerol-3-phosphate acyltransferase, and fatty infiltration of liver during gram-negative sepsis, 693-694
Glycerol-3-phosphate dehydrogenase, adipocyte, long-chain FA effects on, 147-149
Glycerol phosphate shuttle, effects of burn injury on mitochondrial O_2 consumption and, 913-916
Glycine
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
in hepatic failure and uremia, 1106

Glycine (*Continued*)
insulin effects on metabolism of, 73
in pregnancy, 1082-1084
L-Glycine in AA mixture supplying arginine-free or arginine-rich diet, 115
Glycoforms I and II, plasminogen, relationship of catabolism of, to plasminogen synthesis by liver, 1430-1437
Glycogen
effects of TNF-α on, 824, 826
galactose effects on Hep G2 cell content of, 948
hepatic, *see* Hepatic glycogen
in STZ-DM, 65-66, 730
synthesis pathway of, determined with [^{13}C]NMR, 38-43
turnover of, during refeeding, 285-292
in uremia, effects of sucrose on, 407
see also Glycogenolysis; Glycolysis
Glycogenolysis, hepatic, in well-nourished mildly cirrhotic subjects, glucagon failure to stimulate, 85-89
Glycolysis
extracellular pH effects on lactate fluxes and, in hepatocytes, 159
metabolism of, during ischemia in hyperglycemic STZ-DM, myocardial glucose transporters and, 61-69
Glycosylated Hb (hemoglobin)
and hormone-specific defect in insulin regulation of (Ca^{2+}+Mg^{2+})-ATPase activity in kidney BLM, 605, 1056
hyperzincuria in IDDM and Hb glycosylation, 1561-1562
GMP (guanosine monophosphate), cyclic, responses of, to ANF, BNP, and CNP, 1531-1535
G6P (glucose-6-phosphate) in uremia, effects of sucrose on, 407
G6PD (glucose-6-phosphate dehydrogenase), galactose effects on activity of, in Hep G2 cells, 948
Gram-negative sepsis, fatty infiltration of liver during, regulatory factors in development of, 691-696
GRF (growth hormone-releasing factor), effects of calorie restriction with and without D-fenfluramine therapy on GH release after stimulation with, in android obesity, 969-973
Growth factor(s) (GFs)
epidermal, effects of, on apo B secretion following PH, 686-687
PDGF- and FGF-induced ODC in NIH-3T3 cells, Ca^{2+}-calmodulin involvement in, 4-10
see also entries beginning with terms: Insulin-like growth factor
Growth hormone (GH)
effects of calorie restriction with and without D-fenfluramine therapy on release of, after stimulation with GRF in android obesity, 969-973
iodothyronine metabolism and levels of, 795
in multiple trauma victims, 1307
in obesity, *see* Growth hormone, obesity and
octreotide inhibiting secretion of, 24-31
plasma, in congestive heart failure, 176
response of, to GH-RH, *see* Growth hormone–releasing hormone, GH response to
secretion of, effects of FFA-arginine interaction on, 223-226
serum lipid levels in men deficient in, 199-203
theophylline effects on, in IDDM and normal subjects, 777
see also Growth hormone–binding protein; Growth hormone–releasing factor; Growth hormone therapy of children
Growth hormone (GH), obesity and
GH therapy effects on fuel metabolism, EE, and thyroid function in obese women, 872-877
impact of obesity, AT distribution, and restricted energy intake on IGF-I, IGF-BP3 and, 315-319
influence of thyroid status on response of, 514-517
nocturnal, ACX-SR blockade of lipolysis normalizing pulsatility and levels of, 1207-1213
Growth hormone–binding protein (GH-BP), levels of, in ISS subjects, 357-359
Growth hormone–releasing factor (GRF), effects of calorie restriction with and without D-fenfluramine therapy on GH release after stimulation with, in android obesity, 969-973
Growth hormone–releasing hormone (GH-RH), GH response to
preprandial and postprandial GH response in AN, naloxone effects on, 140-143
pyridostigmine effects on, in lean and obese NIDDM subjects, 893-898
Growth hormone (GH) therapy of children
of GH-deficient children, lipids and apos and, 1457-1461
of short children, changes in body composition, REE, and TEF in, 1543-1548
GSH, *see* Reduced glutathione in erythrocytes
Guanosine monophosphate (GMP), cyclic, responses of, to ANF, BNP, and CNP, 1531-1535

Hb (hemoglobin)
autologous blood transfusions for repeated phlebotomies in NIDDM and, 616
glycated, and effects of acute hyperinsulinemia on plasma CETP activity in NIDDM, 1363
glycosylated, *see* Glycosylated Hb
relationship between insulin sensitivity and, 424
HbA_1 (hemoglobin A_1)
and effects of sorbinil combined with insulin on STZ-DM-induced vascular dysfunction, 494, 497
in IDDM, oxidized lipids and, 1198
HbA_{1c} (hemoglobin A_{1c})
in essential hypertension, β-blocker effects on, 458
in IDDM, *see* HbA_{1c} in IDDM
in NIDDM, *see* HbA_{1c} in NIDDM
and postprandial amplification of Lp abnormalities, 271
HbA_{1c} (hemoglobin A_{1c}) in IDDM, 307
ATP release by osmotic shock and HbA_{1c} in erythrocytes, 435-440
with chronic renal failure, pancreas-kidney transplant and, 334, 343
and effects of newly insulin-treated IDDM on cholesterol synthesis, 1234
and erythrocyte aggregation, 1183, 1184
in IDDM subjects using oral contraceptives, 1381
and lipid peroxidation in LDLs and erythrocyte membranes, 1471
PP TGRLP effects on, 1064
RCT alterations associated with implantable IP insulin delivery and, 667
and von Willebrand factor levels after high-MUFA diet, 1407
HbA_{1c} (hemoglobin A_{1c}) in NIDDM
ATP release by osmotic shock and HbA_{1c} in erythrocytes, 435-440
autologous blood transfusions for repeated phlebotomies and, 616
in controlled NIDDM, urea synthesis and, 329
and effects of newly insulin-treated NIDDM on cholesterol synthesis, 1234
insulin sensitivity, Lps and, 502, 505
and lipid peroxidation in LDLs and erythrocyte membranes, 1471
postprandial glucose utilization and, 1550
and relationship between oxidative stress and insulin action, 1427

HCO_3 (bicarbonate)
Na, effects of, with and without Carbicarb on skeletal muscle pH and hemodynamic status in hypovolemic shock, 518-522
in uremia, 405
HDL(s), *see* High-density lipoprotein(s)
HDL-C, *see* High-density lipoprotein-cholesterol
Healthy subjects, *see* Normal adult subjects; Normal children
Heart
NE in, sucrose and 3-OHB supplementation effects on, 181-182
protein of, clenbuterol effects on, 1089
weight of, *see* Organ weight, heart
see also Heart disease; Heart failure; Heart rate *entries beginning with terms*: Myocardial, Ventricular *and element*: Card-
Heart disease, ischemic, prevalence of NIDDM, hypertension and, in former athletes, 1255-1260
Heart failure, congestive, total-body and myocardial substrate oxidation in, 174-179
Heart rate (HR)
β-adrenergic blocker effects on, 457, 567-568
in hyperglycemic STZ-DM, 64
of hyperthyroidic patients, 1024
of malaria patients, 975
of normotensive men, insulin sensitivity and, 884
and relationship between insulin sensitivity and hemorrheologic factors, 424, 425
resting, of exercising moderately obese men, 656, 657
Heat production, *see* Thermogenesis
Height
energy metabolism, skeletal muscle biochemistry and, 482
of exercising men, 566, 634, 837, 1403
of exercising women, *see* Height of exercising women
and four-compartment model, 418, 419
of hyperinsulinemic subjects, 71, 1580
and impact of obesity, AT distribution, and restricted energy intake on IGF-I, IGF-BP3, and GH, 316
of mildly cirrhotic subjects, hepatic glycogenolysis and, 86
and nandrolone effects on serum lipids, 205
of NIDDM subjects, 429, 1550
of obese women, 110, 1518
of PCOS subjects, 1537
of type I-A familial OI subjects, 1262
of vegetarians and nonvegetarians, RMR and, 622
of young postpubertal women, and bone mineral content and density, 264, 265
see also Short stature, children of
Height of exercising women
and brisk walking effects on PP lipemia, 837
and endurance training effects on LPL activity and plasma TG clearance, 809
and exercise effects on IGF-I, 1403
and lipids, apos, and CETP kinetics, 634
and serum CCK response to food intake, 218
Hematocrit
autologous blood transfusions for repeated phlebotomies in NIDDM and, 616
in IDDM with chronic renal failure, 334
of malaria patients, 975
relationship between insulin sensitivity and, 424, 425
Hemodynamics
effects of $NaHCO_3$ with and without Carbicarb on, in hypovolemic shock, 518-522
see also Blood flow; Blood pressure; Heart rate
Hemoglobin, *see entries beginning with acronym*: Hb
Hemorrheologic factors, relationship between insulin sensitivity and, in young men, 423-427
Hep G2 cells
CM-R effects on apo E synthesis in, 44-50
galactose effects on, 945-952
LDL receptor activity in, corticotropin and hydrocortisone effects on, 95
Heparin
effects of, on adipocyte precursor LPL activity, 147
see also Postheparin lipase activities
Hepatectomy
effects of, on glucose metabolism, 670-676
partial, *see* Liver regeneration following PH
Hepatic amino acids (AAs)
effects of D-alanine on levels of, 1154
independent and combined actions of IL-1β, TNF-α, and glucagon on metabolism of, 822-829
metabolism of, during hyperinsulinemia and hyperaminoacidemia in conscious pregnant subjects, 1079-1085
Hepatic arterial blood in pregnancy, 1080-1082
Hepatic blood flow (BF) in pregnancy, 1080
Hepatic cAMP (cyclic adenosine monophosphate) in uremia, sucrose effects on, 407
Hepatic carbohydrate (CHO) metabolism, sucrose enhancing uremia-induced disturbances in, 403-412
Hepatic cells, *see* Hepatocytes
Hepatic cirrhosis, *see* Cirrhosis
Hepatic clearance
functional nitrogen, and urea synthesis in controlled NIDDM, 329-332
of VLDLs, decreased TGs and increased, with MDL 29311, 233-240
Hepatic conversion of amino-nitrogen to urea in hyperthyroidism, 1023-1029
Hepatic failure, and utilization of glutamine-containing dipeptides, 1104-1107
Hepatic gluconeogenesis, effects of stress hormone infusion on, 1313
Hepatic glucose
cycling of, insulin dissociating glucagon-induced thermogenesis from, 1000-1005
in uremia, effects of sucrose on, 407
see also Hepatic glucose production
Hepatic glucose production (HGP)
effects of systemic infusions of endotoxin, TNF, and IL-1 on relationship between peripheral tissue glucose uptake and, 279-284
GLP-1 effects on, in healthy men, 104-108
in mild cirrhosis, hepatic glycogenolysis and, 87
in obesity, 540, 643, 843
Hepatic glycogen
effects of stress hormone infusion on, 1314, 1315
during refeeding, 288
Hepatic glycogenolysis in well-nourished mildly cirrhotic subjects, glucagon failure to stimulate, 85-89
Hepatic HMG-CoA (3-hydroxy-methylglutaryl coenzyme A) reductase
decrease in levels of mRNA and, in small intestine of STZ-DM subjects, 450-454
pravastatin as inhibitor of, and its effects on cholesterol content of VLDLs in heritable hyperlipidemia, 559-564
Hepatic insulin
beta cell response and extraction of, following alcohol withdrawal by noncirrhotic alcoholic subjects, 367-371
lack of delay in transit of, as indicated by insulin secretion and peripheral insulin pulses, 1144-1147

Hepatic lipase (HL)
ACTH and dexamethasone effects on, 92-93
in nephrotic hypertriglyceridemia, 254
postheparin plasma, activities of, in pregnancy with homozygous FH, 1167
in STZ-DM subjects, 303
Hepatic methionine synthase in hyperthyroidism and hypothyroidism, 1576
Hepatic mRNA (messenger ribonucleic acid), CETP levels of, dietary fat effects on, 1006-1012
Hepatic nuclei, metyrapone effects on tryptophan binding to, 79-84
Hepatic peroxisome, role of T in clofibrate-induced proliferation of, 169-173
Hepatic phosphoenolpyruvate carboxykinase (PEPCK) mRNA (messenger ribonucleic acid), cytosolic, in endotoxic shock, 1251
Hepatic pyruvate dehydrogenase, hepatoma cell, PKC role in insulin activation of, 1030-1034
Hepatic uricase, AA-193 and oxonate effects on, 127
Hepatic xanthine dehydrogenase, AA-193 effects on, 127
Hepatoblastoma, *see* Hepatoma; Hepatoma cells
Hepatocytes
lactate in, AICA-ribosome influence on extracellular pH control of utilization of, 157-162
liver regeneration and apo B secretion by, following partial hepatectomy, 681-690
TNF-α effects on albumin and glucose production in, 476-480; *see also* Hepatic glucose production
T_3S uptake by, 1284-1285
Hepatoma
7288CTC, perfused in situ with L-[(U)-^{14}C]lactate or D-[(U)-^{14}C]glucose, lactate release and uptake in, 1488-1497
Yoshida ascites, OKG limiting muscle protein breakdown in, without stimulation of tumor cell growth, 899-905
Hepatoma cells
PKC role in activation of hepatic pyruvate dehydrogenase by insulin in, 1030-1034
vanadate effects on PEPCK mRNA levels in, 1348
see also Hep G2 cells
Heredity
for hypertension in normotensive men, insulin sensitivity, AT distribution and, 883-886
see also Alleles; DNA; Gene(s); Genetic obesity; Heterozygotes; Phenotypes; RNA; Twins *and entries beginning with terms*: Congenital, Familial, Heritable
Heritable hyperlipidemia, pravastatin effects on cholesterol content of VLDLs in, 559-564
Heterozygotes for PKU, effects of high-protein diet with aspartame on plasma phenylalanine in, 413-416
Hexose, Hep G2 cell consumption of, galactose effects on, 948
HFD, *see* High-fat diet
HGP, *see* Hepatic glucose production
High altitude, sympathoadrenal response to, as determined by urinary and arterial EPI and NE, 1226-1232
High-carbohydrate (CHO) diet, hypocaloric, effects of, on glucose oxidation and LBM, 1481-1487
High-density lipoprotein(s) [HDLs; α (alpha)-lipoproteins]
buoyant large, hypertriglyceridemia in late pregnancy associated with formation of small dense LDLs and presence of, 1035-1041
dolichol content of, following partial hepatectomy, 679
effects of low-fat diet, calorie restriction, and running on, in moderately overweight men, 656, 658
in exercising women, 809
in nephrotic hypertriglyceridemia, 253
High-density lipoprotein(s) [HDLs; α (alpha)-lipoproteins] (*Continued*)
in NIDDM, 274-275
plasma, effects of weight loss by diet or exercise on, in men, 917-924
variations in subclasses of, during menstrual cycle, 1438-1441; *see also* High-density lipoprotein$_2$; High-density lipoprotein$_3$
see also High-density lipoprotein-cholesterol
High-density lipoprotein$_2$ (HDL$_2$)
in exercising women, 809
levels of PP, in older athletic men with silent myocardial ischemia, 190-198
in NIDDM with and without CAD, plasma CETP activity and, 1500
High-density lipoprotein$_3$ (HDL$_3$)
endurance exercise and, 809
in NIDDM with and without CAD, plasma CETP activity and, 1500
High-density lipoprotein-cholesterol (HDL-C)
ACTH and dexamethasone effects on, 93
amount of cholesterol relative to apo B in LDLs primarily related to, in children, 1042-1046
and ATP release in erythrocytes, 436
effects of phenotype and dietary fats on, 1008-1009
exercise effects on, *see* High-density lipoprotein-cholesterol, exercise effects on
in FH, 312, 400
in genetically obese subjects, 551-552, 556, 557
GH deficiency and, 200, 1458, 1459
in hyperinsulinemia, 1580
in IDDM, *see* High-density lipoprotein-cholesterol in IDDM
insulin sensitivity and, 501, 505, 525, 526
nandrolone decanoate mechanisms of depression of, 206-207
in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM
in normolipidemia, glucose and insulin regulation of, 1332-1337
in obesity, 1278, 1319
in PCOS, 649, 710
plasma, *see* Plasma high-density lipoprotein-cholesterol
serum, *see* Serum high-density lipoprotein-cholesterol
in STZ-DM, 301
tamoxifen effects on, 532
urinary excretion of epinephrine and, 511
High-density lipoprotein-cholesterol (HDL-C), exercise effects on
brisk walking effects on PP HDL-C in normolipidemic subjects, 837
effects of weight loss by diet or exercise on, in men, 918-920
of endurance exercise, 634, 636, 637
in normotensive obese women, 19, 20
High-density lipoprotein-cholesterol (HDL-C) in IDDM
effects of newly insulin-treated IDDM on synthesis of, 1234, 1237
and erythrocyte aggregation, 1183, 1188
PP TGRLP effects on, 1064
RCT and, 667
High-density lipoprotein-cholesterol (HDL-C) in NIDDM
autologous blood transfusions for phlebotomies and, 616
with and without CAD, plasma CETP activity and, 1500
and effects of acute hyperinsulinemia on plasma CETP activity, 1363
effects of newly insulin-treated NIDDM on synthesis of, 1234, 1237
mepacrine effects on, 132
PB effects on, 350
and postprandial amplification of Lp abnormalities, 276

High-density lipoprotein$_2$-cholesterol (HDL_2-C), serum, serum T level and sex difference in level of, 935-939
High-dose zinc (Zn) supplementation, effects of, on hyperzincuria in IDDM, 1558-1562
High-fat diet (HFD)
effects of, on plasma noncholesterol sterols in FH treated with simvastatin, 311-313
heat production and, 933
monounsaturated, von Willebrand factor levels after, in NIDDM, 1406-1409
High–monounsaturated-fat (MUFA) diet, von Willebrand factor levels after, in NIDDM, 1406-1409
High-protein diet
with aspartame, effects of, on plasma phenylalanine concentrations in heterozygotes for PKU, 413-416
hypocaloric, glucose oxidation improved, and lean body mass spared with, 1481-1487
Hindlimb muscle, *see* Skeletal muscle
Histidine
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
insulin effects on metabolism of, 73
[ring-2-^{14}C]Histidine, folate-mediated incorporation of, into DNA, thyroid hormone effects on, 1575-1578
Histology of pancreatic islets, effects of castration and/or hormonal replacement on, in NIDDM, 1217
HL, *see* Hepatic lipase
HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, *see* Hepatic HMG-CoA reductase; Ileal HMG-CoA reductase
HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, *see* Lovastatin; Pravastatin; Simvastatin
H_2O_2 (hydrogen peroxide), production of, in CF, 719-722
Homocysteine, maternal hyperhomocysteinemia as risk factor for NTDs, 1475-1480
Homozygous familial hypercholesterolemia (FH), pregnancy with, long-term LDL apheresis for, 1164-1170
Hormonal replacement
effects of castration and, on incidence of NIDDM, 1214-1220
with 17β-estradiol-dihydrogesterone in postmenopausal women, LDL changes in, 799-802
Hormone(s)
effects of ICV ODT8-SS on responses of, to stress, 1134-1143
plasma counterregulatory, in congestive heart failure, 176
responses of, to oral glucose ingestion, 99-101
see also Hormonal replacement; Hormone-sensitive lipase *specific hormones and specific conditions*
Hormone-sensitive lipase (HSL), adipocyte, regional differences in expression of, 241-247
HPA (hypothalamus-pituitary-adrenal) axis, ACTH secretagogues facilitating recovery of, suppressed by dexamethasone therapy, 544-548
HPT (hyperparathyroidism), biochemical, long-term lithium therapy and, 1563-1567
HR, *see* Heart rate
HSL (hormone-sensitive lipase), adipocyte, regional differences in expression of, 241-247
Humoral β (beta)-cell tropic factors in acute stress-induced hyperinsulinemia, 1221-1225
Hydrocortisone, *see* Cortisol; 18-Hydrocortisone
Hydrogen peroxide (H_2O_2), production of, in CF, 719-722
β (beta)-Hydroxybutyrate (OHB), and glucagon in control of protein and AA metabolism, 1511, 1522
3-Hydroxybutyrate (3-OHB), blood, in cirrhotic subjects, 1173
D(—)3-Hydroxybutyrate (3-OHB), effects of supplementation with, on SNS activity, 180-185
18-Hydroxycorticosterone, effects of low-dose Ag therapy of breast cancer in postmenopausal women on, 724
21-Hydroxylase, 24-hour pulsatile control of cortisol, 17-hydroxyprogesterone, and androstenedione release in prepubertal children deficient in, and in normal prepubertal children, 372-377
3-Hydroxy-3-methylglutaryl coenzyme A reductase, *see* Hepatic HMG-CoA reductase; Ileal HMG-CoA reductase
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, *see* Lovastatin; Pravastatin; Simvastatin
17-Hydroxypregnenolone, effects of low-dose Ag therapy of breast cancer in postmenopausal women on, 724
17-Hydroxyprogesterone (17-OHP)
concentrations of, in PCOS, AT distribution and, 709
effects of low-dose Ag therapy of breast cancer in postmenopausal women on, 724
24-hour pulsatile control of release of cortisol, androstenedione and, in normal and 21-hydroxylase-deficient prepubertal children, 372-377
Hydroxyproline, glucagon role in control of metabolism of, 1512, 1513
Hyperaminoacidemia, hepatic AA metabolism during hyperinsulinemia and, in conscious pregnant subjects, 1079-1085
Hyperandrogenic women
enhanced adrenocortical activity contributing to NIDDM in, 584-590
see also Hyperandrogenic women with PCOS
Hyperandrogenic women with PCOS
effects of Metformin therapy on, 647-654
insulin metabolism defect in, 1367-1372
see also Polycystic ovary syndrome
Hypercholesterolemia
familial, *see* Familial hypercholesterolemia
in GH-deficient men, 202
lovastatin decreasing plasma and platelet C levels and normalizing platelet fluidity and aggregation in, 11-17
Lp(a) concentrations and phenotype in, 572-578
quantitative characterization of glucose and insulin response to, cilazapril effects on, 360-366
Hyperglycemia
effects of, on preadipocyte differentiation induced by extracellular matrix components, 908-909
insulin versus, in modulation of AA metabolism during IVGTT of lean and obese subjects, 211-216
vanadate normalizing PEPCK mRNA and, in obese STZ-DM subjects, 1346-1354
see also entries beginning with term: Hyperglycemic *and specific hyperglycemic conditions*
Hyperglycemic factor, *see* Glucagon
Hyperglycemic streptozotocin-induced diabetes mellitus (STZ-DM), ischemia in, glycolytic metabolism and myocardial glucose transporters and, 61-69
Hyperhomocysteinemia, maternal, as risk factor for NTDs, 1475-1480
Hyperinsulinemia
acute, effects of, on plasma CETP activity in NIDDM and normal subjects, 1362-1366
acute stress-induced, in response to pertussis toxin, role of humoral β-cell tropic factors in, 1221-1225
associated with menstrual irregularity and altered serum androgens in Pima Indian women, 803-807

Hyperinsulinemia (*Continued*)
with concomitant AA infusions, effects of, on skeletal muscle protein turnover, 70-78
effects of, on plasma ET-1, 879
effects of endotoxin, TNF, and IL-1 infusions on, 281
hepatic AA metabolism during hyperaminoacidemia and, in conscious pregnant subjects, 1079-1085
increased glucose disposal and decreased gluconeogenesis without, in endotoxic shock, 1248-1254
in PCOS, Metformin therapy reducing, 647-654
as predictor of low tPA activity in normal subjects, 1579-1586
Hyperlipidemia (hyperlipemia)
heritable, pravastatin effects on cholesterol content of VLDLs in, 559-564
low levels of EFAs and, 991-992
quantitative characterization of glucose and insulin response to, cilazapril effects on, 360-366
in STZ-DM, 299-305
see also Hypercholesterolemia; Hypertriglyceridemia
Hyperparathyroidism (HPT), biochemical, long-term lithium therapy and, 1563-1567
Hyperplasia, nonclassic congenital adrenal, 24-hour pulsatile control of cortisol, 17-hydroxyprogesterone, and androstenedione release in prepubertal subjects with, 372-377
Hypertension
essential, effects of β-blockers with β_2-agonism on lipid and glucose metabolism in, 455-461
normotensive men with heredity for, insulin sensitivity, AT distribution and, 883-886
polyunsaturated fat effects on, 1-3
prevalence of NIDDM, ischemic heart disease and, in former athletes, 1255-1260
Hyperthyroidism
adaptive changes in T_3 transmembrane transport and metabolism in liver of fed and fasted subjects with, 1355-1361
folate-mediated incorporation of [ring-2-^{14}C]histidine into DNA in, 1575-1578
hepatic conversion of amino-nitrogen to urea in, 1023-1029
Hypertriglyceridemia
in late pregnancy associated with formation of small dense LDLs and presence of large buoyant HDLs, 1035-1041
Lp(a) concentrations and phenotype in, 572-578
mechanisms of, in nephrotic syndrome, 248-255
Hypertrophy, skeletal muscle, due to running, protein content and synthesis with, 994-999
Hyperuricemia
effects of daily alcohol intake on ethanol-induced, 745-748
hypouricemic and uricosuric actions of AA-193 in, 123-128
Hyperzincuria in IDDM, 1558-1562
Hypocaloric diet
high-protein and high-CHO, effects of, on glucose oxidation and lean body mass, compared, 1481-1487
lipolysis and gluconeogenesis from glycerol during weight reduction with very-low-calorie diet, 1293-1300
see also Calorie restriction
Hypoglycemia
in conscious subjects, *see* Hypoglycemia in conscious subjects
in healthy and IDDM subjects, theophylline enhancing recovery of glucose after, 776-781
Hypoglycemia in conscious subjects
moderate, inferior colliculus function impaired by, 1329-1331
redundant parasympathetic and sympathoadrenal mediation of increased glucagon secretion during insulin-induced, 860-866
Hypoglycemic effects, *see* Insulin-dependent diabetes mellitus, glycemic control of; Non–insulin-dependent diabetes mellitus, glycemic control of
Hypogonadal men, effects of T therapy on serum HDL-C and serum HDL_2-C level in, 935-939
Hypothalamic-ventromedial lesions, effects of, on pancreatic insulin content in NIDDM male subjects, 32-37
Hypothalamus-pituitary-adrenal (HPA) axis, ACTH secretagogues facilitating recovery of, suppressed by prolonged dexamethasone therapy, 544-548
Hypothyroidism
adaptive changes in T_3 transmembrane transport and metabolism in liver of fed and fasted subjects with, 1355-1361
folate-mediated incorporation of [ring-2-^{14}C]histidine into DNA in, 1575-1578
Hypouricemic action of AA-193 in hyperuricemia, 123-128
Hypovolemic shock, effects of $NaHCO_3$ with and without Carbicarb on skeletal muscle pH and hemodynamic status in, 518-522

IBAT, *see* Intercapsular brown adipose tissue
IC (inferior colliculus), moderate hypoglycemia impairing function of, in conscious subjects, 1329-1331
ICG (Indocyanine Green) in severe *Plasmodium falciparum* infection, 890
ICV (intracerebroventricular) somatostatin octapeptide, effects of, on hormonal and metabolic responses to stress in normal and diabetic subjects, 1134-1143
Idazoxan, effects of, on acute stress-induced hyperinsulinemia, 1223
IDDM, *see* Insulin-dependent diabetes mellitus
Idiopathic Fanconi syndrome, renal brush border membrane lipid composition in, 1073-1078
Idiopathic short stature (ISS) children, GH-BP levels in, 357-359
Ig, *see entries beginning with term*: Immunoglobulin
IGF, *see* Insulin-like growth factor-I; Insulin-like growth factor-II
IGF-BP, *see entries beginning with terms*: Insulin-like growth factor–binding protein
IGT, *see* Impaired glucose tolerance
IL, *see* Interleukin-1; Interleukin-1β
Ileal HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase
deficient activity of, in sitosterolemia, 855-859
role of lovastatin and bile acids in regulation of, 1446-1450
Immobilization
effects of, on GLUT4 mRNA expression in skeletal muscle, 1389-1394
see also Sedentary subjects
Immunoglobulin A (IgA) in IDDM, 1183
Immunoglobulin G (IgG)
in IDDM, 1183, 1184
urinary excretion of, in STZ-DM treated with insulin and sorbinil, 497
Immunoglobulin M (IgM) in IDDM, 1183
Immunoreactive hormone-sensitive lipase (HSL), regional differences in expression of, in adipocytes, 243
Immunoreactive insulin
nocturnal, ACX-SR effects on, 1211
plasma concentrations of, in acute stress-induced hyperinsulinemia, 1222
Immunosuppression, *see* FK506, immunosuppression with
Impaired glucose tolerance (IGT)
insulin production following IV glucose, arginine, and valine in NIDDM with, 385-389

Impaired glucose tolerance (IGT) (*Continued*)
insulin sensitivity, insulin secretion, and glucose effectiveness with, minimal model analysis of, 714-718
Implantable intraperitoneal (IP) insulin delivery in IDDM, alterations in RCT associated with, 665-669
Incidence
of NIDDM, effects of castration and hormonal replacement on, 1214-1220
see also specific conditions
Indirect calorimetry
of glucagon-induced thermogenesis, 1002
of hypocaloric high-protein diet effects, 1483-1484
in measurement of GH therapy effects on fuel metabolism, thyroid function, and EE in obese women, 873-874
of postprandial glucose utilization in NIDDM, 1553, 1555
Indocyanine Green (ICG) in severe *Plasmodium falciparum* infection, 890
Infection
albumin TER correlating with plasma albumin concentrations in acute, 697-705
gram-negative, fatty infiltration of liver during, regulatory factors in development of, 696-696
Plasmodium falciparum, *see* Severe *Plasmodium falciparum* malaria
Inferior colliculus (IC), moderate hypoglycemia impairing function of, in conscious subjects, 1329-1331
Injury, *see* Trauma and injury
Insulin
alanine and thionamide effects on, in hyperthyroidism, 1025
concentrations of, in nondiabetic men with decreased testosterone and DHEA concentrations, 599-603
dietary protein restriction effects on metabolism of, in normal subjects, 461-467
differential effects of, on whole-body proteolysis and glucose metabolism in normal-weight women, 441-445
effects of, on apo B secretion following PH, 686-687
effects of ICV ODT8-SS on responses of, to stress, 1136, 1139-1141
effects of supratherapeutic dose of androgenic steroids on glucose and amino acid metabolism stimulated by, 1266-1274
ET-1 release in endothelial cells increased by, 878-882
fasting, *see* Fasting insulin
HDL-C regulation by, in normolipidemia, 1332-1337
hepatic, *see* Hepatic insulin
hepatic glucose cycling and glucagon-induced thermogenesis dissociated by, 1000-1005
hyperglycemia versus, in modulation of AA metabolism during IVGTT of lean subjects, 211-216
hypoglycemia induced by, redundant parasympathetic and sympathoadrenal mediation of increased glucagon secretion during, in conscious subjects, 860-866
immunoreactive, *see* Immunoreactive insulin
in multiple trauma victims, 1307
in obesity, *see* Insulin in obesity
ODC in NIH-3T3 cells induced by, Ca^{2+}-calmodulin involvement in, 4-10
in PCOS, *see* Polycystic ovary syndrome, insulin in
PKC role in activation of hepatic pyruvate dehydrogenase in hepatoma cells by, 1030-1034
plasma, *see* Plasma insulin
quantitative characterization of response of, in hyperlipidemia and hypercholesterolemia, cilazapril effects on, 360-366
serum, *see* Serum insulin
stress hormone infusion effects on, 1312-1313
Insulin (*Continued*)
in vegetarians and nonvegetarians, 623
see also Alloxan-diabetes; $(Ca^{2+}+Mg^{2+})$-ATPase in kidney BLM, hormone-specific defect in insulin regulation of; Gestational diabetes mellitus; Hyperinsulinemia; Insulin-dependent diabetes mellitus; Insulin propeptides; Insulin receptor gene mutation; Insulin release and secretion; Insulin resistance; Insulin sensitivity; Neonatal diabetic subjects; Non–insulin-dependent diabetes mellitus; Proinsulin gene; Streptozotocin-induced diabetes mellitus *and entries beginning with terms*: Insulin-like growth factor
Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus)
cholesterol in, *see* Cholesterol in IDDM
effects of dietary protein restriction on glucose and insulin metabolism in, 461-467
endothelial function during oral contraception in women with, 1379-1383
erythrocytes in, *see* Insulin-dependent diabetes mellitus, erythrocytes in
glucose transport regulation and GLUT3 transporter mRNA expression in CMCs in, 591-598
glycemic control of, *see* Insulin-dependent diabetes mellitus, glycemic control of
hyperzincuria in, 1558-1562
Japanese, lack of association between TAP and, 1013-1017
leucine kinetics during fasting in, 378-384
lipids in, *see* Lipids in IDDM
Lps in, *see* Insulin-dependent diabetes mellitus, Lps in
theophylline enhancing recovery of glucose after hypoglycemia in, 776-781
Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus), erythrocytes in
ATP release by osmotic shock and HbA_{1c} in erythrocytes, 435-440
effects of glycemic control, race, and IDDM duration on erythrocyte GSH content, 306-309
increased erythrocyte aggregation in, and its relationship to plasma factors, 1182-1186
Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus), glycemic control of
effects of race, IDDM duration, and glycemic control on erythrocyte GSH content, 306-309
newly insulin-treated, effects of, on cholesterol synthesis, 1233-1240
in women using oral contraceptives, 1381
Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus), Lps in
Lp composition in IDDM with chronic renal failure, effects of pancreas-kidney transplantation on, 333-347
PP TGRLP increasing esterified cholesterol accumulation in THP-1 macrophages, 1063-1072
sex and oxidized lipids in, 1196-1200
Insulin-like growth factor-I (IGF-I)
in acromegaly before and after adenomectomy, 579-583
effects of, on ET-1 concentration, 880
effects of endurance training by older men and women on, 1401-1406
glucose transport in CMCs and, 593-594
in multiple trauma victims, 1307
in obesity, *see* Insulin-like growth factor-I in obesity
Insulin-like growth factor-I (IGF-I) in obesity
impact of obesity, AT distribution, and restricted energy intake on IGF-BP3, GH and, 315-319
nocturnal, ACX-SR effects on, 1211

Insulin-like growth factor-II (IGF-II) in acromegaly before and after adenomectomy, 579-583
Insulin-like growth factor–binding protein-1 (IGF-BP1) in acromegaly before and after adenomectomy, 579-583
Insulin-like growth factor–binding protein-2 (IGF-BP2) in acromegaly before and after adenomectomy, 579-583
Insulin-like growth factor–binding protein-3 (IGF-BP3)
in acromegaly before and after adenomectomy, 579-583
impact of obesity, AT distribution, and restricted energy intake on IGF-I, GH and, 315-319
Insulin in obesity
differential effects of, on whole-body proteolysis and glucose metabolism in reduced-obese and obese women, 441-445
effects of short-term pulsatile versus continuous delivery of insulin on lipid metabolism and whole-body glucose metabolism in obesity, 842-846
fasting, *see* Fasting insulin in obesity
hyperglycemia versus, in modulation of AA metabolism during IVGTT, 211-216
in JCR:LA corpulent subjects, 538-543
with and without NIDDM, insulin-induced decline in plasma AA metabolism concentrations and, 640-646
in uncomplicated obesity, association between insulin sensitivity, FFAs, and TG metabolism independent of, 1275-1281
Insulin propeptides in conditions associated with insulin resistance, 446-449
Insulin receptor (IR) gene mutation
absence of, in insulin resistance with PCOS, 1568-1574
at tyrosines 1162 and 1163, effects of, on IR serine phosphorylation and desensitization, 757-765
Insulin release and secretion
C-terminal glucagon fragments effects on, 771-775
insulin sensitivity, glucose effectiveness and, in IGT, minimal model analysis of, 714-718
insulin therapy effects on relative hypersecretion of amylin to insulin in STZ-induced NIDDM, 766-770
lack of delay in hepatic insulin transit as indicated by, 1144-1147
octreotide as inhibitor of, 24-31
PACAP effects on, in conscious subjects, 739-744
regulation of GDH activity in pancreatic islets and its consequences on, 1187-1195
VMH effects on pancreatic insulin content in male subjects, 32-37
Insulin resistance
endotoxin, TNS, IL-1 infusions and, 279-284
GDM and, 382
in hyperlipidemia and hypercholesterolemia, cilazapril effects on, 360-366
insulin propeptides in conditions associated with, 446-449
in lean and obese NIDDM subjects, effects of glucose and AA infusions on glucose turnover in, 428-434
in PCOS, *see* Polycystic ovary syndrome, insulin resistance in
Insulin sensitivity
association between FFAs, TG metabolism and, independent of uncomplicated obesity, 1275-1281
AT distribution, heredity for hypertension and, in normotensive men, 883-886
determinants of, and their consequences for Lps and BP in NIDDM, 501-508; *see also* Blood pressure, insulin sensitivity and
and insulin MCR in cystic fibrosis, 163-167
insulin secretion, glucose effectiveness and, in IGT, minimal model analysis of, 714-718
relationship between hemorrheologic factors and, in young men, 423-427
Insulin sensitivity (*Continued*)
sex difference in association of plasma insulin level with serum lipids and Lps in, 523-528
Intercapsular brown adipose tissue (IBAT)
dietary fat effects on, 51-60
sucrose and 3-OHB supplementation effects on, 181-182
Interleukin-1 (IL-1), effects of systemic infusions of endotoxin, TNF and, on glucose metabolism, 279-284
Interleukin-1β (IL-1β), independent and combined actions of TNF-α, glucagon and, on hepatic amino acid metabolism, 822-829
Intestinal pseudo-obstruction, chronic, Cu deficiency and, 1463-1464
Intestine, small, of STZ-DM subjects, decreased levels of hepatic HMG-CoA reductase and mRNA in, 450-454
Intraabdominal adipose tissue (AT), relationship between total serum testosterone and, in obese women, 390-395; *see also* Adipose tissue distribution in obese women
Intracellular triglycerides (TGs), gemfibrozil effects on, 257-262
Intracerebroventricular (ICV) somatostatin octapeptide (ODT8-SS), effects of, on hormonal and metabolic responses to stress in normal and diabetic subjects, 1134-1143
Intramuscular free amino acids (AAs), and OKG effects on Yoshida ascites hepatoma, 902
Intraperitoneal (IP) insulin delivery, implantable, in IDDM, alterations in RCT associated with, 665-669
Intravenous (IV) arginine, insulin production following IV glucose, IV valine and, in patients with impaired glucose tolerance and in NIDDM, 385-389
Intravenous (IV) fed state, leucine turnover in, 1338-1345
Intravenous (IV) fructose (F) in cirrhosis, lipid metabolism and substrate oxidation with, 1171-1181
Intravenous (IV) glucose
insulin production following IV arginine, IV valine and, in patients with impaired glucose tolerance and in NIDDM, 385-389
see also Intravenous glucose tolerance test
Intravenous glucose tolerance test (IVGTT)
effects of cilazapril on, in hypercholesterolemia and hyperlipidemia, 362, 363
frequently sampled, *see* Frequently sampled intravenous glucose tolerance test
insulin versus hyperglycemia in modulation of AA metabolism in lean and obese subjects during, 211-216
Intravenous (IV) valine, insulin production following IV glucose, IV arginine and, in patients with impaired glucose tolerance and in NIDDM, 385-389
Iodothyronine, sex-related differences in metabolism of, 793-797
IP (intraperitoneal) insulin delivery, implantable, in IDDM, alterations in RCT associated with, 665-669
IR, *see* Insulin receptor gene mutation
Iron (Fe), autologous blood transfusions for phlebotomies in NIDDM and, 616
Ischemia
arterial, ET release in myocutaneous island flaps in response to gradually inserting, 1201-1206
in hyperglycemic STZ-DM, glycolytic metabolism and myocardial glucose transporters and, 61-69
silent myocardial, reduced adipose tissue LPL responses, and levels of postprandial lipemia and HDL-2 in older athletic men, 190-198
Ischemic heart disease, prevalence of NIDDM, hypertension and, in former athletes, 1255-1260
Islets of Langerhans, *see* Pancreatic islets

Isoleucine
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
in pregnancy, 1082-1084
see also L-Isoleucine; Plasma isoleucine
L-Isoleucine in AA mixture supplying arginine-rich or arginine-free diet, 115
Isotopic enrichment
plasma and urine, following L-[1-^{13}C]phenylalanine and L-[ring-$^{2}H_5$]phenylalanine infusions, as evidence for isotope effect on renal function, 487-491
see also specific radiolabeled substances
ISS (idiopathic short stature) children, GH-BP levels in, 357-359
IV (intravenous) arginine, insulin production following IV glucose, IV valine and, in patients with impaired glucose tolerance and in NIDDM, 385-389
IV (intravenous) fed state, leucine turnover in, 1338-1345
IV (intravenous) fructose (F) in cirrhosis, lipid metabolism and substrate oxidation with, 1171-1181
IV (intravenous) glucose, *see* Intravenous glucose
IV (intravenous) valine, insulin production following IV glucose, IV arginine and, in patients with impaired glucose tolerance and in NIDDM, 385-389
IVGTT, *see* Intravenous glucose tolerance test

Japanese insulin-dependent diabetes mellitus (IDDM), lack of association between TAP and, 1013-1017
JCR:LA corpulent subjects, insulin and glucose metabolism in, 538-543

K (potassium), $Na^+ + K^+$-ATPase in kidney BLM of STZ-induced NIDDM subjects, 606
α (alpha)-Ketoglutarate, ornithine, limiting muscle protein breakdown without stimulation of tumor cell growth in Yoshida ascites hepatoma, 899-905
Ketoisocaproate (KIC), *see* Plasma ketoisocaproate
[^{14}C]α (alpha)-Ketoisocaproic acid (α-KIC), hyperinsulinemia effects on kinetics of, 74
Ketones, total plasma, in STZ-DM subjects, 301
KIC, *see* [^{14}C]α-Ketoisocaproic acid; Plasma ketoisocaproate
Kidney, *see* $(Ca^{2+} + Mg^{2+})$-ATPase in kidney BLM, hormone-specific defect in insulin regulation of; Nephrotic syndrome *and entries beginning with term*: Renal
Kinase, *see* Protein kinase C
Kinetics
of calcium uptake by renal brush border membrane, 1096
of dipeptide disappearance, 1374-1375
GDH, 1189
glucose, *see* Kinetics, glucose
glycerol, *see* Kinetics, glycerol
lactate, effects of partial hepatectomy on, 673
leucine, *see* Kinetics, leucine
NE, in vegetarians and nonvegetarians, 623
NEFA, in cirrhosis, 1174-1176
of [^{3}H]phenylalanine and α-KIC in hyperinsulinemia, 73-74
plasma arginine, in men, in response to arginine-free diet, 114-122
of plasma lipids, apos, and CETP after bicycle marathon, 633-639
see also Oxidation
Kinetics, glucose
effects of hepatectomy on, 673
during fasting in GDM, 380-381
and PB treatment of NIDDM, 351-352
Kinetics, glycerol
in cirrhosis, 1174, 1176
in severe *Plasmodium falciparum* malaria, 888-889
Kinetics, leucine, 442
during fasting in GDM, 378-384
and glucagon role in control of protein and AA metabolism, 1512
of [^{14}C]leucine in hyperinsulinemia, 73-74

Lactate
blood, *see* Blood lactate
DCA effects on, 977, 979
effects of ICV ODT8-SS on responses of, to stress, 1139, 1140
effects of partial hepatectomy on kinetics of, 673
glucagon role in control of metabolism of, 1512
hepatic cell, extracellular pH and control of utilization of, AICA-ribosome influence on, 157-162
in hyperglycemic STZ-DM, 65, 66
plasma, *see* Plasma lactate
release of, by skeletal muscle, glucose disposal and, 1050
release and uptake of, in hepatoma 7288CTC perfused in situ with L-[(U)-^{14}C]lactate or D-[(U)-^{14}C]glucose, 1488-1497
in uremia, effects of sucrose on, 406, 407
L-[(U)-^{14}C]Lactate, lactate release and uptake in hepatoma 7288CTC perfused in situ with, 1488-1497
Lactic acid, glucose conversion to, during organogenesis, 833
Lactic acidosis in severe malaria, DCA for, 974-981
Laminin, effects of, on preadipocyte differentiation induced by extracellular matrix components, 909
Large buoyant high-density lipoproteins (HDLs), hypertriglyceridemia in late pregnancy associated with formation of small dense LDLs and presence of, 1035-1041
Large neutral amino acids, *see* Amino acid(s)
LAT (lysolecithin acyltransferase) in NS, 1129-1130
Late pregnancy, hypertriglyceridemia in, associated with formation of small dense LDLs and presence of large buoyant HDLs, 1035-1041
Lathosterol, serum, in newly insulin-treated NIDDM and IDDM, 1237
LBM, *see* Lean body mass
LCAT, *see* Lecithin:cholesterol acyltransferase
LCFAs, *see* Long-chain saturated fatty acids
LDL(s), *see* Low-density lipoprotein(s)
LDL-C, *see* Low-density lipoprotein-cholesterol
LDL-R, *see* Low-density lipoprotein receptor
Lean body mass (LBM)
and bone mineral content and density in young postpubertal women, 264
DEXA and near-infrared interactance in study of, in normal adult subjects, 417-422
effects of hypocaloric high-protein diet on glucose oxidation and, 1481-1487
and effects of insulin on glucose metabolism and whole-body proteolysis, 443
in NIDDM subjects, and relationship between oxidative stress and insulin action, 1427
Lean subjects, *see* Non-obese subjects
Lecithin:cholesterol acyltransferase (LCAT)
effects of phenotype and dietary fats on, 1009-1010
in IDDM with chronic renal failure, 340, 343
in NS, 1128-1129
Left ventricular function in hyperglycemic STZ-DM, 64-65

Lesions, VMH, effects of, on pancreatic insulin content in male NIDDM subjects, 32-37
Leucine (Leu)
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
GDH activity in pancreatic islets and, 1189
glucagon role in control of metabolism of, 1512, 1513
insulin effects on metabolism of, 73
kinetics of, during fasting in GDM, 378-384
plasma, *see* Plasma leucine
in pregnancy, 1082-1084
R_a of, in obese women, insulin effects on, 441-445
turnover of, in IV fed state, 1338-1345
see also [^{14}C]Leucine; L-Leucine; Plasma leucine
[^{14}C]Leucine (Leu)
hyperinsulinemia effects on kinetics of, 73-74
metyrapone effects on incorporation of, into proteins, 83
L-Leucine (Leu) in AA mixture supplying arginine-free or arginine-rich diet, 115
Leukocytes
autologous blood transfusions for phlebotomies in NIDDM and, 616
see also specific types of leukocytes
Leydig cell function, FK506 effects on, 533-537
LFD, *see* Low-fat diet
LH, *see* Luteinizing hormone in PCOS
Linoleic acid, balance method to determine accumulation, metabolism, and oxidation of, in pregnancy, 940-944
α (alpha)-Linoleic acid, balance method to determine accumulation, metabolism, and oxidation of, in pregnancy, 940-944
Lipase, *see* Hepatic lipase; Hormone-sensitive lipase; Lipoprotein lipase activities; Pancreatic lipase inhibitor; Postheparin lipase activities
Lipemia, *see* Hyperlipidemia; Postprandial lipemia
Lipids
alterations in, following pancreas-kidney transplantation, sex difference in, 1241-1247
disorders in metabolism of CHOs and, in paraplegic or quadriplegic veterans, 749-756
effects of, on plasma activity and hepatic CETP mRNA levels, 1000-1005
effects of β-blockers with β_2-agonism on metabolism of, in essential hypertension, 455-461
in familial hypercholesterolemia, effects of lipid-lowering diet on, 400
fasting, *see* Fasting lipids
in GH-deficient children during GH therapy, 1457-1461
in Hep G2 cells, CM-R effects on, 46
in IDDM, *see* Lipids in IDDM
in NIDDM, *see* Lipids in NIDDM
in NS, 1128
in obesity, *see* Lipids in obese women
PACAP effects on metabolism of, in conscious subjects, 739-744
in PCOS, 650, 651, 709
peroxidation of, *see* Lipoperoxidation
plasma, *see* Plasma lipids
in postmenopausal women, effects of 17β-estradiol-dihydrogesterone therapy in, 800
renal brush border membrane composition of, with idiopathic Fanconi syndrome, 1073-1078
secretion of, during gram-negative sepsis, 692-693
serum, *see* Serum lipids
substrate oxidation and metabolism of, during IV fructose administration in cirrhosis, 1171-1181
Lipids (*Continued*)
see also Dietary fats; Hyperlipidemia; Normolipidemic subjects; Phospholipids; Steroids *entries beginning with term*: Fatty *element*: Lip- *and specific lipids*
Lipids in IDDM
peroxidation of, 1196-1200, 1470-1474
PP TGRLP effects on, 1064-1067
RCT alterations associated with implantable IP insulin delivery and, 667
Lipids in NIDDM
with and without CAD, plasma CETP activity and, 1499, 1500
effects of lipid infusions on glucose R_a in, 1300-1304
increased susceptibility of lipids to peroxidation, 1470-1474
PB effects on insulin-mediated lipid metabolism in, 348-356
serum, short-term effects of mepacrine on, 131-134
Lipids in obese women
EE and oxidation of, 112
effects of GH therapy on metabolism of, 875
effects of short-term pulsatile versus continuous insulin delivery on metabolism of, 842-846
Lipolysis
ACX-SR blockade of, normalizes nocturnal GH levels and pulsatility in obesity, 1207-1213
from glycerol during weight reduction with very–low-calorie diet, 1283-1300
Lipoperoxidation
effects of STZ-DM, insulin, and glucose load on, 1442-1445
in IDDM, 1196-1200, 1470-1474
in NIDDM, 1470-1474
Lipoprotein (Lp)
and brisk walking effects on PP lipemia in normolipidemic subjects, 838
changes in mass of, during pregnancy, 1038
dolichol content of, following partial hepatectomy, 679
effects of low-fat diet, calorie restriction, and running on concentrations of subfractions of, in moderately overweight men, 655-663
effects of Metformin therapy of PCOS on, 650
in FH, effects of lipid-lowering diet on, 400
in IDDM, *see* Insulin-dependent diabetes mellitus, Lps in
in nephrotic hypertriglyceridemia, 251
in NIDDM, *see* Non–insulin-dependent diabetes mellitus, Lps in
plasma, *see* Plasma lipoprotein(s)
serum, *see* Serum lipoprotein(s)
THL effects on, 296
see also Apolipoprotein(s); High-density lipoprotein(s); Lipoprotein(a); Lipoprotein lipase activities; Low-density lipoprotein(s); Very–low-density lipoprotein(s)
Lipoprotein(a) [Lp(a)]
in breast cancer, tamoxifen decreasing, 531-532
mepacrine effects on, in NIDDM, 132
in NS, 1126-1133
phenotypes and concentrations of, in hypercholesterolemia or hypertriglyceridemia, 572-578
plasma, in late pregnancy, 1036
Lipoprotein lipase (LPL) activities
ACTH and dexamethasone effects on, 92-93
in adipocyte precursors, effects of LCFAs on, 144-151
AT, *see* Adipose tissue lipoprotein lipase activities
increased plasma TG clearance and, in endurance exercising women, 808-813
MDL 29311 effects on, 236-237
in nephrotic hypertriglyceridemia, 254
postheparin plasma, in pregnancy with homozygous FH, 1167
in STZ-DM, 303

Lithium therapy, long-term, biochemical hyperparathyroidism and bone mineral status with, 1563-1567
Liver
of fed and fasted hypothyroidic and hyperthyroidic subjects, adaptive changes in T_3 transmembrane transport and metabolism in, 1355-1361
regulatory factors in development of fatty infiltration of, during gram-negative sepsis, 691-696
relationship of plasminogen synthesis by, to catabolism of plasminogen glycoforms I and II, 1430-1437
see also Liver regeneration following PH; Liver weight *entries beginning with term*: Arteriohepatic *and element*: Hepat-
Liver regeneration following PH, 677-690
and apo B secretion by hepatocytes, 681-690
changes in plasma dolichol levels, transport, and hepatic delivery during, 677-680
Liver weight
clofibrate effects on, 169
effects of sucrose on, in uremia, 405
in pregnancy, linoleic and α-linoleic acid effects on, 941
propionate effects on, in STZ-DM, 730
LNAAs (large neutral amino acids), *see* Amino acid(s)
Long-chain saturated fatty acids (LCFAs)
effects of, on adipocyte precursor LPL activity, 144-151
octanoic acid conversion into, in premature infants fed an MCT-containing formula, 1287-1292
Long-term therapy
with clenbuterol, anabolic effects of withdrawal and, 1086-1092
with dexamethasone, ACTH secretagogues facilitating recovery of HPA axis suppressed by, 544-548
LDL apheresis as, in pregnancy with homozygous FH, 1164-1170
with lithium, biochemical hyperparathyroidism and bone mineral status with, 1563-1567
Lovastatin
bile acids and, *see* Bile acids, lovastatin and
effects of, on plasma and platelet C levels, and on platelet fluidity and aggregation in hypercholesterolemia, 11-17
Low-density lipoprotein(s) [LDLs; β (beta)-lipoproteins]
acetylated and oxidative-modified, effects of, on cholesterol synthesis, and apo E synthesis in peritoneal macrophages, 1523-1530
amount of cholesterol relative to apo B in, primarily related to HDL-C in children, 1042-1046
apheresis of, as long-term therapy of pregnancy with homozygous FH, 1164-1170
changes in, in postmenopausal women on 17β-estradiol-dihydrogesterone therapy, 799-802
dolichol content of, following partial hepatectomy, 679
effects of low-fat diet, calorie restriction, and running on, in moderately overweight men, 656, 658
in exercising women, 809
in IDDM, *see* Low-density lipoprotein in IDDM
in NIDDM, and increased susceptibility to lipoperoxidation, 1470-1474
relationship between improved PP lipemia, and metabolism of, during tetrahydrolipstatin therapy, 293-298
small dense, hypertriglyceridemia in late pregnancy associated with formation of, and presence of large buoyant HDLs, 1035-1041
in STZ-DM, 301
see also Low-density lipoprotein-cholesterol; Low-density lipoprotein receptor; Very–low-density lipoprotein(s)
Low-density lipoprotein(s) in IDDM
with chronic renal failure, effects of pancreas-kidney transplantation on, 335, 337, 338
and lipoperoxidation, 1198, 1470-1474
Low-density lipoprotein-cholesterol (LDL-C)
ACTH and dexamethasone effects on, 93
in exercising men, 634, 637
in exercising normotensive obese women, 19, 20
in FH, 312, 400
GH deficiency and, 200, 1458, 1459
in hypertriglyceridemic, hypercholesterolemic, and/or normolipidemic subjects, 573
in IDDM, *see* Low-density lipoprotein-cholesterol in IDDM
insulin sensitivity and, 505, 525
in NIDDM, *see* Low-density lipoprotein-cholesterol in NIDDM
in PCOS, 649, 710
serum, *see* Serum low-density lipoprotein-cholesterol
tamoxifen effects on, 532
in uncomplicated obesity, association between insulin sensitivity, FFAs, and TG metabolism independent of, 1278
urinary excretion of epinephrine and, 511
VAT, androgens and, in obese men, 1319
Low-density lipoprotein-cholesterol (LDL-C) in IDDM
effects of newly insulin-treated IDDM on synthesis of, 1234, 1237
PP TGRLP effects on, 1064
RCT alterations associated with implantable IP insulin delivery in, 667
Low-density lipoprotein-cholesterol (LDL-C) in NIDDM
and effects of acute hyperinsulinemia on plasma CETP activity, 1363
effects of newly insulin-treated NIDDM on synthesis of, 1234, 1237
mepacrine effects on, 132
Low-density lipoprotein receptor (LDL-R)
ACTH effects on activity of, 93, 95
lack of deficiency of, in FH, 397-402
Low-dose aminoglutethimide (Ag) therapy alone for advanced breast cancer in postmenopausal women, adrenal effects of, 723-727
Low-fat diet (LFD)
effects of, on plasma noncholesterol sterols in FH treated with simvastatin, 311-313
effects of calorie restriction, running and, on Lp subfraction concentrations in moderately obese men, 655-663
heat production and, 933
Low-protein diet, *see* Dietary protein restriction
Lp, *see* Lipoprotein
Lp(a), *see* Lipoprotein(a)
LPL, *see* Lipoprotein lipase activities
Luteinizing hormone (LH) in PCOS
AT distribution and concentrations of, 709
and insulin action in adipocytes, 1537
Metformin therapy effects on, 649
Lymphocytes
LDL receptor of, in FH, 399, 400
levels of GLUT3 mRNA in, in IDDM and nondiabetic subjects, 595
Lysine
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
insulin effects on metabolism of, 73

L-Lysine in AA mixture supplying arginine-rich or arginine-free diet, 115
Lysolecithin acyltransferase (LAT) in NS, 1129-1130

α (alpha)-Macroglobulin, effects of high-MUFA diet on, 1408
Macrophages
peritoneal, effects of acetylated and oxidative-modified LDLs on apo E synthesis in, 1523-1530
THP-1, PP TGRLP increasing esterified cholesterol accumulation in, in IDDM, 1063-1072
Magnesium (Mg)
effects of, on GDH, 1189-1190
see also $(Ca^{2+}+Mg^{2+})$-ATPase in kidney BLM, hormone-specific defect in insulin regulation of
Malaria, *see* Severe *Plasmodium falciparum* malaria
Male subjects
differential effects of dietary fats on SNS in, 51-60
NIDDM, effects of VMH lesions on pancreatic insulin content in, 32-37
see also Men
Malignant disease
chronic, albumin TER correlating with plasma albumin concentrations in, 697-705
see also Breast cancer; Hepatoma
Maltase in kidney BLM
in obesity, 1056
in STZ-induced NIDDM, 606
Maternal hyperhomocysteinemia, as risk factor for NTDs, 1475-1480
MCR, *see* Metabolic clearance rate
MCTs (medium-chain triglycerides), octanoic acid conversion into LCFAs in premature infants fed formula containing, 1287-1292
MDL 29311, increased hepatic clearance of VLDLs and decreased TG clearance with, 233-240
Meals, *see* Diet
Medium-chain triglycerides (MCTs), octanoic acid conversion into LCFAs in premature infants fed formula containing, 1287-1292
Medullary thick ascending limb (mTAL), CNP, ANF, and BNP receptors in, 1531-1535
Men
ACTH effects on plasma Lp metabolism in, 90-97
CHO and lipid metabolism disorders in paraplegic or quadriplegic veterans, 749-756
exercising, *see* Men, exercising
GH-deficient, serum lipid levels in, 199-203
GLP-1 effects on HGP in, 104-108
hypogonadal, effects of T therapy on serum HDL-C and serum HDL_2-C level in, 935-939
nondiabetic, with decreased testosterone and DHEA concentrations, insulin and glucose concentrations in, 599-603
non-obese, *see* Non-obese subjects
normotensive, with heredity for hypertension, insulin sensitivity and AT distribution in, 883-886
obese, *see* Men, obese
plasma arginine kinetics in, in response to arginine-free diet, 114-122
young, *see* Young men
see also Male subjects; Normal adult subjects; Sex
Men, exercising
and β-adrenoceptor blockade of post-exercise O_2 consumption, 565-571
kinetics of plasma lipids, apos, and CETP after bicycle marathon by, 633-639
Men, exercising (*Continued*)
obese, *see* Men, obese exercising
prevalence of NIDDM, hypertension, and ischemic heart disease in formerly, 1255-1260
see also Older men, exercising; Young men, exercising
Men, obese
VAT, androgens, and plasma lipids in, 1318-1323
see also Men, obese exercising; Obesity
Men, obese exercising
effects of exercise on anthropometric indices, fat-free mass, and REE in, 1148-1152
effects of low-fat diet, calorie restriction, and running on Lp subfraction concentrations in moderately obese men, 655-663
see also Men, obese exercising, weight loss by
Men, obese exercising, weight loss by
effects of weight loss by diet alone or combined with aerobic exercise on body composition of older, 867-871
effects of weight loss by diet or exercise on plasma HDL levels in, 917-924
Menses
insulin action in adipocytes of amenorrheic subjects with PCOS, 1536-1542
normal, Metformin therapy of PCOS facilitating, 647-654
see also Menstrual cycle
Menstrual cycle
irregular, hyperinsulinemia associated with altered serum androgens and, in Pima Indian women, 803-807
variations in HDL subclasses during, 1438-1441
Mepacrine, short-term effects of, on serum lipids, Lps, and apos in NIDDM, 131-134
Messenger ribonucleic acid, *see* mRNA
Metabolic clearance rate (MCR)
effects of ICV ODT8-SS on responses of, to stress, 1136, 1141
insulin, insulin sensitivity in CF and, 163-167
of molecular weight glucagon in mild cirrhosis, hepatic glycogenolysis and, 87
Metabolic rate, *see* Metabolic clearance rate; Resting metabolic rate
Metabolites
liver, in uremia, effects of sucrose on, 405-407
see also specific metabolites
Metformin
glucose transport in CMCs and, 593-594
for PCOS reducing hyperinsulinemia, insulin resistance, hyperandrogenemia, systolic BP, and facilitating normal menses and pregnancy, 647-654
Methionine
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
insulin effects on metabolism of, 73
plasma, after adaptation to diets with different protein content, 1341
L-Methionine in AA mixture supplying arginine-rich or arginine-free diet, 115
Methionine synthase, hepatic, in hyperthyroidism and hypothyroidism, 1576
N-Methyl-D-aspartate (NMDA) receptor antagonists, effects of, on glucose-deprivation neurotoxicity, 1110
2-Methyl-1,2-di-3-pyridyl-1-propanone (metyrapone), effects of, on tryptophan binding to hepatic nuclei, 79-84

5,10-Methylenetetrahydrofolate reductase in hypothyroidism and hyperthyroidism, 1576
Methylhistidine, and glucagon role in control of protein and AA metabolism, 1512, 1513
Metoprolol, effects of, on lipid and glucose metabolism in essential hypertension, 455-461
Metyrapone (2-methyl-1,2-di-3-pyridyl-1-propanone), effects of, on tryptophan binding to hepatic nuclei, 79-84
Mg, *see* Magnesium
Microvascular endothelial cells, extracellular matrix components secreted by, stimulating preadipocyte differentiation, 906-912
Mild cirrhosis, well-nourished subjects with, glucagon failure to stimulate hepatic glycogenolysis in, 85-89
Mineral content, *see* Total-body bone mineral content
Minimal model analysis of insulin sensitivity, insulin secretion, and glucose effectiveness in IGT, 714-718
Mitochondrial oxygen (O_2) consumption, effects of burn injury on glycerol phosphate shuttle and, 913-916
Moderate hypoglycemia, inferior colliculus function impaired by, in conscious subjects, 1329-1331
Moderate obesity, effects of low-fat diet, calorie restriction, and running on Lp subfractions in men with, 655-663
Mononuclear cells, circulating, regulation of glucose transport and GLUT3 transporter mRNA expression in, in IDDM and nondiabetic subjects, 591-598
Monophosphate
  cyclic adenosine, *see* cAMP
  cyclic guanosine, responses of, to ANF, BNP, and CNP, 1531-1535
Monounsaturated-fat (MUFA) diet, high, von Willebrand factor levels after, in NIDDM, 1406-1409
Morphology, Hep G2 cell, galactose effects on, 946
mRNA (messenger ribonucleic acid)
  adipocyte, long-chain FA effects on, 147-149
  decreased levels of hepatic HMG-CoA reductase and, in small intestine of STZ-DM subjects, 450-454
  HSL, levels of, and HSL expression in adipocytes, 244
  levels of hepatic CETP, dietary fat effects on, 1006-1012
  PEPCK, *see* Phosphoenolpyruvate carboxykinase mRNA
  see also GLUT1 transporter mRNA; GLUT2 transporter mRNA; GLUT3 transporter mRNA; GLUT4 transporter mRNA
mTAL (medullary thick ascending limb), CNP, ANF, and BNP receptors in, 1531-1535
MUFA (monounsaturated-fat) diet, high, von Willebrand factor levels after, in NIDDM, 1406-1409
Multiple trauma victims, influence of diet with and without AAs on polyamine urinary excretion in, 1305-1309
Muscle
  MDL 29311 effects on LPL activities in, 237
  see also Muscle cells; Muscle protein; Skeletal muscle *and entries beginning with element*: Myo-
Muscle cells, pioglitazone regulating glucose transport in, 953-958
Muscle protein
  clenbuterol effects on, 1089, 1122, 1123
  OKG limiting breakdown of, without stimulation of tumor cell growth in Yoshida ascites hepatoma, 899-905
  salbutamol effects on, 1122, 1123
  see also Skeletal muscle protein
Mutation, IR, *see* Insulin receptor gene mutation
Myocardial blood flow (BF), regional, in hyperglycemic STZ-DM, 65
Myocardial glucose transporters, and glycolytic metabolism during ischemia in hyperglycemic STZ-DM, 61-69
Myocardial ischemia, silent, older athletes with, reduced adipose tissue LPL responses, and levels of postprandial lipemia and HDL-2 in, 190-198
Myocardial substrate oxidation in congestive heart failure, 174-179
Myocutaneous island flaps, ET release in, in response to gradually insetting venous stasis or arterial ischemia, 1201-1206

N (nitrogen)
  amino-, hepatic conversion of, to urea in hyperthyroidism, 1025
  functional hepatic clearance of, and urea synthesis in controlled NIDDM, 329-332
  hypocaloric high-protein diet effects on balance of, 1484
  protein restriction effects on metabolism of, 324
  urea, *see* Urea nitrogen
Na (sodium) in vegetarian and nonvegetarian diet, 623
NADPH (nicotinamide adenine dinucleotide diphosphate) cytochrome C reductase in kidney BLM
  in obesity, 1056
  in STZ-induced NIDDM, 606
$NaHCO_3$ (sodium bicarbonate), effects of, with and without Carbicarb on skeletal muscle pH and hemodynamic status in hypovolemic shock, 518-522
$Na^+ + K^+$-ATPase (sodium$^+$ + potassium$^+$-adenosine triphosphatase) in kidney BLM of STZ-induced NIDDM subjects, 606
Naloxone, effects of, on preprandial and postprandial GH response to GH-RH in AN, 140-143
Nandrolone decanoate, effects of, on serum lipids, 204-210
Natriuretic factor, atrial, cGMP responses to, 1531-1535
Natriuretic peptide, brain and C-type, cGMP responses to, 1531-1535
NCCAH (nonclassic congenital adrenal hyperplasia), 24-hour pulsatile control of cortisol, 17-hydroxyprogesterone, and androstenedione release in prepubertal subjects with, 372-377
NE, *see* Norepinephrine; [^{3}H]Norepinephrine
Near-infrared interactance, DEXA and, in study of four-compartment model, 417-422
NEFAs, *see* Nonesterified fatty acids
Neonatal diabetic subjects
  lean, glucose and arginine injections in, enhancing diabetes and increasing pancreatic islet antigen expression, 1410-1418
  with STZ-DM, Ca^{2+}-channel currents in, 1395-1400
Nephrotic syndrome (NS)
  abnormal acyltransferase activities and accelerated CET in, 1126-1133
  mechanisms of hypertriglyceridemia in, 248-255
Nervous system, *see* Sympathetic nervous system
Neural-tube defects (NTDs), maternal hyperhomocysteinemia as risk factor for, 1475-1480
Neurotoxicity, alcohol intake and glucose-deprivation, in cortical cells, 1108-1113
Neutrophils, increased chemiluminescence production by, in CF, 719-722
NH_3, *see* Ammonia
Nicotinamide adenine dinucleotide diphosphate, *see* NADPH cytochrome C reductase in kidney BLM
NIDDM, *see* Non–insulin-dependent diabetes mellitus
NIH-3T3 cells, PDGF-, FGF-, and insulin-induced ODC in, Ca^{2+}-calmodulin system in, 4-10
Nitrendipine, beta cell binding sites for, in neonatal STZ-DM, 1395-1400
Nitrogen, *see* N
NMDA (*N*-methyl-D-aspartate) receptor antagonists, effects of, on glucose-deprivation neurotoxicity, 1110

[^{13}C]NMR (nuclear magnetic resonance), glycogen synthesis pathway determined with, 38-43
Nocturnal growth hormone (GH), ACX-SR blockade of lipolysis normalizing pulsatility and levels of, in obesity, 1207-1213
Noncholesterol sterols, plasma, dietary fat effects on concentrations of, in FH treated with simvastatin, 311-313
Noncirrhotic alcoholic subjects, hepatic insulin extraction in, following alcohol withdrawal, 367-371
Nonclassic congenital adrenal hyperplasia (NCCAH), 24-hour pulsatile control of cortisol, 17-hydroxyprogesterone, and androstenedione release in prepubertal subjects with, 372-377
Nondiabetic subjects
  frequency of TAP alleles in, 1015
  glucose transport regulation and GLUT3 transporter mRNA expression in CMCs in, 591-598
  glycolytic metabolism in, 61-69
  insulin and glucose concentrations in nondiabetic men with decreased testosterone and DHEA concentrations, 599-603
  mepacrine effects in, 131-134
  PB effects on lipid and insulin-mediated glucose metabolism in, 348-356
  postprandial glucose utilization in, 1549-1557
  zinc status in, 1558-1562
Nonesterified fatty acids (NEFAs)
  effects of supratherapeutic dose of androgenic steroids on, 1270
  kinetics of, in cirrhotic subjects, 1174-1176
  plasma, *see* Plasma nonesterified fatty acids
Non–insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus)
  castration and hormonal replacement effects on incidence of, 1214-1220
  cholesterol in, *see* Cholesterol in NIDDM
  enhanced adrenocortical activity contributing to, in hyperandrogenic women, 584-590
  erythrocytes in, *see* Non–insulin-dependent diabetes mellitus, erythrocytes in
  glycemic control, *see* Non–insulin-dependent diabetes mellitus, glycemic control of
  with impaired glucose tolerance, insulin production following IV glucose, arginine, and valine in, 385-389
  in lean subjects, *see* Non–insulin-dependent diabetes mellitus, non-obese subjects with
  lipids in, *see* Lipids in NIDDM
  Lps in, *see* Non–insulin-dependent diabetes mellitus, Lps in
  obesity and, *see* Non–insulin-dependent diabetes mellitus, obesity and
  PB effects on insulin-mediated glucose metabolism in, 348-356
  plasma CETP activity in, *see* Plasma cholesteryl ester transfer protein in NIDDM
  prevalence of hypertension, ischemic heart disease and, in former athletes, 1255-1260
  relationship between insulin action and oxidative stress in, 1426-1429
  repeated phlebotomies in, autologous blood transfusions for, 614-620
  short-term mepacrine effects on serum apos in, 131-134
  STZ-induced, *see* Streptozotocin-induced non–insulin-dependent diabetes mellitus
  VMH lesions effects on pancreatic insulin content in male subjects with, 32-37
  von Willebrand factor levels after high-MUFA diet in, 1406-1409
Non–insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), erythrocytes in
Non–insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), erythrocytes in (*Continued*)
  AR inhibition effects on erythrocyte GSH redox status in, 965-968
  ATP release in erythrocytes by osmotic shock and HbA_{1c} in, 435-440
  in autologous blood transfusions for repeated phlebotomies, 616
Non–insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), glycemic control of
  hepatic efficacy for urea synthesis and, 329-332
  insulin therapy effects on relative hypersecretion of amylin to insulin in streptozotocin-induced, 766-770
  newly insulin-treated NIDDM, effects of, on cholesterol synthesis, 1233-1240
Non–insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), Lps in
  determinants of insulin sensitivity and their consequences for Lps and BP in NIDDM, 501-508
  plasma CETP and, 1363, 1499, 1500
  postprandial amplification of Lp abnormalities in NIDDM and its relationship to postprandial lipemia, to C-peptide and glucagon levels, 270-278; *see also* C-peptides in NIDDM
  short-term mepacrine effects of serum Lps in, 131-134
Non–insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), non-obese subjects with
  insulin-resistant subjects, effects of glucose and AA infusions on glucose turnover in, 428-434
  plasma AA concentrations in, 640-646
  pyridostigmine effects on GH response to GH-RH in, 893-898
Non–insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), obesity and
  insulin-induced decline of plasma AA concentrations in, 640-646
  and insulin resistance, effects of glucose and AA infusions on glucose turnover in, 428-434
  pyridostigmine effects on GH response to GH-RH in, 893-898
  and SM glucose metabolism, 1047-1054
Non-obese subjects
  AAs in, *see* Non-obese subjects, AAs in
  ACX-SR in blockade of lipolysis in, 1207-1213
  CCK associated with reduced food intake in, 735-738
  decreased (Ca^{2+}+Mg^{2+})-ATPase activity in kidney BLM of, 1055-1061
  effects of ACX-SR blockade of lipolysis on nocturnal GH levels and pulsatility in, 1207-1213
  neonatal diabetic, glucose and arginine injections in, enhancing diabetes and increasing pancreatic islet antigen expression, 1410-1418
  NIDDM, *see* Non–insulin-dependent diabetes mellitus, non-obese subjects with
  uric acid homeostasis in non-obese prepubertal girls, 819-821
  women, differential effects of insulin on glucose metabolism and whole-body proteolysis in, 441-445
Non-obese subjects, AAs in
  in insulin-resistant NIDDM subjects, effects of glucose and AA infusions on glucose turnover, 428-434
  insulin versus hyperglycemia in AA metabolism modulation during IVGTT in, 211-216
  with and without NIDDM, plasma AA concentrations in, 640-646
Nonprotein respiratory quotient (NPRQ;RQ_{np})
  EE and, in obese women, 111
  and effects of dietary fat and CHOs on substrate utilization, 163
Nonvegetarians, sympathetic nervous system activity and RMR in, 621-625
Norepinephrine (NE)
  in determination of sympathoadrenal response at high altitude, 1226-1232

Norepinephrine (NE) (*Continued*)
dietary fat effects on, 55-56
effects of ICV ODT8-SS on responses of, to stress, 1136, 1139-1141
effects of stress hormone infusion on, 1312-1313
heart, 3-OHB supplementation effects on, 181
in IDDM and normal subjects, theophylline effects on, 777
kinetics of, in vegetarians and nonvegetarians, 623
plasma, *see* Plasma norepinephrine
see also [^{3}H]Norepinephrine; Norepinephrine, urinary excretion of
[^{3}H]Norepinephrine (NE), dietary fat effects on turnover of, 53-54, 56-58
Norepinephrine (NE), urinary excretion of
in determination of sympathoadrenal response at high altitude, 1226-1232
and serum lipid levels, 511
Normal adult subjects
conscious, *see* Conscious subjects
DEXA and near-infrared interactance in study of four-compartment models in, 417-422
dietary protein restriction in, *see* Normal adult subjects, dietary protein restriction in
endothelin release in endothelial cells of, 878-882
erythrocytes in, *see* Normal adult subjects, erythrocytes in
fatty acid metabolism in, 982-993
FFA and arginine interaction effects on GH secretion in, 223-226
glucagon stimulation of hepatic glycogenolysis in, 85-89
ICV somatostatin octapeptide effects on hormonal and metabolic responses to stress by, 1134-1143
IGF-I, IGF-II, IGF-BP1, -BP2, and -BP3 in, 579-583
insulin, *see* Normal adult subjects, insulin in
lipid metabolism and substrate oxidation during fructose administration to, 1171-1181
Lp(a) concentrations and phenotypes in, 572-578
Lps in, *see* Normal adult subjects, Lps in
neutrophil chemiluminescence production in, 719-722
plasma CETP activity in, 1362-1366
plasma glucose thresholds for GCR following OGTT of, 98-103
protein ingestion effects on splanchnic and whole-body O_2 consumption, blood flow, and blood temperature in, 626-632
renal brush border membrane lipid composition in, 1075, 1076
stress hormone and AA infusions effects on protein synthesis and AA metabolism in skeletal muscle of, 1158-1163
sympathetic response to high altitude in, 1226-1232
theophylline enhancing glucose recovery after hypoglycemia in, 776-781
tPA activity in, 1579-1586
vanadate effects on reproductive efficiency of, 1384-1388
young, *see* Young men; Young women
see also Men; Women
Normal adult subjects, dietary protein restriction in
effects of, on glucose and insulin metabolism, 462-467
short-term adaptation to dietary protein restriction, 320-327
Normal adult subjects, erythrocytes in
aldose reductase inhibition effects on GSH redox status of erythrocytes, 965-968
ATP release by osmotic shock and HbA_{1c} in erythrocytes, 435-440
erythrocyte aggregation, 1183
erythrocyte GSH content, 306-309
Normal adult subjects, insulin in
hepatic insulin transit in, 1144-1147
insulin effects on cholesterol synthesis in, 1233-1240
Normal adult subjects, insulin in (*Continued*)
insulin effects on ET-1 release in endothelial cells, 878-882
insulin production following IV glucose, IV arginine, and IV valine in, 385-389
and PB effects on insulin-mediated glucose metabolism in, 348-356
Normal adult subjects, Lps in
effects of TG-rich Lps on cholesterol accumulation in THP-1 macrophages of, 1063-1072
postprandial amplification of Lp abnormalities in, 270-278
Normal children, prepubertal, 24-hour pulsatile control of cortisol, 17-hydroxyprogesterone, and androstenedione release in, 372-377
Normal glucose tolerance, insulin sensitivity, insulin secretion, and glucose effectiveness with, minimal model analysis of, 714-718
Normal menses and pregnancy, Metformin therapy of PCOS facilitating, 647-654
Normolipidemic subjects
effects of brisk walking on PP lipemia in young, 836-841
HDL-C in, glucose and insulin regulation of, 1332-1337
Lp(a) concentrations in, 572-578
Normoponderal subjects, *see* Non-obese subjects
Normotension
high resting blood pressure during submaximal exercise as CV risk factor in obese women with, 18-23
insulin sensitivity, AT distribution, and heredity for hypertension in men with, 883-886
NPRQ, *see* Nonprotein respiratory quotient
NS, *see* Nephrotic syndrome
NTDs (neural-tube defects), maternal hyperhomocysteinemia as risk factor for, 1475-1480
NTPase (nucleoside triphosphatase), metyrapone effects on activity of, 83
[^{13}C]Nuclear magnetic resonance (NMR), glycogen synthesis pathway determined with, 38-43
Nuclear RNA (ribonucleic acid), [^{14}C]orotate-labeled, metyrapone effects on release of, 83
Nucleoside triphosphatase (NTPase), metyrapone effects on activity of, 83
Nutrition, *see* Diet

O_2 (oxygen) consumption
excess post-exercise, effects of β-adrenergic blockers on, 565-571
and glucagon role in control of protein and AA metabolism, 1513
mitochondrial, effects of burn injury on glycerol phosphate shuttle and, 913-916
in myocutaneous island flaps with gradually insetting venous stasis and/or arterial ischemia, 1203
splanchnic and whole-body, effects of protein ingestion on, 626-632
see also $\dot{V}O_{2max}$
Obesity
AAs in, *see* Obesity, AAs in
ACX-SR blockade of lipolysis normalizing nocturnal GH levels and pulsatility in, 1207-1213
android, effects of calorie restriction with and without D-fenfluramine therapy on GH release after stimulation with GRF in, 969-973
decreased activity of (Ca^{2+}+Mg^{2+})-ATPase in kidney BLM in, hormone-specific defect in insulin regulation of ATPase and, 1055-1061
genetic, *see* Genetic obesity
GH in, *see* Growth hormone, obesity and
glucose in, *see* Glucose in obesity

Obesity (*Continued*)
hyperinsulinemia and, 1583
insulin in, *see* Insulin in obesity
with NIDDM, *see* Non–insulin-dependent diabetes mellitus, obesity and
in prepubertal girls, uric acid homeostasis in, 819-821
relationship between serum Lps and, in children with different apo E phenotypes, 470-475
STZ-DM with, vanadate normalizing hyperglycemia and PEPCK mRNA in, 1346-1354
see also Men, obese; Women, obese
Obesity, AAs in
AA metabolism modulation during IVGTT in obesity, insulin versus hyperglycemia and, 211-216
insulin-induced decline of plasma AA concentrations with or without NIDDM, 640-646
in NIDDM, effects of glucose and AA infusions on glucose turnover, 428-434
OCs, *see* Oral contraceptives
Octanoic acid, conversion of, into LCFAs in premature infants fed a formula containing MCTs, 1287-1292
Octapeptide, effects of ICV somatostatin, on hormonal and metabolic responses to stress in normal and diabetic subjects, 1134-1143
Octreotide, as inhibitor of insulin, glucagon, and GH secretion, 24-31
ODC (ornithine decarboxylase), PDGF-, FGF-, and insulin-induced, in NIH-3T3 cells, Ca^{2+}-calmodulin system in, 4-10
ODT8-SS (somatostatin octapeptide), effects of ICV, on hormonal and metabolic responses to stress in normal and diabetic subjects, 1134-1143
OGTT, *see* Oral glucose tolerance test
OHB (β-hydroxybutyrate), and glucagon in control of protein and AA metabolism, 1511, 1512
3-OHB, *see* 3-Hydroxybutyrate; D(—)3-Hydroxybutyrate
17-OHP, *see* 17-Hydroxyprogesterone
OI (osteogenesis imperfecta), type I-A familial, serum PICP in, 1261-1265
Oil, fish, suppressing Ca^{2+}-dependent heat production in skeletal muscle, 931-934
OKG (ornithine α-ketoglutarate) limiting muscle protein breakdown without stimulation of tumor cell growth in Yoshida ascites hepatoma, 899-905
Older men, exercising
athletic, with silent myocardial ischemia, reduced adipose tissue LPL responses, and levels of postprandial lipemia and HDL-2 in, 190-198
effects of exercise on body composition and plasma insulin responses in, 847-854
endurance training effects on IGF-1 in, 1401-1406
obese, effects of weight loss by diet alone or combined with aerobic exercise on body composition of, 867-871
Older subjects
effects of clenbuterol and salbutamol on skeletal muscle mass in, 1119-1125
see also Older men, exercising; Older women, exercising
Older women, exercising
effects of exercise on body composition and plasma insulin responses in, 847-854
endurance training effects on IGF-I in, 1401-1406
Oleic acid, effects of, on adipocyte precursor LPL activity, 147-149
Opioids, dysregulation of, in AN, 140-143
Oral contraceptives (OCs)
and adaptation of glucose metabolism to short-term fasting, 1503-1508
Oral contraceptives (OCs) (*Continued*)
endothelial function with, in IDDM women, 1379-1383
and insulin propeptide levels, 446-449
Oral glucose
glucose absorption and production following, compartmental and arteriovenous-difference methods in measurement of, 1419-1425
and glycogen turnover during refeeding, 286-287
see also Oral glucose tolerance test
Oral glucose tolerance test (OGTT)
effects of endurance exercising on, in older men and women, 848, 849
of IGT subjects, 715
in NIDDM, 587, 1216
plasma glucose thresholds for GCR following, 98-103
Organ weight
adrenal, dexamethasone effects on, 545
clenbuterol effects on, 961, 962
heart, *see* Organ weight, heart
kidney, *see* Organ weight, kidney
liver, *see* Liver weight
Organ weight, heart
clenbuterol effects on, 1089
dietary fat effects on, 53
Organ weight, kidney
and $(Ca^{2+}+Mg^{2+})$-ATPase activity in kidney BLM, 1056
in NIDDM, 606
Organogenesis, embryonic glucose metabolism during, 830-835
Ornithine
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1160, 1161
glucagon role in control of metabolism of, 1512, 1513
in multiple trauma victims, 1308
plasma, arginine-free diet effects on, 119
see also Ornithine decarboxylase; Ornithine α-ketoglutarate
Ornithine decarboxylase (ODC), PDGF-, FGF-, and insulin-induced, in NIH-3T3 cells, Ca^{2+}-calmodulin system in, 4-10
Ornithine α-ketoglutarate (OKG) limiting muscle protein breakdown without stimulation of tumor cell growth in Yoshida ascites hepatoma, 899-905
Orosomucoid
in acute infectious disease, 699
in chronic malignant disease, 702
[^{14}C]Orotate, nuclear RNA labeled with, metyrapone effects on release of, 83
Osmotic shock (OS), ATP release by HbA_{1c} and, in erythrocytes of IDDM and NIDDM subjects, 435-440
Osteogenesis imperfecta (OI), type I-A familial, serum PICP in, 1261-1265
Osteopenia, CsA-induced, 1114-1118
Osteoporosis
Cu deficiency and, 1464-1465
severe, vitamin B_{12} and etidronate reversing, in pernicious anemia, 468-469
Overweight, *see* Obesity
Oxaloacetate transaminase, serum glutamate, in well-nourished mildly cirrhotic subjects, 86
Oxidase
deficiency in D-amino acid, effects of D-alanine infusions on, 1153-1157
see also Cytochrome oxidase in kidney BLM
Oxidation
glucose, *see* Oxidation, glucose
histidine, in hyperthyroidism and hypothyroidism, 1576

Oxidation (*Continued*)
of linoleic and α-linoleic acids, balance method to determine accumulation, metabolism and, in pregnancy, 940-944
lipid, *see* Oxidation, lipid
see also Carbohydrate oxidation; Kinetics; Lipoperoxidation; β-Oxidation; Oxidative stress; Redox status; Substrate oxidation *and entries beginning with term*: Oxidative
Oxidation, glucose
of [^{14}C-1]glucose and [^{14}C-6]glucose to $^{14}CO_2$ during organogenesis, 833
hypocaloric high-protein diet improving, 1481-1487
Oxidation, lipid
in cirrhotic subjects, 1172
in IDDM, sex difference in, 1196-1200
β (beta)-Oxidation, hepatic peroxisomal, 169
Oxidative-modified low-density lipoproteins (LDLs), effects of, on cholesterol synthesis and apo E synthesis in peritoneal macrophages, 1523-1530
Oxidative stress, relationship between insulin action and, in NIDDM, 1426-1429
2-Oxoglutarate, effects of, on GDH, 1188
Oxonate, effects of AA-193 and, on hepatic uricase, 127
Oxygen, *see* O_2 consumption

P, *see* Phosphate
P falciparum malaria, *see* Severe *Plasmodium falciparum* malaria
PA (plasminogen activator), tissue, hyperinsulinemia and activity of, 1579-1586
PACAP (pituitary adenylate cyclase-activating polypeptide), effects of, on secretion of adrenal hormone, glucagon, and insulin, and on glucose and lipid metabolism in conscious subjects, 739-744
PAI-1, *see* Plasminogen activator inhibitor-1
Pancreas
effects of VMH lesions on insulin content of, in male subjects, 32-37; *see also* Insulin release and secretion
see also Pancreas-kidney transplantation *entries beginning with term*: Pancreatic
Pancreas-kidney transplantation (PKT)
effects of, on Lp composition in IDDM with chronic renal failure, 333-347
sex difference in lipid alterations following, 1241-1247
Pancreatic hormones, *see* Glucagon; Insulin
Pancreatic islets
antigen to, neonatal glucose and arginine injections increasing expression of, in non-obese diabetic subjects, 1410-1418
effects of castration and/or hormonal replacement on, in NIDDM, 1217, 1219
FK506 immunosuppression and transplantation of, in STZ-DM, 135-139
regulation of GDH activity in, and its consequence on insulin release, 1187-1195
see also Beta cells
Pancreatic lipase inhibitor, tetrahydrolipstatin as, relationship between improved PP lipemia and LDL metabolism during therapy with, 293-298
Pancreatic polypeptides, plasma, in insulin-induced hypoglycemia, 861-862
Paraplegic veterans, CHO and lipid metabolism disorders in, 749-756
Parasympathetic mediation, redundant, of increased glucagon secretion during insulin-induced hypoglycemia in conscious subjects, 860-866
Parathyroid hormone (PTH), defect in, and insulin regulation of (Ca^{2+}+Mg^{2+})-ATPase activity in kidney BLM of NIDDM subjects, 604-613
Partial hepatectomy, *see* Liver regeneration following PH
PB (phenobarbital), effects of, on insulin-mediated glucose and lipid metabolism in NIDDM, 348-356
PCOS, *see* Polycystic ovary syndrome
PDGF (platelet-derived growth factor), ODC in NIH-3T3 cells induced by, Ca^{2+}-calmodulin involvement in, 4-10
PDH, *see* Phosphate dehydrogenase
PEP, *see* Phosphoenolpyruvate
PEPCK, *see* Phosphoenolpyruvate carboxykinase mRNA
Peptides, *see* C-peptides; Dipeptides; Glucagon-like peptide-1; Natriuretic peptide; Octapeptide; Polypeptides; Propeptide(s)
Peripheral insulin, lack of delay in hepatic insulin transit as indicated by, 1144-1147
Peripheral tissue, effects of systemic infusions of endotoxin, TNF, and IL-1 on relationship between HGP and glucose uptake by, 279-284
Peritoneal macrophages, effects of acetylated and oxidative-modified LDLs on apo E synthesis in, 1523-1530
Pernicious anemia, vitamin B_{12} and etidronate reversing severe osteoporosis in, 468-469
Peroxidation, *see* Lipoperoxidation
Peroxide, hydrogen, production of, in CF, 719-722
Peroxisome, hepatic, role of testosterone in clofibrate-induced proliferation of, 169-173
Pertussis toxin, acute stress-induced hyperinsulinemia in response to, role of humoral β-cell tropic factors in, 1221-1225
PGM (phosphoglucomutase), galactose effects on activity of, in Hep G2 cells, 948
pH
extracellular, hepatic cell lactate utilization controlled by, 157-162
skeletal muscle, effects of $NaHCO_3$ with and without Carbicarb on, in hypovolemic shock, 518-522
PH (partial hepatectomy), *see* Liver regeneration following PH
Phe, *see* Phenylalanine
Phenobarbital (PB), effects of, on insulin-mediated glucose and lipid metabolism in NIDDM, 348-356
Phenotypes
apo E, relationship between serum Lps and obesity in children with different, 470-475
effects of dietary fat and, on plasma cholesterol, HDL-C, apo A-I, LCAT, and CETP, 1008-1010
hypercholesterolemia and/or hypertriglyceridemia, 572-578
Phenylalanine (Phe)
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
insulin effects on metabolism of, 73
plasma, *see* Plasma phenylalanine
see also [^{3}H]Phenylalanine; L-Phenylalanine; L-[1-^{13}C]Phenylalanine; L-[ring-$^2H_5$]Phenylalanine; L-Phenylalanine methyl ester; Plasma phenylalanine
[^{3}H]Phenylalanine (Phe), hyperinsulinemia effects on kinetics of, 73-74
L-Phenylalanine (Phe)
in AA mixture supplying arginine-free or arginine-rich diet, 115
CCK release by, and association with reduced food intake, 735-738
L-[1-^{13}C]Phenylalanine (Phe), plasma and urine isotopic enrichment following infusions of, 487-491

L-[ring-$^2H_5$]Phenylalanine (Phe), plasma and urine isotopic enrichment following infusions of, 487-491
L-Phenylalanine (Phe) methyl ester, L-aspartyl-, with high-protein diet, effects of, on plasma phenylalanine concentrations in heterozygotes for PKU, 413-416
L-Phenylhydrazine, effects of, on lipid peroxidation in LDLs and erythrocyte membranes in IDDM and NIDDM, 1471
Phenylketonuria (PKU), heterozygotes for, effects of high-protein diet with aspartame on plasma phenylalanine in, 413-416
Phlebotomies, repeated, in NIDDM, autologous blood transfusions and, 614-620
4β-Phorbol 12β-myristate 13α-acetate (PMA)
  effects of, on pyruvate dehydrogenase activity in hepatoma cells, 1032
  IR serine phosphorylation and desensitization with IR gene mutation at tyrosines 1162 and 1163 and, 757-765
Phosphatase, alkaline, in malaria patients, 975
Phosphate (P)
  dihydroxyacetone, effects of, in uremia, 407
  insulin effects on ($Ca^+ + Mg^+$)-ATPase in STZ-induced NIDDM and, 606
  see also ATP; Diphosphate; Fructose-6-phosphate; Glucose-6-phosphate; Glycerol-3-phosphate; Glycerol-3-phosphate acyltransferase; Monophosphate; Phosphate dehydrogenase; Phosphate shuttle
Phosphate dehydrogenase (PDH)
  adipocyte glycerol-3-, long-chain FA effects on, 147-149
  glucose-6-, galactose effects on activity of, in Hep G2 cells, 948
  glyceraldehyde-3, vanadate effects on levels of, in obese STZ-DM subjects, 1347-1350
Phosphate shuttle, glycerol, effects of burn injury on mitochondrial O_2 consumption and, 913-916
Phosphoenolpyruvate (PEP)
  effects of uremia on, 407
  see also Phosphoenolpyruvate carboxykinase mRNA
Phosphoenolpyruvate carboxykinase (PEPCK) mRNA (messenger ribonucleic acid)
  cytosolic hepatic, in endotoxic shock, 1251
  vanadate normalizing hyperglycemia and, in obese STZ-DM subjects, 1346-1354
Phosphoglucomutase (PGM), galactose effects on activity of, in Hep G2 cells, 948
Phosphohydrolase, phosphotidate, G3P and activities of, and fatty infiltration of liver during gram-negative sepsis, 693-694
Phospholipids (PLs)
  autologous blood transfusions for phlebotomies in NIDDM and, 616
  in FH, effects of lipid-lowering diet on, 400
  in NIDDM with and without CAD, plasma CETP activity and, 1500
  in NS, 1129
  phospholipid to protein ratio in IDDM, 1069
  plasma, *see* Plasma phospholipids
  pravastatin effects on cholesterol content of, in heritable hyperlipidemia, 560
  renal brush border membrane, in idiopathic Fanconi syndrome, 1075, 1076
  T therapy effects on, 936, 937
Phosphorylation
  desensitization and, of IR serine, effects of IR gene mutation at tyrosines 1162 and 1163 on, 757-765
  in uremia, sucrose effects on, 407, 409
Phosphotidate phosphohydrolase (PPH), G3P and activities of, and fatty infiltration of liver during gram-negative sepsis, 693-694
Physical activity, *see* Men, exercising; Women, exercising *and specific forms of physical activity; for example*: Running
PICP (carboxy-terminal propeptide of type I procollagen), serum, in familial type I-A osteogenesis imperfecta, 1261-1265
Pioglitazone, glucose transport regulation by, in muscle cells, 953-958
Pituitary adenylate cyclase-activating polypeptide (PACAP), effects of, on secretion of adrenal hormone, glucagon, and insulin, and on glucose and lipid metabolism in conscious subjects, 739-744
Pituitary cells, anterior, T_3S uptake and suppression of TSH secretion in, 1282-1286
PKC, *see* Protein kinase C
PKT, *see* Pancreas-kidney transplantation
PKU (phenylketonuria), heterozygotes for, effects of high-protein diet with aspartame on plasma phenylalanine in, 413-416
PL(s), *see* Phospholipids
Placental examination in pregnancy with homozygous FH, 1167
Plasma, isotopic enrichment of, following L-[1-^{13}C]phenylalanine and L-[ring-$^2H_5$]phenylalanine infusions, as evidence for isotope effect in renal tubular reabsorption, 487-491
Plasma alanine
  after adaptation to diets with different protein content, 1341
  very–low-calorie diet effects on, 1295
Plasma albumin
  albumin TER correlating with concentrations of, in acute infectious disease and chronic malignant disease, 697-705
  in cirrhosis, 1172
  in nephrotic hypertriglyceridemia, 249
Plasma amino acids (AAs)
  after adaptation to diets with different protein content, 1341
  effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1161
  hyperinsulinemia and concentration of, 73
  insulin-induced decline in, in obesity with or without NIDDM, 640-646
  in mild cirrhosis, hepatic glycogenolysis and, 87
  and OKG effects on Yoshida ascites hepatoma, 901-902
  see also specific plasma amino acids
Plasma androstenedione with insulin resistance, 1569
Plasma apolipoprotein(s) (apos)
  ACTH and dexamethasone effects on, 93
  concentrations of, in PCOS, AT distribution and, 710
  kinetics of, after endurance exercise, 633-639
  in late pregnancy, 1036-1037
  see also specific apolipoproteins
Plasma apolipoprotein A-I (apo A-I)
  in genetically obese subjects, 557
  kinetics of, and endurance exercise, 634, 636, 637
Plasma apolipoprotein A-II (apo A-II)
  in genetically obese subjects, 557
  kinetics of, and endurance exercise, 634, 636, 637
Plasma apolipoprotein B (apo B)
  in IDDM with chronic renal failure, 335, 337
  kinetics of, and endurance exercise, 637
Plasma arginine, kinetics of, in men, 114-122
Plasma aspartate transaminase in cirrhotic subjects, 1172
Plasma bile acid, lovastatin effects on, 1020
Plasma bilirubin in cirrhosis, 1172
Plasma cAMP (cyclic adenosine monophosphate), PACAP effects on concentrations of, in conscious subjects, 740-742
Plasma catecholamines
  β-adrenoceptor blocker effects on, EPOC and, 568-569
  see also Plasma epinephrine; Plasma norepinephrine

Plasma cholestanol in CTX, effects of lovastatin and CDCA on bile acid metabolism and levels of, compared, 1018-1022
Plasma cholesterol (C)
effects of phenotype and dietary fats on, 1008-1009
fasting, propionate effects on concentrations of, in STZ-DM, 731
in genetically obese subjects, 550-551, 555
in IDDM with chronic renal failure, 335, 337
kinetics of, and endurance exercise, 634, 637
lovastatin effects on, in hypercholesterolemia, 11-17
in nephrotic hypertriglyceridemia, 251
PACAP effects on concentrations of, in conscious subjects, 740-742
Plasma cholesteryl ester transfer protein (CETP)
acute hyperinsulinemia effects on activity of, in normal subjects, 1362-1366
dietary fat effects on hepatic CETP mRNA levels and on activities of, 1006-1012
kinetics of, after endurance exercise, 633-639
in NIDDM, *see* Plasma cholesteryl ester transfer protein in NIDDM
Plasma cholesteryl ester transfer protein (CETP) in NIDDM
acute hyperinsulinemia effects on activity of, 1362-1366
with and without coronary artery disease, 1498-1502
Plasma citrulline, arginine-free diet effects on, 119
Plasma corticosterone, dexamethasone effects on, 545-546
Plasma corticotropin (ACTH; adrenocorticotropin hormone), dexamethasone effects on, 545-546
Plasma cortisol
and adaptation of glucose metabolism to short-term fasting, sex difference in, 1506
in congestive heart failure, 176
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1160-1161
PACAP effects on concentrations of, in conscious subjects, 740-742
in women with Cushing's syndrome, 1518
Plasma C-peptides (connecting peptides)
and cholesterol synthesis in newly insulin-treated NIDDM and IDDM, 1235, 1237
fasting, 133, 391, 1237
and relationship between total serum T and intraabdominal AT in obese women, 391
and sex difference in adaptation of glucose metabolism to short-term fasting, 1506
Plasma creatinine (Cr) in cirrhosis, 1172
Plasma dehydroepiandrosterone (DHEA), effects of endurance exercising on, in older men and women, 848, 849
Plasma dolichol, changes in levels, transport, and hepatic delivery of, during liver regeneration following partial hepatectomy, 677-680
Plasma endothelin-1 (ET-1), effects of hyperinsulinemia on, 879
Plasma epinephrine (E; EPI; adrenaline)
in congestive heart failure, 176
in insulin-induced hypoglycemia, 862, 863
insulin sensitivity and, 424, 425
PACAP effects on concentrations of, in conscious subjects, 740-742
and sex difference in adaptation of glucose metabolism to short-term fasting, 1506
Plasma factors, erythrocyte aggregation in IDDM and its relationship to, 1182-1186
Plasma fibrinogen in hyperinsulinemia, 1581
Plasma flow, hyperinsulinemia, AA infusions and, 73
Plasma free-fatty acids (FFAs)
ACTH and dexamethasone effects on, 93
β-adrenoceptor blocker effects on, EPOC and, 568
effects of supratherapeutic dose of androgenic steroids on, 1272
in essential hypertension, β-adrenergic blocker effects on, 459
mepacrine effects on, in NIDDM, 133
PACAP effects on concentrations of, in conscious subjects, 740-742
Plasma fructose (F) in cirrhosis, 1173
Plasma glucagon
AA infusions effects on, 72
in congestive heart failure, 176
in controlled NIDDM, urea synthesis and, 330
effects of C-terminal glucagon fragments on, 773-774
and hepatic glycogenolysis in mild cirrhosis, 86-87
in insulin-induced hypoglycemia, 862, 863
PACAP effects on concentrations of, in conscious subjects, 740-742
and sex difference in adaptation of glucose metabolism to short-term fasting, 1506
in STZ-DM, 301
very–low-calorie diet effects on, 1295
Plasma glucose
AA infusions effects on, 72
in acute stress-induced hyperinsulinemia in response to pertussis toxin, 1222
basal concentrations of, in lean subjects, 212
in cirrhosis, 1173
effects of endotoxin, TNF, and IL-1 infusions on, 281
effects of glucagon on, 1001-1002
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1160-1161
fasting, *see* Fasting plasma glucose
and glucagon role in control of protein and AA metabolism, 1511
in insulin-induced hypoglycemia, 861
and insulin resistance in PCOS, 1569
in mild cirrhosis, hepatic glycogenolysis and, 87
in NIDDM, *see* Plasma glucose in NIDDM
in obesity, 212, 539, 551-552
PACAP effects on concentrations of, in conscious subjects, 740-742
in STZ-DM, 301, 494, 497
thresholds of, for GCR following OGTT, 98-103
in uremia, effects of sucrose on, 406
very–low-calorie diet effects on, 1295
Plasma glucose in NIDDM
fasting, mepacrine effects on, 133
PB effects on, 350
STZ-induced NIDDM, dexamethasone effects on, 767
VMH lesion effects on, in male subjects, 34, 35
Plasma glutamate after adaptation to diets with different protein content, 1341
Plasma glycerol
ACTH and dexamethasone effects on, 93
and glucagon role in control of protein and AA metabolism, 1511
Plasma growth hormone (GH) in congestive heart failure, 176
Plasma high-density lipoprotein(s) (HDLs), effects of weight loss by diet or exercise on, in men, 917-924
Plasma high-density lipoprotein-cholesterol (HDL-C)
in genetically obese subjects, 551, 556
and lipid peroxidation in LDLs and erythrocyte membranes in IDDM and NIDDM, 1471

Plasma hormones
counterregulatory, in congestive heart failure, 176
see also specific hormones
Plasma insulin
AA infusions effects on, 72
basal concentrations of, in lean subjects, 212
in cirrhosis, 1172-1174
effects of C-terminal glucagon fragments on, 773-774
effects of endotoxin, TNF, and IL-1 infusions on, 281
effects of endurance exercise on responses of, in older men and women, 847-854
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1160-1161
effects of Metformin therapy of PCOS on, 650-651
in endotoxic shock, 1249-1250
fasting, *see* Fasting plasma insulin
and glucagon role in control of protein and AA metabolism, 1511
immunoreactive, in acute stress-induced hyperinsulinemia, 1222
and insulin resistance in PCOS, 1569
in mild cirrhosis, hepatic glycogenolysis and, 87
in NIDDM, *see* Plasma insulin in NIDDM
in normotensive men, insulin sensitivity and, 885
in obesity, 121, 539, 1350
PACAP effects on concentrations of, in conscious subjects, 740-742
and sex difference in adaptation of glucose metabolism to short-term fasting, 1506
sex difference in association between insulin sensitivity and level of, with serum lipids and Lps, 523-528
in STZ-DM, 301
very–low-calorie diet effects on, 1295
Plasma insulin in NIDDM
in controlled NIDDM, urea synthesis and, 330
mepacrine effects on, 133
PB effects on, 350
VMH lesion effects on, in male subjects, 34, 35
Plasma isoleucine
after adaptation to diets with different protein content, 1341
basal concentration of, in lean and obese subjects, 212
in obese NIDDM and nondiabetic subjects, 642, 644
Plasma ketoisocaproate (KIC)
after adaptation to diets with different protein content, 1341
arginine-free diet effects on, 118
Plasma ketones, total, in STZ-DM, 301
Plasma lactate
in endotoxic shock, 1250
glucagon role in control of metabolism of, 1511
in uremia, effects of sucrose on, 406
Plasma leucine (Leu)
after adaptation to diets with different protein content, 1341
arginine-free diet effects on, 118
basal concentrations of, in lean and obese subjects, 212
in obese NIDDM and nondiabetic subjects, 642, 644
Plasma lipids
ACTH and dexamethasone effects on, 92, 93
dietary fat effects on, in FH treated with simvastatin, 312
fasting, 294-296, 730, 731
kinetics of, after endurance exercise, 633-639
in late pregnancy, 1036-1037
in nephrotic hypertriglyceridemia, 251
in NIDDM, 272, 1216
in normolipidemic subjects, 1333, 1334
in obesity, *see* Plasma lipids in obesity
in PCOS, AT distribution and, 710
Plasma lipids (*Continued*)
in STZ-DM, 301
see also specific lipids
Plasma lipids in obesity
in genetically obese subjects, 549-553, 555-556
VAT, androgens and, in obese men, 1318-1323
Plasma lipoprotein(s) (Lps)
CETP role in, 1011
corticotropin effects on metabolism of, 90-97
dietary fat effects on, in FH treated with simvastatin, 312
in NIDDM, *see* Plasma lipoprotein(s) in NIDDM
Plasma lipoprotein(s) (LPs) in NIDDM
postprandial amplification of Lp abnormalities, 272
and plasma CETP activity, 1363, 1499, 1500
Plasma lipoprotein(a) [Lp(a)] in late pregnancy, 1036
Plasma methionine after adaptation to diets with different protein content, 1341
Plasma noncholesterol sterols, dietary fat effects on concentrations of, in FH treated with simvastatin, 311-313
Plasma nonesterified fatty acids (NEFAs)
and glucagon role in control of protein and AA metabolism, 1511, 1512
in STZ-DM, 301
Plasma norepinephrine (NE)
and adaptation of glucose metabolism to short-term fasting, sex difference in, 1506
in congestive heart failure, 176
in insulin-induced hypoglycemia, 862
insulin sensitivity and, 424, 425
PACAP effects on concentrations of, in conscious subjects, 740-742
Plasma ornithine decarboxylase (ODC), arginine-free diet effects on, 119
Plasma pancreatic polypeptides in insulin-induced hypoglycemia, 861-862
Plasma phenylalanine (Phe)
basal concentrations of, in lean and obese subjects, 212
in heterozygotes for PKU, effects of high-protein diet with aspartame on, 413-416
in obese NIDDM and nondiabetic subjects, 642, 644
Plasma phospholipids (PLs)
and lipid peroxidation in LDLs and erythrocyte membranes in IDDM and NIDDM, 1471
in STZ-DM, 301
Plasma postheparin lipase activities, lipoprotein and hepatic, in pregnancy with homozygous FH, 1167
Plasma protein
in IDDM, erythrocyte aggregation and, 1183, 1184
synthesis of, by Hep G2 cells, galactose effects on, 947
total, insulin sensitivity and, 424, 425
Plasma serine after adaptation to diets with different protein content, 1341
Plasma substrates
in endotoxic shock, 1249-1250
see also specific substrates
Plasma testosterone (T) in PCOS subjects with insulin resistance, 1569
Plasma threonine after adaptation to diets with different protein content, 1341
Plasma total cholesterol (TC), and lipid peroxidation in LDLs and erythrocyte membranes in IDDM and NIDDM, 1471
Plasma triacylglycerol (TAG) in severe *Plasmodium falciparum* infection, 889

Plasma triglycerides (TGs)
endurance exercise and, *see* Plasma triglycerides, endurance exercise and
fasting, 550, 731
in genetically obese subjects, 550, 555
in IDDM with chronic renal failure, 335, 337, 339
and lipid peroxidation in LDLs and erythrocyte membranes in IDDM and NIDDM, 1471
Plasma triglycerides (TGs), endurance exercise and, 634, 637
increased LPL activities and clearance of, in endurance exercising women, 808-813
Plasma tyrosine
MDL 29311 effects on, 235-236
in NIDDM, 350, 642, 644
in obesity, 642, 644
PACAP effects on concentrations of, in conscious subjects, 740-742
in STZ-DM, 303
in uremia, effects of sucrose on, 406
Plasma urea
arginine-free diet effects on, 118
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1160-1161
Plasma valine
after adaptation to diets with different protein content, 1341
in obese NIDDM and nondiabetic subjects, 642, 644
Plasma very–low-density lipoprotein-cholesterol (VLDL-C) in genetically obese subjects, 556
[^{125}I]Plasminogen I, clearance of, 1432-1433
[^{131}I]Plasminogen I, clearance of, 1432-1433
Plasminogen activator (PA), tissue, hyperinsulinemia and activity of, 1579-1586
Plasminogen activator inhibitor-1 (PAI-1)
in hyperinsulinemia, 1582-1585
insulin sensitivity and, 424, 425
Plasminogen glycoforms I and II, relationship of catabolism of, to plasminogen synthesis by liver, 1430-1437
Plasmodium falciparum malaria, *see* Severe *Plasmodium falciparum* malaria
Platelet(s)
in autologous blood transfusions for phlebotomies in NIDDM, 616
see also entries beginning with term: Platelet
Platelet aggregation and fluidity, lovastatin normalizing, in hypercholesterolemia, 11-17
Platelet cholesterol (C), lovastatin effects on, in hypercholesterolemia, 11-17
Platelet-derived growth factor (PDGF), ODC in NIH-3T3 cells induced by, Ca^{2+}-calmodulin involvement in, 4-10
PMA, *see* 4β-Phorbol 12β-myristate 13α-acetate
Polyamines
effects of, on GDH, 1189-1190, 1193
influence of diet with and without AAs, on urinary excretion of, in multiple trauma victims, 1305-1309
Polycystic ovary syndrome (PCOS)
insulin in, *see* Polycystic ovary syndrome, insulin in
weight-independent effects of AT distribution on clinical, hormonal, and metabolic features of, 706-713
Polycystic ovary syndrome (PCOS), insulin in
AT distribution and, 708, 710
insulin action in adipocytes of amenorrheic subjects with PCOS, 1536-1542
insulin metabolism defect in, 1367-1372
see also Polycystic ovary syndrome, insulin resistance in
Polycystic ovary syndrome (PCOS), insulin resistance in
absence of IR gene mutation in, 1568-1574
Metformin therapy reducing hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic BP, and facilitating normal menses and pregnancy, 647-654; *see also* Hyperandrogenic women with PCOS
Polypeptides
pituitary adenylate cyclase-activating, effects of, on adrenal hormone, glucagon, and insulin secretion, and glucose and lipid metabolism in conscious subjects, 739-744
plasma pancreatic, in insulin-induced hypoglycemia, 861-862
Polyribosomes, metyrapone effects on status of, 83
Polyunsaturated fat
hypertensive effects of, 1-3
see also specific substances
Portal blood, AA concentrations in, in pregnancy, 1082
Portal blood flow (BF) in pregnancy, 1080
Postabsorptive rate of appearance (R_a)
of glucose, *see* Postabsorptive rate of appearance, glucose
of leucine in obese women, insulin effects on, 441-445
Postabsorptive rate of appearance (R_a), glucose
AV-difference and compartment methods in measurement of, following oral glucose, 1419-1425
effects of dietary protein restriction on, 462-467
in NIDDM, effects of lipid infusions on, 1300-1304
Post-exercise O_2 (oxygen) consumption, excess, effects of β-adrenergic blockers on, 565-571
Postheparin lipase activities
ACTH and dexamethasone effects on, 95
adipose tissue LPL activities and, in older athletic men with silent myocardial ischemia, 194-195
in nephrotic hypertriglyceridemia, 254
plasma lipoprotein and hepatic, in pregnancy with homozygous FH, 1167
in STZ-DM, 303
Postmenopausal women
on 17β-estradiol-dihydrogesterone therapy, changes in LDL in, 799-802
low-dose Ag therapy alone for advanced breast cancer in, adrenal effects of, 723-727
Postprandial (PP) amplification of Lp abnormalities in NIDDM, relationship of, to postprandial lipemia, and to C-peptide and glucagon levels, 270-278
Postprandial (PP) glucose utilization in NIDDM, 1549-1557
Postprandial (PP) growth hormone (GH) response to GH-RH in AN, naloxone effects on, 140-143
Postprandial (PP) high-density lipoprotein-2 (HDL-2), levels of, in older athletic men with silent myocardial ischemia, 190-198
Postprandial (PP) lipemia
exercise effects on, *see* Postprandial lipemia, exercise effects on
postprandial amplification of Lp abnormalities in NIDDM, and its relationship to C-peptide and glucagon levels, 270-278
relationship between improved, and LDL metabolism during tetrahydrolipstatin therapy, 293-298
Postprandial (PP) lipemia, exercise effects on
effects of brisk walking by normolipidemic young adults on, 836-841
levels of, in older athletes with silent myocardial ischemia, 190-198
Postprandial (PP) triglyceride-rich lipoproteins (TGRLP) increasing esterified cholesterol accumulation in THP-1 macrophages in IDDM, 1063-1072
Postpubertal women, normal young, total-body and regional bone mineral content and bone density in, 263-266

Potassium (K), $Na^+ + K^+$-ATPase in kidney BLM of STZ-induced NIDDM subjects, 606
PP, *see entries beginning with term*: Postprandial
PPH (phosphotidate phosphohydrolase), G3P and activities of, and fatty infiltration of liver during gram-negative sepsis, 693-694
Pravastatin, effects of, on VLDL-C in heritable hyperlipidemia, 559-564
Prazosin, effects of, in acute stress-induced hyperinsulinemia, 1223
Preadipocytes, *see* Adipocyte precursors
Prealbumin
  in acute infectious disease, 699
  autologous blood transfusions for phlebotomies in NIDDM and, 616
  in chronic malignant disease, 702
Pregnancy
  balance method to determine accumulation, metabolism, and oxidation of linoleic and α-linoleic acids in, 940-944
  hepatic AA metabolism during hyperinsulinemia and hyperaminoacidemia in conscious pregnant subjects, 1079-1085
  with homozygous FH, long-term LDL apheresis for, 1164-1170
  hypertriglyceridemia in late, associated with formation of small dense LDLs and presence of large buoyant HDLs, 1035-1041
  leucine kinetics during fasting in GDM, 378-384
  Metformin therapy of PCOS facilitating normal, 647-654
Premature infants fed an MCT-containing formula, octanoic acid conversion into LCFAs in, 1287-1292
Preprandial growth hormone (GH), response of, to GH-RH in AN, naloxone effects on, 140-143
Prepubertal children
  normal and 21-hydroxylase-deficient, 24-hour pulsatile control of cortisol, 17-hydroxyprogesterone, and androstenedione release in, 372-377
  uric acid homeostasis in lean and obese prepubertal girls, 819-821
Prevalence
  of NIDDM, hypertension, and ischemic heart disease in former athletes, 1255-1260
  see also specific conditions
PRL (prolactin), concentrations of, in PCOS, AT distribution and, 709
Probucol analog, MDL 29311 as, increased hepatic clearance of VLDLs and decreased TG clearance with, 233-240
Procollagen, serum carboxy-terminal propeptide of type I, in familial type I-A osteogenesis imperfecta, 1261-1265
Progesterone, effects of low-dose Ag therapy of advanced breast cancer in postmenopausal women on, 724
Proglucagon 78-107 amide, *see* Glucagon-like peptide-1
Proinsulin gene, expression of, in beta TC-1 cells, interaction between GLP-1 and somatostatin-14 characterized on signal transduction and, 787-792
Prolactin (PRL), concentrations of, in PCOS, AT distribution and, 709
Proline
  effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159
  glucagon role in control of metabolism of, 1512, 1513
L-Proline in AA mixture supplying arginine-free or arginine-rich diet, 115
Propeptide(s)
  carboxy-terminal, of type I procollagen in familial type I-A OI, reduced serum levels of, 1261-1265
  insulin, in conditions associated with insulin resistance, 446-449
Propionate, effects of, on CHO metabolism in STZ-DM, 728-734
Protein(s)
  adipocyte precursor, long-chain FA effects on synthesis of, 147-149
  binding, *see* Binding protein(s)
  cholesteryl ester transfer, *see* Cholesteryl ester transfer protein
  C-reactive, *see* C-reactive protein
  dietary, *see* Dietary protein
  dietary fat and CHO effects on balance of, 155
  GH therapy effects on metabolism of, in obese women, 873-874
  glucagon role in control of metabolism of, 1509-1516
  hepatic, TNF-α effects on, 824, 826
  MDL 29311 effects on, 235
  metyrapone effects on [^{14}C]leucine incorporation into, 83
  muscle, *see* Muscle protein
  phospholipid to protein ratio in IDDM, 1069
  plasma, *see* Plasma protein
  renal brush border membrane total lipid to protein ratio in idiopathic Fanconi syndrome, 1075
  tissue, effects of D-alanine on levels of, 1155
  total, *see* Total protein
  urinary excretion of, in nephrotic hypertriglyceridemia, 249; *see also* Urinary excretion, albumin
  values of, during organogenesis, 832
  see also Protein kinase C *and specific proteins*
Protein kinase C (PKC)
  IR serine phosphorylation and, 761-762
  role of, in hepatic pyruvate dehydrogenase activation by insulin in hepatoma cells, 1030-1034
Proteolysis, whole-body, differential effects of insulin on glucose metabolism and, in normal-weight, obese, and reduced-obese women, 441-445
Prothrombin time (PT)
  in cirrhosis, 1173
  in well-nourished mildly cirrhotic subjects, 86
Pseudo-obstruction, chronic intestinal, Cu deficiency and, 1463-1464
PT, *see* Prothrombin time
PTH (parathyroid hormone), defect in, and insulin regulation of $(Ca^{2+} + Mg^{2+})$-ATPase activity in kidney BLM of NIDDM subjects, 604-613
Puberty, *see entries beginning with terms*: Postpubertal, Prepubertal
Pulmonary arterial O_2 (oxygen) difference, aorto-, protein ingestion and, 627
Pulmonary O_2 (oxygen) uptake, protein ingestion and, 627
Pulsatile control, 24-hour, of cortisol, 17-hydroxyprogesterone, and androstenedione release in prepubertal subjects with nonclassic congenital adrenal hyperplasia, 372-377
Pulsatile insulin delivery, effects of continuous versus short-term, on lipid metabolism and whole-body glucose metabolism in obesity, 842-846
Pulsatile thyrotropin (TSH), secretion of, in Cushing's syndrome, 782-786
Pulsatility
  nocturnal GH levels and, ACX-SR blockade of lipolysis normalizing, in obesity, 1207-1213
  see also entries beginning with term: Pulsatile
Pulse rate, *see* Heart rate
Pyridostigmine, effects of, on GH response to GH-RH in lean and obese NIDDM subjects, 893-898
Pyruvate
  blood, hypocaloric high-protein diet effects on, 1482
  DCA effects on, 977
  in uremia, effects of sucrose on, 407

Pyruvate (*Continued*)
see also Phosphoenolpyruvate; Phosphoenolpyruvate carboxykinase mRNA; Pyruvate dehydrogenase
Pyruvate dehydrogenase, hepatic, PKC role in activation of, by insulin in hepatoma cells, 1030-1034

Quadriplegic veterans, CHO and lipid metabolism disorders in, 749-756

R_a, *see* Postabsorptive rate of appearance
Race and ethnicity
and amount of cholesterol relative to apo B in LDLs related primarily to HDL-C in children, 1042-1044
apo E phenotype distribution in obese children by, 471
and excretion rate of adrenal androgens during adrenarche, 188
hyperinsulinemia associated with menstrual irregularity and altered serum androgens in Pima Indian women, 803-807
of IDDM subjects, *see* Race and ethnicity of IDDM subjects
and T and DHEA concentrations in nondiabetic men, glucose and insulin concentrations and, 601
Race and ethnicity of IDDM subjects
with chronic renal failure, 334
effects of glycemic control, IDDM duration and, on erythrocyte GSH content, 306-309
lack of association between TAP and Japanese IDDM, 1013-1017
Rate of appearance (R_a), *see* Postabsorptive rate of appearance
RCT (reverse cholesterol transport), alterations in, associated with implantable IP insulin delivery in IDDM, 665-669
Red blood cells, *see* Erythrocyte membranes; Insulin-dependent diabetes mellitus, erythrocytes in; Non–insulin-dependent diabetes mellitus, erythrocytes in; Reduced glutathione in erythrocytes
Redox status
AR inhibition effects on erythrocyte GSH, in NIDDM, 965-968
in uremia, sucrose effects on, 407, 409
see also Oxidation
Reduced food intake, *see* Restricted diet
Reduced glutathione (GSH) in erythrocytes
in IDDM, effects of glycemic control, race, and IDDM duration on, 306-309
in NIDDM, AR inhibition effects on redox status of, 965-968
Reduced-obese subjects, *see* Weight loss
Reducing diet, *see* Weight-reducing diet, weight loss with *and specific types of diet; for example*: Hypocaloric diet
Reductase
aldose, effects of inhibition of, on erythrocyte GSH redox status in NIDDM, 965-968
inhibitors of HMG-CoA, *see* Lovastatin; Pravastatin; Simvastatin
5,10-methylenetetrahydrofolate, in hypothyroidism and hyperthyroidism, 1576
see also Hepatic HMG-CoA reductase; Ileal HMG-CoA reductase; NADPH cytochrome C reductase in kidney BLM
Redundant parasympathetic (and sympathoadrenal) mediation of increased glucagon secretion during insulin-induced hypoglycemia in conscious subjects, 860-866
REE, *see* Resting energy expenditure
Refeeding, glycogen turnover during, 285-292
Regional blood flow (BF), myocardial, in hyperglycemic STZ-DM, 65
Regional bone mineral content, bone density and, in postpubertal normal young women, 263-266
Regional differences in HSL expression in adipocytes, 241-147
Renal amino acids (AAs), effects of D-alanine on levels of, 1155
Renal brush border membrane
Ca fluidity and transport by, vitamin D and enterocyte effects on, 1093-1103
lipid composition in, in idiopathic Fanconi syndrome, 1073-1078
Renal failure, chronic, *see* Uremia
Renal function, effects of sorbinil combined with insulin on, in STZ-DM, 495-496
Renal transplantation, *see* Pancreas-kidney transplantation
Renal tubular reabsorption, plasma and urine isotopic enrichment following L-[1-^{13}C]phenylalanine and L-[ring-$^{2}H_5$]phenylalanine infusions, as evidence for isotope effect in, 487-491
Repeated phlebotomies in NIDDM, autologous blood transfusions and, 614-620
Reproductive efficiency of STZ-DM and normal subjects, vanadate effects on, 1384-1388
Respiratory quotient (RQ)
changes in, with GH therapy of children of short stature, 1545
dietary fat and CHO effects on substrate utilization and, 154
and glucagon role in control of protein and AA metabolism, 1513
of multiple trauma victims, 1306
nonprotein, *see* Nonprotein respiratory quotient
in vegetarians and nonvegetarians, 623
Resting blood pressure (BP), high, during submaximal exercise, as cardiovascular disease risk factor in obese normotensive women, 18-23
Resting energy expenditure (REE)
changes in, with GH therapy of children of short stature, 1543-1548
effects of exercise on anthropometric indices, FFM and, in obese men, 1148-1152
of multiple trauma victims, 1306
in NIDDM, insulin sensitivity, Lps and, 505
very-low-calorie diet and, 1296-1297
Resting heart rate (HR) of exercising moderately obese men, 656, 657
Resting metabolic rate (RMR)
and glucagon role in control of protein and AA metabolism, 1513
and sympathetic nervous system activity in young vegetarian men, 621-625
Restricted diet
CCK associated with, 735-738
impact of energy intake restriction, obesity, and AT distribution on IGF-I, IGF-BP3, insulin, and GH, 315-319
see also Calorie restriction; Dietary protein restriction; Low-fat diet; Weight-reducing diet, weight loss with
Reticulocytes in autologous blood transfusions for repeated phlebotomies in NIDDM, 616
Retinal degeneration, Cu deficiency and, 1463
Reverse cholesterol transport (RCT), alterations in, associated with implantable IP insulin delivery in IDDM, 665-669
Ribonucleic acid, *see* RNA
Ribosome
AICA-, influence of, on extracellular pH effects on hepatocyte lactate uptake, 159-160
metyrapone effects on polyribosome status, 83
Risk factor(s)
for CV disease, high resting blood pressure during submaximal exercise as, in obese normotensive women, 18-23
for NTDs, maternal hyperhomocysteinemia as, 1475-1480
see also specific risk factors
RMR, *see* Resting metabolic rate
RNA (ribonucleic acid)
messenger, *see* mRNA

RNA (ribonucleic acid) (*Continued*)
[^{14}C]orotate-labeled nuclear, metyrapone effects on release of, 83
RQ, *see* Respiratory quotient
RQ_{np}, *see* Nonprotein respiratory quotient
Running
effects of low-fat diet, calorie restriction and, on Lp subfraction concentrations in moderately obese men, 655-663
skeletal muscle protein content and synthesis after, 994-999
RU38486 (antiglucocorticoid), effects of, on metabolism of skeletal muscle protein in unweighted muscle, 1451-1455

S, *see* Sucrose
Salbutamol, effects of clenbuterol and, on skeletal muscle mass, 1119-1125
Saturated fatty acids, *see* Long-chain saturated fatty acids
SBP (systolic blood pressure), *see* Blood pressure
Secretagogues, ACTH, facilitating recovery of HPA axis suppressed by prolonged dexamethasone therapy, 544-548
Sedentary subjects
glycogen synthesis pathway in, 41
LPL activity and plasma TG clearance in sedentary women, 808-813
Senescent subjects, *see* Older subjects
Sepsis, *see* Infection
Serine
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
insulin effects on metabolism of, 73
phosphorylation and desensitization of IR, effects of IR gene mutation at tyrosines 1162 and 1163 on, 757-765
plasma, after adaptation to diets with different protein content, 1341
in pregnancy, 1082-1084
L-Serine in AA mixture supplying arginine-free or arginine-rich diet, 115
Serum acetate, drinking habits and changes in, 747
Serum albumin
changes in, during liver regeneration, 683, 684
in malaria patients, 975
Serum amino acids (AAs), effects of D-alanine on levels of, 1154
Serum androgens, hyperinsulinemia associated with irregular menses and altered, in Pima Indian women, 803-807
Serum apolipoprotein(s) (apos)
changes in, following PH and during liver regeneration, 683-685
and cholesterol synthesis in newly insulin-treated NIDDM and IDDM, 1237
in GH-deficient men, 200
mepacrine short-term effects on, in NIDDM, 131-134
see also specific apolipoproteins
Serum apolipoprotein A-I (apo A-I)
ACTH and dexamethasone effects on, 93
fasting, mepacrine effects on, in NIDDM, 132
in obese children with different apo E phenotypes, 471
of pregnant patients with homozygous FH, 1167
Serum apolipoprotein B (apo B)
ACTH and dexamethasone effects on, 93
fasting, mepacrine effects on, in NIDDM, 132
in obese children with different apo E phenotypes, 471
PH effects on levels of, 685
of pregnant patients with homozygous FH, 1167
Serum carboxy-terminal propeptide of type I procollagen (PICP) in familial type I-A osteogenesis imperfecta, 1261-1265
Serum cholecystokinin (CCK), response of, to food intake by female athletes, 217-222
Serum cholesterol (C)
ACTH and dexamethasone effects on, 93
and brisk walking effects on PP lipemia in normolipidemic subjects, 838
in essential hypertension, β-adrenergic blocker effects on, 459
hypocaloric high-protein diet effects on, 1482
MDL 29311 effects on, 235
PH effects on, 685
tamoxifen effects on, 532
total, in pregnancy with homozygous FH, 1167
Serum clofibrate, levels of, and proliferation of hepatic peroxisome, 169
Serum cortisol, ACTH and dexamethasone effects on level of, 92
Serum C-peptides (connecting peptides), fasting, in NIDDM, pyridostigmine effects on GH response to GH-RH and, 894
Serum creatinine (Cr)
in IDDM with chronic renal failure, pancreas and kidney transplants and, 334, 335, 343
in malaria patients, 975
Serum glucose
changes in, during liver regeneration following PH, 683, 684
in obese NIDDM and nondiabetic subjects, 642-643
urinary excretion of epinephrine and, 511
Serum glutamate oxaloacetate transaminase (SGOT) in well-nourished mildly cirrhotic subjects, 86
Serum high-density lipoprotein-cholesterol (HDL-C)
hypocaloric high-protein diet effects on, 1482
in obese children with different apo E phenotypes, 471
of pregnant patients with homozygous FH, 1165, 1167
serum T level and sex difference in level of, 935-939
Serum high-density lipoprotein$_2$-cholesterol (HDL_2-C), serum T level and sex difference in level of, 935-939
Serum insulin
changes in, during liver regeneration following PH, 683, 684
in cirrhosis, 1173
hypocaloric high-protein diet effects on, 1482
in obese NIDDM and nondiabetic subjects, 642-644
urinary excretion of epinephrine and, 511
Serum lathosterol in newly insulin-treated NIDDM and IDDM, 1237
Serum lipids
effects of endurance exercising on, in older men and women, 848, 849
levels of, in GH-deficient men, 199-203
nandrolone decanoate effects on, 204-210
in newly insulin-treated NIDDM and IDDM, 1237
in NIDDM, mepacrine short-term effects on, 131-134
in pregnancy with homozygous FH, 1165
relationship between urinary excretion of epinephrine and levels of, 509-513
sex difference in association of plasma insulin level and insulin sensitivity with, 523-528
tamoxifen effects on, 532
see also specific lipids
Serum lipoprotein(s) (Lps)
changes in, following PH, 683
in NIDDM, mepacrine short-term effects on, 131-134
relationship between obesity and, in children with different apo E phenotypes, 470-475
sex difference in association of plasma insulin level and insulin sensitivity with, 523-528
Serum lipoprotein(a) [Lp(a)] of pregnant patients with homozygous FH, 1167

Serum low-density lipoprotein-cholesterol (LDL-C)
in obese children with different apo E phenotypes, 471
of pregnant patients with homozygous FH, 1165, 1167
Serum testosterone (T)
level of, and role in proliferation of clofibrate-induced hepatic peroxisome, 169
level of, and sex difference in serum HDL-C and serum HDL_2-C level, 935-939
total, in obese women, relationship between intraabdominal AT and, 390-395
Serum total cholesterol (TC) in pregnancy with homozygous FH, 1165, 1167
Serum total protein, changes in, during liver regeneration following PH, 683, 684
Serum triglycerides (TGs)
ACTH and dexamethasone effects on, 93
in cirrhosis, 1173
in essential hypertension, β-adrenergic blocker effects on, 459
fasting, mepacrine effects on, in NIDDM, 132
hypocaloric high-protein diet effects on, 1482
in obese children with different apo E phenotypes, 471
of pregnant patients with homozygous FH, 1165, 1167
Serum urate in essential hypertension, β-adrenergic blocker effects on, 459
Serum uric acid in prepubertal lean and obese girls, 820
Serum very–low-density lipoprotein-cholesterol (VLDL-C) in obese children with different apo E phenotypes, 471
Serum vitamin B_{12}, maternal hyperhomocysteinemia and, 1477
Serum vitamin D, effects of vitamin D and enterocytes on, 1095
7288CTC hepatoma perfused in situ with L-[(U)-^{14}C]lactate or D-[(U)-^{14}C]glucose, lactate release and uptake in, 1488-1497
Severe osteoporosis, vitamin B_{12} and etidronate reversing, in pernicious anemia, 468-469
Severe *Plasmodium falciparum* (*P falciparum*) malaria
DCA for lactic acidosis in, 974-981
glycerol metabolism in, 887-892
Sex
and adaptation of glucose metabolism to short-term fasting, 1503-1508
and amount of cholesterol relative to apo B in LDLs related primarily to HDL-C, 1042-1044
and association of plasma insulin level and insulin sensitivity with serum lipids and Lps, 523-528
and brisk walking effects on PP lipemia in normolipidemic subjects, 837
of CF subjects, 164
of congestive heart failure subjects, 175
and difference in serum HDL-C and serum HDL_2-C level, serum T level and, 935-939
and effects of ACX-SR blockade of lipolysis on nocturnal GH levels and pulsatility, 1208
energy metabolism, skeletal muscle biochemistry and, 483
of essential hypertension subjects, and effects of β-adrenergic blockers, 457
and excretion rate of adrenal androgens during adrenarche, 187, 188
and hyperinsulinemia effects on SM protein turnover, 71
of hypertriglyceridemic and/or hypercholesterolemic subjects, 573
of IDDM subjects, *see* Sex of IDDM subjects
iodothyronine metabolism and, 793-797
and lipid alterations following pancreas-kidney transplantation, 1241-1247
of mildly cirrhotic subjects, hepatic glycogenolysis and, 86
Sex (*Continued*)
of multiple trauma victims, 1306
of NCCAH subjects, 373
of nephrotic hypertriglyceridemic subjects, 249
of NIDDM subjects, *see* Sex of NIDDM subjects
of noncirrhotic alcoholic subjects, 368
of obese subjects, 471, 539, 641
of pregnant patients with homozygous FH, 1165
and relationship between oxidative stress and insulin action, 1427
of type I-A familial OI patients, 1262
see also Men; Women
Sex hormone(s), *see specific sex hormones*
Sex hormone–binding globulin (SHBG)
decreased concentrations of, associated with increased insulin and glucose concentrations in nondiabetic men, 599-603
effects of T therapy on, 936
in PCOS, 649, 708, 709
VAT, androgens and, in obese men, 1319
Sex of IDDM subjects
with chronic renal failure, and effects of pancreas-kidney transplantation on lipid composition, 334, 336-339
and effects of newly insulin-treated IDDM on cholesterol synthesis, 1234
oxidized lipids and, 1196-1200
and RCT, 666
Sex of NIDDM subjects
and acute hyperinsulinemia effects on plasma CETP activity, 1363
and effects of glucose and AA infusions on glucose turnover, 429
incidence and, 1214-1220
insulin sensitivity, Lps and, 505, 506
and lipid infusion effects on glucose R_a, 1301
mepacrine effects and, 132
and newly insulin-treated NIDDM effects on cholesterol synthesis, 1234
obese, 641, 1048
and pyridostigmine effects on GH response to GH-RH, 894
SFAs (saturated fatty acids), *see* Long-chain saturated fatty acids
SGOT (serum glutamate oxaloacetate transaminase) in well-nourished mildly cirrhotic subjects, 86
SHBG, *see* Sex hormone–binding globulin
Shock
endotoxic, increased glucose disposal and decreased gluconeogenesis without hyperinsulinemia in, 1248-1254
hypovolemic, effects of $NaHCO_3$ with and without Carbicarb on skeletal muscle pH and hemodynamic status in, 518-522
osmotic, ATP release by HbA_{1c} and, in erythrocytes of IDDM and NIDDM subjects, 435-440
Short stature, children of
GH therapy of, changes in body composition, REE, and TEF with, 1543-1548
idiopathic, GH-BP levels in, 357-359
Short-term adaptation to protein restriction, 320-327
Short-term effects of mepacrine on serum lipids, Lps, and apos in NIDDM, 131-134
Short-term fasting, adaptation of glucose metabolism to, sex difference in, 1503-1508
Short-term pulsatile insulin delivery, effects of continuous versus, on lipid metabolism and whole-body glucose metabolism in obesity, 842-846
Signal transduction, and proinsulin gene expression in beta TC-1 cells, interaction between GLP-1 and somatostatin-14 characterized on, 787-792

Silent myocardial ischemia, older athletes with, reduced adipose tissue LPL responses, and levels of postprandial lipemia and HDL-$_2$ in, 190-198
Simvastatin, FH treated with, dietary fat effects on plasma noncholesterol sterols on, 311-313
Sitosterolemia, deficient activity of ileal HMG-CoA reductase in, 855-859
Skeletal muscle (SM)
effects of Cushing's syndrome therapy on, 1519-1520
fish oil suppressing Ca^{2+}-dependent heat production in, 931-934
glucose metabolism in, effects of NIDDM and obesity and, 1047-1054
immobilization effects on GLUT4 mRNA expression in, 1389-1394
impact of endurance exercise on body fat and metabolism of, in young adults, 814-818
mass of, effects of clenbuterol and salbutamol on, 1119-1125
pH of, effects of $NaHCO_3$ with and without Carbicarb on, in hypovolemic shock, 518-511
protein in, *see* Skeletal muscle protein
whole-body energy metabolism and biochemical characteristics of, 481-485
Skeletal muscle (SM) protein
AAs in, *see* Skeletal muscle protein, AAs in
clenbuterol effects on, 960, 961
content and synthesis of, after running, 994-999
in unweighted muscle, RU38486 effects on metabolism of, 1451-1455
Skeletal muscle (SM) protein, AAs in
effects of hyperinsulinemia with concomitant AA infusions on protein turnover, 70-78
effects of stress hormone and AA infusions on synthesis of, in normal adult subjects, 1158-1163
SKF 525A, effects of, on tryptophan binding to hepatic nuclei, 82
SM, *see* Skeletal muscle
Small dense low-density lipoproteins (LDLs), hypertriglyceridemia in late pregnancy associated with formation of, and presence of large buoyant HDLs, 1035-1041
Small intestine, decreased levels of hepatic HMG-CoA reductase and mRNA in STZ-DM, 450-454
Smoking, *see* Cigarette smoking
SNS, *see* Sympathetic nervous system
Sodium, *see* Na; $NaHCO_3$; $Na^+ + K^+$-ATPase
Soleus muscle, *see* Skeletal muscle
Somatostatin-14, interaction between GLP-1 and, characterized on signal transduction, proinsulin gene expression in beta TC-1 cells and, 787-792
Somatostatin analog, octreotide as, inhibiting insulin, glucagon, and GH secretion, 24-31
Somatostatin octapeptide (ODT8-SS), effects of ICV, on hormonal and metabolic responses to stress in normal and diabetic subjects, 1134-1143
Sorbinil, effects of insulin and, on STZ-DM-induced vascular dysfunction, 492-500
Splanchnic O_2 (oxygen) consumption, effects of protein ingestion on, 626-632
Standing position, β-adrenergic blocker effects on essential hypertension in, 457
Starvation
effects of, on PEPCK, GAPDH, and GLUT2 in obese STZ-DM subject, 1349-1350
extracellular pH and hepatic cell lactate utilization in, 158-159
Stature, *see* Body weight; Height; Short stature, children of
Steroids, *see specific steroids*
Sterols
and deficient ileal HMG-CoA reductase activity in sitosterolemia, 855-859
plasma noncholesterol, dietary fat effects on concentrations of, in FH treated with simvastatin, 311-313
see also specific sterols
Streptozotocin-induced diabetes mellitus (STZ-DM)
effects of combined insulin and sorbinil on vascular dysfunction induced by, 492-500
effects of insulin, glucose and, on lipid peroxidation, 1442-1445
hepatic HMG-CoA reductase and mRNA levels in small intestine decreased in, 450-454
hyperglycemic, ischemia in, glycolytic metabolism and myocardial glucose transporters and, 61-69
hyperlipidemia in, 299-305
islet transplantation with FK506 immunosuppression in, 135-139
neonatal, Ca^{2+}-channel currents of, 1395-1400
NIDDM, *see* Streptozotocin-induced non–insulin-dependent diabetes mellitus
propionate effects on CHO metabolism in, 728-734
vanadate effects in, *see* Vanadate in STZ-DM
Streptozotocin-induced non–insulin-dependent diabetes mellitus (STZ-induced NIDDM)
hormone-specific defect in insulin regulation of $(Ca^+ + Mg^+)$-ATPase in kidney BLM in, 604-613
insulin therapy effects on relative hypersecretion of amylin to insulin in, 766-770
Stress
effects of ICV somatostatin octapeptide on hormonal and metabolic responses to, in normal and diabetic subjects, 1134-1143
hyperinsulinemia induced by acute, in response to pertussis toxin, role of humoral β-cell tropic factors in, 1221-1225
oxidative, relationship between insulin action and, in NIDDM, 1426-1429
Stress hormone infusions
in conscious subjects, effects of acute glucagon removal on metabolic response to, 1310-1317
effects of, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1158-1163
STZ-DM, *see* Streptozotocin-induced diabetes mellitus
Submaximal exercise, high resting BP during, as cardiovascular disease risk factor in obese normotensive women and, 18-23
Substrate(s)
concentrations of, in lean and obese NIDDM subjects, 429-431
oxidation of, *see* Substrate oxidation
during refeeding, 288
see also specific substrates
Substrate oxidation
and glucagon role in control of protein and AA metabolism, 1513
lipid metabolism and, during IV fructose administration in cirrhosis, 1171-1181
rates of, unaffected by AT distribution in obese women, 109-113
substrate utilization and, dietary fat and CHO effects on, 152-156
total-body and myocardial, in congestive heart failure, 174-179
very–low-calorie diet and, 1296-1297
see also specific substrates
Sucrose (S)
effects of, on heart NE and IBAT, 181-182
uremia-induced disturbances in hepatic carbohydrate metabolism enhanced by, 403-412
Sugars, *see specific sugars*
Superoxide, production of, in CF, 719-722
Supine position, β-blocker effects on essential hypertension in, 457

Supplementation, *see specific substances*
Supratherapeutic dose of androgenic steroids, effects of, on basal and insulin-stimulated glucose and amino acid metabolism, 1266-1274
Sympathetic nervous system (SNS)
activity of, and RMR in young vegetarian men, 621-625
differential effects of dietary fats on, 51-60
3-OHB supplementation effects on activity of, 180-185
Sympathoadrenal system
redundant mediation by, of increased glucagon secretion during insulin-induced hypoglycemia in conscious subjects, 860-866
response of, at high altitude, urinary and arterial NE and E in determination of, 1226-1232
Synthase, hepatic methionine, in hyperthyroidism hypothyroidism, 1576
Synthetase, glutamine, effects of RU38486 and unweighting on activity of, in skeletal muscle, 1453
Systemic infusions, *see specific substances*
Systolic blood pressure, *see* Blood pressure

T, *see* Testosterone
T_3, *see* Triiodothyronine
T_4, *see* Thyroxine
TAG (triacylglycerol), plasma, in severe *Plasmodium falciparum* infection, 889
TAL (thick ascending limb), medullary, CNP, ANF, and BNP receptors in, 1531-1535
Tamoxifen, Lp(a) in breast cancer decreased by, 531-532
TAP (transporter associated with antigen processing), lack of association between Japanese IDDM and, 1013-1017
Taurine
glucagon role in control of metabolism of, 1512, 1513
insulin effects on metabolism of, 73
TBARS (thiobarbituric acid reactive substances), measurement of, in IDDM, oxidized lipids and, 1196-1200
TBBMC, *see* Total-body bone mineral content
TBW (total body water), DEXA and near-infrared interactance in study of, in normal adult subjects, 417-422
TC, *see* Total cholesterol
TEF (thermic effect of food), changes in, with GH therapy of children of short stature, 1543-1548
Temperature
blood, effects of protein ingestion on, 626-632
see also entries beginning with element: Therm-
TER (transcapillary escape rate), albumin, correlating with plasma albumin concentrations in acute infectious disease and chronic malignant disease, 697-705
Testicular failure, Cu deficiency and, 1464
Testosterone (T)
decreased concentrations of, associated with increased insulin and glucose concentrations in nondiabetic men, 599-603
FK506 effects on secretion of, by Leydig cells, 535
in hyperandrogenic women with NIDDM, 585
level of, and sex difference in serum HDL-C and serum HDL_2-C level, 935-939
in PCOS, *see* Testosterone in PCOS
role of, in clofibrate-induced hepatic peroxisome proliferation, 169-173
serum, *see* Serum testosterone
total, *see* Total testosterone
Testosterone (T) in PCOS, 709
hyperandrogenemia and, 1368, 1369
insulin action in adipocytes and, 1537
Metformin therapy and, 649
plasma testosterone in PCOS with insulin resistance, 1569
Tetrahydrolipstatin (THL), relationship between improved PP lipemia and LDL metabolism during therapy with, 293-298
TG(s), *see* Triglyceride(s)
TGRLP (triglyceride-rich lipoproteins), PP, increasing esterified cholesterol accumulation in THP-1 macrophages in IDDM, 1063-1072
Theophylline, glucose recovery enhanced by, after hypoglycemia in healthy and IDDM subjects, 776-781
Thermal injury, effects of, on mitochondrial oxygen consumption and glycerol phosphate shuttle, 913-916
Thermic effect of food (TEF), changes in, with GH therapy of children of short stature, 1543-1548
Thermogenesis
fish oil suppressing Ca^{2+}-dependent, in skeletal muscle, 931-934
glucagon-induced, insulin dissociating hepatic glucose cycling from, 1000-1005
see also Calorie(s) *and entries beginning with term*: Energy
Thick ascending limb (TAL), medullary, CNP, ANF, and BNP receptors in, 1531-1535
Thiobarbituric acid reactive substances (TBARS), measurement of, in IDDM, oxidized lipids and, 1196-1200
Thionamide, effects of alanine and, on NH_3 in hyperthyroidism, 1025
THL (tetrahydrolipstatin), relationship between improved PP lipemia and LDL metabolism during therapy with, 293-298
THP-1 macrophages, PP TGRLP increasing esterified cholesterol accumulation in, in IDDM, 1063-1072
Threonine
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
insulin effects on metabolism of, 73
plasma, after adaptation to diets with different protein content, 1341
in pregnancy, 1082-1084
L-Threonine in AA mixture supplying arginine-rich or arginine-free diet, 115
Thyroid function
GH therapy effects on EE, fuel metabolism and, in obese women, 872-877
see also Hyperthyroidism; Hypothyroidism; Thyroid hormones
Thyroid hormones
effects of, on folate-mediated incorporation of [ring-2-^{14}C]histidine into DNA, 1575-1578
influence of status of, on GH response to TRH in obesity, 514-517
see also Thyroxine; Triiodothyronine
Thyroid-releasing hormone (TRH), influence of thyroid status on GH response to, in obesity, 514-517
Thyrotropin (TSH)
in hyperthyroidic patients, 1024
levels of, in hypothyroidism and hyperthyroidism, 1356
pulsatile, secretion of, in Cushing's syndrome, 782-786
T_3S uptake and suppressed secretion of, in anterior pituitary cells, 1282-1286
Thyroxine (T_4)
free, *see* Free thyroxine
iodothyronine metabolism and levels of, 795
levels of, in hypothyroidism and hyperthyroidism, 1356
levels of, during liver regeneration following partial hepatectomy, 683
in vegetarians and nonvegetarians, 623
very–low-calorie diet effects on, 1295

Time course of liver regeneration following partial hepatectomy, 683
Tissue plasminogen activator (tPA), hyperinsulinemia and activity of, 1579-1586
Tissue protein, effects of D-alanine on levels of, 1155
Tissue type
and iodothyronine metabolism, 793-797
see also specific tissues
Tissue weight, OKG effects on, in Yoshida ascites hepatoma, 901
TNF, *see* Tumor necrosis factor; Tumor necrosis factor-α
Total-body bone mineral content (TBBMC)
bone density and, in postpubertal young normal women, 263-266
DEXA and near-infrared interactance in study of, in normal adult subjects, 417-422
Total body substrates, oxidation of, in congestive heart failure, 174-179
Total body water (TBW), DEXA and near-infrared interactance in study of, in normal adult subjects, 417-422
Total cholesterol (TC)
and association between insulin sensitivity, FFAs, and TG metabolism independent of uncomplicated obesity, 1278
and ATP release in erythrocytes, 436
effects of bile acids and lovastatin on, 1448
exercise effects on, 809, 837
in genetically obese subjects, 550
GH deficiency and, 200, 1459
in IDDM, 1183, 1471
in NIDDM, *see* Total cholesterol in NIDDM
in PCOS, 649, 710
serum, in pregnancy with homozygous FH, 1165, 1167
in STZ-DM, 301
T therapy effects on, 936, 937
urinary excretion of epinephrine and, 511
VAT, androgens and, in obese men, 1319
Total cholesterol (TC) in NIDDM, 1216
and effects of acute hyperinsulinemia on plasma CETP activity, 1363
effects of mepacrine on, 132
phenobarbital effects on, 350
plasma, and lipid peroxidation in LDLs and erythrocyte membranes, 1471
Total energy expenditure (EE), protein ingestion and, 627
Total energy intake (EI), insulin sensitivity, Lps and, in NIDDM, 502
Total lipid to protein ratio, renal brush border membrane, in idiopathic Fanconi syndrome, 1075
Total protein
in acute infectious disease, 699
in chronic malignant disease, 702
plasma, insulin sensitivity and, 424, 425
serum, changes in, during liver regeneration following PH, 683-684
Total testosterone (T)
concentrations of, in nondiabetic men, glucose and insulin concentrations and, 600-602
serum, in obese women, relationship between intraabdominal AT and, 390-395
Total triglycerides (TGs), insulin sensitivity and, 525
Toxicity, DCA, 978
tPA (tissue plasminogen activator), hyperinsulinemia and activity of, 1579-1586
Training, *see* Men, exercising; Women, exercising *and specific forms of exercise; for example*: Running
Transaminase
plasma aspartate, in cirrhotic subjects, 1172
serum glutamate oxaloacetate, in well-nourished mildly cirrhotic subjects, 86
Transcapillary escape rate (TER), albumin, correlating with plasma albumin concentrations in acute infectious disease and chronic malignant disease, 697-705
Transfer protein, *see* Cholesteryl ester transfer protein
Transferase
UDP-glucuronyltransferase activity and proliferation of hepatic peroxisome, 170, 171
see also Acyltransferase
Transferrin
in acute infectious disease, 699
autologous blood transfusions for phlebotomies in NIDDM and, 616
in chronic malignant disease, 702
Transfusions, autologous blood, for phlebotomies in NIDDM, 614-620
Transmembrane transport, adaptive changes in T_3 metabolism and, in livers of fed and fasted hypothyroidic and hyperthyroidic subjects, 1355-1361
Transplantation
islet, and immunosuppression with FK506 in STZ-DM, 135-139
pancreas-kidney, *see* Pancreas-kidney transplantation
Transporter associated with antigen processing (TAP), lack of association between Japanese IDDM and, 1013-1017
Transsexual women, effects of T therapy on serum HDL-C and serum HDL_2-C level in, 935-939
Trauma and injury
burn, effects of, on mitochondrial O_2 consumption and glycerol phosphate shuttle, 913-916
multiple, influence of diet with and without AAs on polyamine urinary excretion in, 1305-1309
TRH (thyroid-releasing hormone), influence of thyroid status on GH response to, in obesity, 514-517
Triacylglycerol (TAG), plasma, in severe *Plasmodium falciparum* infection, 889
Triglyceride(s) (TGs)
association between LDLs and, in late pregnancy, 1037
and ATP release in erythrocytes, 436
and $(Ca^{2+}+Mg^{2+})$-ATPase activity in kidney BLM, 605, 606, 1056
in exercising men, 193, 837, 918
in exercising women, *see* Triglyceride(s) in exercising women
in FH, 312, 400
GH deficiency and, 200, 1458, 1459
in hypercholesterolemia, cilazapril effects on, 362
in hyperinsulinemia, 1580
in hyperlipidemia, 362, 560
in IDDM, *see* Triglyceride(s) in IDDM
insulin sensitivity, 502, 505, 506, 525-526
intracellular, gemfibrozil effects on, 257-262
MDL 29311 and decreased hepatic clearance of, 233-240
medium-chain, octanoic acid conversion into LCFAs in premature infants fed a formula containing, 1287-1292
in multiple trauma victims, 1307
in NIDDM, *see* Triglyceride(s) in NIDDM
in normolipidemic subjects, 1333, 1334
in obesity, *see* Triglyceride(s) in obesity
in PCOS, 649, 710
PH effects on levels of, 685
plasma, *see* Plasma triglycerides
serum, *see* Serum triglycerides
in STZ-DM, 301, 303

Triglyceride(s) (TGs) (*Continued*)
T therapy effects on, 936, 937
tamoxifen effects on, 532
urinary excretion of epinephrine and, 511
see also Hypertriglyceridemia; Triglyceride-rich lipoproteins
Triglyceride(s) (TGs) in exercising women
effects of brisk walking on TGs, 837
in normotensive women, 19, 20
and plasma TG clearance, 808-813
Triglyceride(s) (TGs) in IDDM, 667
effects of newly insulin-treated IDDM on synthesis of, 1234, 1237
erythrocyte aggregation and, 1183, 1184
oxidized lipids and, 1198
Triglyceride(s) (TGs) in NIDDM
and acute hyperinsulinemia effects on plasma CETP activity, 1363
and autologous blood transfusions for phlebotomies, 616
castration and/or hormonal replacement effects on, 1216
and insulin effects on $(Ca^{+}+Mg^{+})$-ATPase, 605, 606
insulin sensitivity, Lps and, 502, 505, 506
newly insulin-treated NIDDM effects on synthesis of, 1234, 1237
and PB effects on insulin-mediated glucose metabolism in NIDDM, 353-354
Triglyceride(s) (TGs) in obesity
association between insulin sensitivity, FFAs and TG metabolism independent of uncomplicated obesity, 1275-1281
in genetic obesity, 550
VAT, androgens and, in obese men, 1319
Triglyceride-rich lipoproteins (TGRLP), PP, increasing esterified cholesterol accumulation in THP-1 macrophages in IDDM, 1063-1072
Triiodothyronine (T_3)
adaptive changes in transmembrane transport and metabolism of, in livers of fed and fasted hypothyroidic and hyperthyroidic subjects, 1355-1361
free, *see* Free triiodothyronine
iodothyronine metabolism and levels of, 795
levels of, during liver regeneration following partial hepatectomy, 683
in vegetarians and nonvegetarians, 623
very–low-calorie diet effects on, 1295
Triiodothyronine sulfate (T_3S), uptake of, and suppression of TSH secretion in anterior pituitary cells, 1282-1286
Triphosphatase
nucleoside, metyrapone effects on activity of, 83
see also ATPase
Triphosphate, *see* ATP
Tropic factors, humoral β-cell, role of, in acute stress-induced hyperinsulinemia in response to pertussis toxin, 1221-1225
Tryptophan
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159
glucagon role in control of metabolism of, 1512, 1513
insulin effects on metabolism of, 73
metyrapone effects on binding of, to hepatic nuclei, 79-84
see also [^{3}H]Tryptophan; L-Tryptophan
[^{3}H]Tryptophan, metyrapone effects on binding of, to hepatic nuclei, 80-82
L-Tryptophan in AA mixture supplying arginine-free or arginine-rich diet, 115
T_3S (triiodothyronine sulfate), uptake of, and suppression of TSH secretion in anterior pituitary cells, 1282-1286
TSH, *see* Thyrotropin
Tubular reabsorption, renal, plasma and urine isotopic enrichment following L-[1-^{13}C]phenylalanine and L-[ring-$^2H_5$]phenylalanine infusions, as evidence for isotope effect in, 487-491
Tumor(s), *see* Malignant disease
Tumor necrosis factor (TNF), effects of systemic infusions of endotoxin, IL-1 and, on glucose metabolism, 279-284
Tumor necrosis factor-α (TNF-α)
effects of, on glucose and albumin production in hepatocytes, 476-480
independent and combined actions of IL-1β, glucagon and, on hepatic amino acid metabolism, 822-829
24-hour energy expenditure (EE), substrate oxidation rates and, unaffected by AT distribution in obese women, 109-113
24-hour pulsatile control of cortisol, 17-hydroxyprogesterone, and androstenedione release in normal and 21-hydroxylase-deficient prepubertal children, 372-377
Twins, excretion rate of adrenal androgens by, during adrenarche, 186-189
Type I diabetes mellitus, *see* Insulin-dependent diabetes mellitus
Type I procollagen, serum PICP of, in familial type I-A osteogenesis imperfecta, 1261-1265
Type I-A osteogenesis imperfecta (OI), familial, serum PICP in, 1261-1265
Type II diabetes mellitus, *see* Non–insulin-dependent diabetes mellitus
Type IV collagen, effects of, on preadipocyte differentiation induced by extracellular matrix components, 909
Tyrosine
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
effects of IR gene mutation at tyrosine 1162 and 1163 on IR serine phosphorylation and desensitization, 757-765
and glucagon role in control of metabolism of, 1512, 1513
insulin effects on metabolism of, 73
see also Plasma tyrosine; L-Tyrosine
L-Tyrosine, AA mixture with, supplying arginine-rich and arginine-free diet, 115

U, *see* Uremia
UDP (uridine diphosphate)-glucuronyltransferase, activity of, and proliferation of hepatic peroxisome, 170, 171
Ultrasound, fetal, in pregnancy with homozygous FH, 1167
Uncomplicated obesity, association between insulin sensitivity, FFAs, and TG metabolism independent of, 1275-1281
Unweighted skeletal muscle, RU38486 effects on protein metabolism in, 1451-1455
Urate, serum, in essential hypertension, β-blocker effects on, 459
Urea
hepatic conversion of amino-nitrogen to, in hyperthyroidism, 1023-1029
plasma, *see* Plasma urea
synthesis of, in controlled NIDDM, FHNC and, 329-332
in uremia, 405
Urea nitrogen (N)
after adaptation to diets of differing protein content, 1342
blood, in multiple trauma victims, 1307
excretion of, during fasting in GDM, 381
in nephrotic hypertriglyceridemia, 249
Uremia (U; chronic renal failure)
glutamine-containing dipeptides in, 1104-1107
with IDDM, effects of pancreas-kidney transplantation on Lp composition in, 333-347
sucrose enhancing hepatic carbohydrate metabolism disturbances induced by, 403-412

Uric acid
homeostasis of, in prepubertal lean and obese girls, 819-821
see also Hyperuricemia
Uricase, hepatic, AA-193 and oxonate effects on, 127
Uricosuric action of AA-193 in hyperuricemia, 123-128
Uridine diphosphate (UDP)-glucuronyltransferase, activity of, and proliferation of hepatic peroxisome, 170, 171
Urinary excretion
adrenal androgen, familial influences on rate of, during adrenarche, 186-189
bile acid, lovastatin effects on, 1020
cortisol, *see* Urinary excretion, cortisol
dipeptide and AA, 1375-1376
epinephrine, *see* Epinephrine, urinary excretion of
hyperzincuria in IDDM, effects of high-dose zinc supplementation on, 1558-1562
IgG, in STZ-DM treated with insulin and sorbinil, 495, 497
of linoleic acid in pregnancy, 942
norepinephrine, *see* Norepinephrine, urinary excretion of
polyamine, influence of diet with and without AAs on, in multiple trauma victims, 1305-1309
protein, in nephrotic hypertriglyceridemia, 249; *see also* Urinary excretion, albumin
of urea nitrogen during fasting in GDM, 381
Urinary excretion, albumin
and effects of newly insulin-treated NIDDM and IDDM on cholesterol synthesis, 1234
in STZ-DM treated with insulin and sorbinil, 495, 497
Urinary excretion, cortisol
in Cushing's syndrome, 1518
relationship between total serum T and intraabdominal AT and, 391
Urine
isotopic enrichment of, following L-[1-^{13}C]phenylalanine and L-[ring-$^{2}H_5$]phenylalanine infusions, as evidence for isotope effect in renal tubular reabsorption, 487-491
see also Urinary excretion

$\dot{V}O_{2max}$
exercise effects on, *see* $\dot{V}O_{2max}$, exercise effects on
insulin sensitivity, Lps and, in NIDDM, 502, 505
in vegetarians, RMR and, 622
$\dot{V}O_{2max}$, exercise effects on
β-adrenoceptor blocker effects on, EPOC and, 566
brisk walking effects in normolipidemia, 837
effects of running, low-fat diet, and calorie restriction in moderately obese men, 656, 657
endurance exercise effects, 809, 1403
in older athletic men with silent myocardial ischemia, 193
and weight loss in exercising older obese men, 869
Valine
effects of infusions of stress hormone and, on protein synthesis and AA metabolism in skeletal muscle of normal adult subjects, 1159-1161
glucagon role in control of metabolism of, 1512, 1513
insulin effects on metabolism of, 73
plasma, *see* Plasma valine
in pregnancy, 1082-1084
see also L-Valine; Valine in NIDDM
L-Valine, and AA mixture supplying arginine-free or arginine-rich diet, 115
Valine in NIDDM
insulin production following IV glucose, arginine and, in patients with NIDDM, 385-389
plasma, in obese NIDDM subjects, 642, 644
Vanadate in STZ-DM
effects of, on reproductive efficiency, 1384-1388
hyperglycemia and PEPCK mRNA normalized by, in obese STZ-DM subjects, 1346-1354
Vascular dysfunction, STZ-DM–induced, effects of insulin and sorbinil on, 492-500
VAT (visceral adipose tissue), androgens, plasma lipids and, in obese men, 1318-1323
Vegetarian young men, sympathetic nervous system activity and RMR in, 621-625
Venous-arterial differences, deep, in AAs, hyperinsulinemia and, 73
Venous O_2 (oxygen) difference, arteriohepatic, protein ingestion and, 627
Venous stasis, ET release in myocutaneous island flaps in response to gradually insetting, 1201-1206
Ventricular function, left, in hyperglycemic STZ-DM, 64-65
Ventromedial-hypothalamic (VMH) lesions, effects of, on pancreatic insulin content in NIDDM male subjects, 32-37
Very–low-calorie diet (VLCD), lipolysis and gluconeogenesis from glycerol during weight reduction with, 1293-1300
Very–low-density lipoprotein(s) (VLDLs)
decreased TGs and increased hepatic clearance of, with MDL 29311, 233-240
dolichol content of, following partial hepatectomy, 679
effects of low-fat diet, calorie restriction, and running on, in moderately overweight men, 656, 658
in IDDM with chronic renal failure, 335, 337
in nephrotic hypertriglyceridemia, 252, 254
in STZ-DM, 301, 302
see also Very–low-density lipoprotein-cholesterol; Very–low-density lipoprotein-triglycerides
Very–low-density lipoprotein-cholesterol (VLDL-C)
concentrations of, in PCOS, AT distribution and, 710
in FH, 312, 400
GH deficiency and, 1458, 1459
insulin sensitivity and, 505, 525, 526
in NIDDM, and effects of acute hyperinsulinemia on plasma CETP activity, 1363
in obesity, 471, 556
pravastatin effects on, in heritable hyperlipidemia, 559-564
T therapy effects on, 936, 937
Very–low-density lipoprotein-triglycerides (VLDL-TGs)
in NIDDM, and effects of acute hyperinsulinemia on plasma CETP activity, 1363
in STZ-DM, 303
Veterans, paraplegic or quadriplegic, CHO and lipid metabolism disorders in, 749-756
Visceral adipose tissue (VAT), androgens, plasma lipids and, in obese men, 1318-1323
Vitamin A, role of, in neutrophil chemiluminescence production in CF, 719-722
Vitamin B_6, maternal hyperhomocysteinemia and, 1477
Vitamin B_{12}
etidronate and, reversing severe osteoporosis in pernicious anemia, 468-469
serum, maternal hyperhomocysteinemia and, 1477
Vitamin C, and oxidized lipids in IDDM, 1299
Vitamin D
effects of enterocytes and, on fluidity and transport of calcium by renal brush border membrane, 1093-1103
see also specific vitamin D metabolites

Vitamin E
and oxidized lipids in IDDM, 1299
role of, in neutrophil chemiluminescence production in CF, 719-722
VLCD (very–low-calorie diet), lipolysis and gluconeogenesis from glycerol during weight reduction with, 1293-1300
VLDLs, *see* Very–low-density lipoprotein(s)
VMH (ventromedial-hypothalamic) lesions, effects of, on pancreatic insulin content in NIDDM male subjects, 32-37
Von Willebrand factor (vWF), levels of, after high-MUFA diet in NIDDM, 1406-1409

Waist-to-hip ratio (WHR)
of congestive heart failure subjects, 175
and effects of insulin on glucose metabolism and whole-body proteolysis, 443
of essentially hypertensive patients, effects of β-adrenergic blockers and, 457
exercise and, 175, 192
of hyperinsulinemic subjects, 1580
hypocaloric high-protein diet effects on, 1482
insulin sensitivity and, *see* Waist-to-hip ratio, insulin sensitivity and
of obese men, 316, 317, 1319
of obese women, *see* Waist-to-hip ratio of obese women
PCOS and, 649, 708
and relationship between oxidative stress and insulin action, 1427
and testosterone and DHEA concentrations in nondiabetic men, glucose and insulin concentrations and, 600, 601
of vegetarians and nonvegetarians, RMR and, 622
Waist-to-hip ratio (WHR), insulin sensitivity and
Lps and, in NIDDM, 502, 505
in normotensive men, 884, 885
serum lipids and Lps and, 525-527
Waist-to-hip ratio (WHR) of obese women
and impact of obesity, AT distribution, and restricted energy intake on IGF-I, IGF-BP3, and GH, 316, 317
of normotensive exercising obese women, 175
relationship between total serum T and intraabdominal AT in, 391
24-hour energy expenditure and substrate oxidation rates unaffected by, 109-113
Waist-to-thigh circumference ratio, energy metabolism and skeletal muscle biochemistry and, 482
Walking, effects of brisk, on PP lipemia in normolipidemic young adults, 836-841
Weight, *see* Body weight; Organ weight; Tissue weight; Weight gain; Weight loss
Weight gain
clenbuterol effects on, 1087
PB and, in NIDDM, 350
and sucrose feeding in uremia, 405
Weight loss
by obese women, differential effects of insulin on glucose metabolism and whole body proteolysis in, 441-445
see also Weight-reducing diet, weight loss with
Weight-reducing diet, weight loss with
alone or combined with aerobic exercise, effects of, on body composition of older obese men, 867-871
effects of exercise or, on plasma HDL levels in obese men, 917-924
lipolysis and gluconeogenesis from glycerol during weight loss with very–low-calorie diet, 1293-1300
Weight-reducing diet, weight loss with (*Continued*)
Well-nourished subjects, mildly cirrhotic, glucagon failure to stimulate hepatic glycogenolysis in, 85-89
White subjects, *see* Race and ethnicity
Whole-body energy metabolism
skeletal muscle biochemical characteristics and, 481-485
see also Metabolic rate; Substrate oxidation
Whole-body glucose, effects of short-term pulsatile versus continuous insulin delivery on metabolism of, in obesity, 842-846
Whole-body O_2 (oxygen) consumption, effects of protein ingestion on, 626-632
Whole-body proteolysis, differential effects of insulin on glucose metabolism and, in normal-weight, obese, and reduced-obese women, 441-445
WHR, *see* Waist-to-hip ratio
Withdrawal
alcohol, beta cell response and hepatic insulin extraction following, in noncirrhotic alcoholics, 367-371
from clenbuterol, effects of, 1086-1092
Women
with breast cancer, *see* Breast cancer
dietary fat and CHO effects on substrate utilization in, 152-156
exercising, *see* Women, exercising
hyperandrogenic, *see* Hyperandrogenic women
non-obese, differential effects of insulin on glucose metabolism and whole-body proteolysis in, 441-445; *see also* Non-obese subjects
obese, *see* Women, obese
PCOS, *see* Polycystic ovary syndrome
postmenopausal, *see* Postmenopausal women
pregnant, *see* Pregnancy
transsexual, effects of T therapy on serum HDL-C and serum HDL_2-C level in, 935-939
using oral contraceptives, *see* Oral contraceptives
young, *see* Young women
see also Menses; Menstrual cycle; Normal adult subjects
Women, exercising
high resting blood pressure during submaximal exercise as cardiovascular disease risk factor in obese normotensive women, 18-23
increased LPL activities and plasma TG clearance in, 808-813
serum CCK response to food intake and, 217-222
see also Older women, exercising; Young women, exercising
Women, obese
AT distribution in, *see* Adipose tissue distribution in obese women
differential effects of insulin on whole-body proteolysis and glucose metabolism in reduced-obese women and in, 441-445
effects of Metformin therapy of PCOS in, 649-650
GH therapy effects on fuel metabolism, EE, and thyroid function in, 872-877
lipids in, *see* Lipids in obese women
with or without NIDDM, insulin-induced decrease in plasma AA concentrations in, 640-646
normotensive, high resting blood pressure during submaximal exercise as CV risk factor in, 18-23
see also Obesity

Xanthine dehydrogenase, hepatic, AA-193 effects on, 127
Xanthomatosis, cerebrotendinous, effects of lovastatin and CDCA on plasma cholestanol and bile acid metabolism in, compared, 1018-1022
X-ray absorptiometry, dual-energy, near-infrared interactance and, in study of four-compartment model, 427-422

Yohimbine, effects of, in acute stress-induced hyperinsulinemia, 1223
Yoshida ascites hepatoma (YAH), OKG limiting muscle protein breakdown in, without stimulation of tumor cell growth, 899-905
Young men
  relationship between insulin sensitivity and hemorrheologic factors in, 423-427
  vegetarian, sympathetic nervous system activity and RMR in, 621-625
  see also Young men, exercising
Young men, exercising
  effects of β-adrenoceptor blockade on EPOC in, 565-571
  effects of brisk walking on PP lipemia in normolipidemic, 836-841
Young men, exercising (*Continued*)
  impact of endurance exercise on body and skeletal muscle metabolism in, 814-818
Young women
  postpubertal normal, total-body and regional bone mineral content and bone density in, 263-266
  see also Young women, exercising
Young women, exercising
  effects of brisk walking on PP lipemia in normolipidemic, 836-841
  impact of endurance exercise on body fat and skeletal muscle metabolism in, 814-818

Zinc, effects of high-dose supplementation with, on hyperzincuria in IDDM, 1558-1562